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ABSTRACT 
Hypertension is prevalent in older adults and associated with impaired cognitive 
function compared to normotensive peers. The effect of antihypertensive therapy on 
preventing or reducing the rate of cognitive decline is unclear. The studies in this 
thesis examined the association of elevated blood pressure in older adults on changes 
in specific cognitive domains and tested the hypothesis that antihypertensive treatment 
reduces the rate of cognitive decline in older adults with mild hypertension. 507 older 
individuals (70-89 years) were recruited from a general practice population (250 
normotensives, and 257 hypertensives who participated in an international, placebo-
controlled trial of candesartan). Cognition was assessed annually for 3-5 years using a 
comprehensive computerised assessment battery and tests of executive function. 
Analysis of cognitive function at baseline showed hypertensive subjects performed 
worse than normotensives across a range of tasks (Chapter 3). Exploratory factor 
analyses were conducted on the baseline data to derive composite scores used to 
characterise five domains of cognition and reduce the number of statistical 
comparisons (Chapter 4). Regression analyses were performed for each participant to 
calculate individual slopes of decline on the five domains, to provide a sensitive 
method of analysing repeated assessment data with differential length of follow-up. 
The primary analysis showed that candesartan-based therapy reduced cognitive 
decline associated with hypertension on Attention and Episodic Memory, with a trend 
for Speed of Cognition; effect sizes were small-to-moderate. There were no effects on 
Working Memory or Executive Function (Chapter 6). The normotensive subjects 
showed less cognitive decline than the hypertensives (Chapter 7). These data suggest 
that the rate of cognitive decline associated with hypertension in older adults may be 
reduced by blood-pressure-lowering. Analysing individual slopes of decline on 
empirically-derived domains of cognition provides a sensitive and feasible 
methodology for assessing the effects. 
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CHAPTER 1: INTRODUCTION 
1.1 Epidemiological changes and the greying society 
The population of the UK is ageing. The population has grown by 8 per cent over the 
last few decades, from 55.9 million in 1971 to 60.6 million in mid-2006, but this 
change has not occurred evenly across all age groups: the population aged over 65 
grew by 31%, from 7.4 to 9.7 million. The largest percentage growth in population in 
the year to mid-2006 was at ages 85 and over (5.9%); the number of people aged 85+ 
grew by 69,000, reaching a record 1.2 million 1. This large increase reflects improving 
survival and the post World War One baby boomers now reaching this age group. The 
trend towards a greying society is also reflected in other major Western societies.  
As the population ages, diseases and morbidity associated with age will increase the 
social and healthcare burden of society. The challenge for researchers is to identify the 
conditions where morbidity can be treated or prevented. Hypertension and cognitive 
decline are two such areas worthy of investigation. 
1.2 Cognitive function  
1.2.1 Definition and description 
The word cognition derives from the Latin cognoscere, ‘to know’. The American 
Heritage Medical Dictionary defines it as, ‘the mental faculty of knowing, which 
includes perceiving, recognizing, conceiving, judging, reasoning, and imagining’ 2.  
Cognitive function refers to the underlying mental processes we often take for granted 
that enable us to go about our conscious everyday activities. Although a number of 
inter-related processes can be involved in any particular task, such as reading, or 
driving a car, for the purpose of description and investigation it is useful to separate 
cognition into different functions. The level to which each function is broken down 
and the descriptive terminology used often varies depending on the interests, 
discipline and hypotheses of the researcher or clinician. The general domains include, 
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but are not limited to: attention, information processing, working memory, long-term 
or episodic memory, and executive function.   
1.2.1.1 Attention 
Attention refers to the focus of resources being brought to bear on the task at hand. It 
reflects the intensity of concentration at any particular moment and the ability to 
sustain concentration for the period of time required whilst ignoring distraction. By 
virtue of its moment-to-moment fleeting nature, attention can be difficult to measure. 
An example of attention is listening intently to the school register waiting for your 
name to be called. 
1.2.1.2 Information processing 
This refers to the ability to select information relevant to the task at hand, and reject 
extraneous information, to make simple but appropriate decisions quickly. 
Information processing is allied to attention to a large extent, as without paying due 
attention the information will not be available for processing. Measurement is often 
based on both the speed and the quality of the processing decisions made. An example 
is responding correctly with ‘Yes Sir’ and not ‘Yes Miss’ in response to your name 
being called in the school register, and responding before the teacher marks you as 
absent. 
1.2.1.3 Working memory 
Working memory is sometimes referred to as short-term memory, and relates to any 
information that is currently being held temporarily for manipulation or calculation. 
The two primary modes of information are images and sounds, held in the visuo-
spatial scratchpad and auditory loop respectively (temporary information from other 
senses is dealt with by somatic memory, not usually considered a major part of 
cognitive function). Working memory provides a temporary store for information 
relevant to the task at hand. An example is holding the words from the beginning of a 
teacher’s sentence until they get to the end, so you can make sense of the instruction to 
attend detention after school.  
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1.2.1.4 Episodic memory 
Sometimes called long-term memory, the term episodic implies that a period of time 
has elapsed and refers to any information recalled or recognised after it is no longer 
being held in the temporary working memory store. This can be a matter of minutes, 
hours, days or years. The information may be verbal or visual, and is generally 
declarative so that the information can be described. An example is remembering to 
attend a detention session after school and recalling the misdemeanour from earlier 
that day that put you there. 
1.2.1.5 Executive function  
This is a general term that covers a range of higher level complex abilities, often 
composed of a number of the more discrete functions such as attention and working 
memory. Planning, organisation, problem-solving and managing multiple tasks are 
typically involved. An example is finding the quickest method to complete the 
punishment of writing out the sentence 100 times, ‘I must address my teacher with the 
correct gender-specific salutation’. 
During everyday activities, cognitive function can go unnoticed if there are no 
problems and tasks can be completed satisfactorily. However, there are many factors 
that can have detrimental effects on performance, to lesser or greater degrees, 
including age, disease, effects of drugs, diet and sleep deprivation. When cognition is 
affected to the extent that task performance is disrupted, the cognitive deficits become 
apparent. However, even subtle deficits can be problematic and interfere with quality 
of life, or be early indicators of future declines. In order to detect such changes, 
measurement of cognitive function becomes an important issue. 
1.2.2 Measurement 
In the same way that individual researchers and clinicians have their own interests in 
specific areas of cognition, so there is a proliferation of tests to measure these 
functions. In recent decades the cognitive testing market has become a sizeable 
industry and there are a range of tests available from commercial and academic 
sources, both public domain and proprietary tools sold under copyright licence. 
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However, the wide range of tests used in research can make comparison between 
studies somewhat problematic. The main distinction between test types reflects the 
theoretical background of their development and original intentions for use. 
1.2.2.1 Neuropsychological tests 
Neuropsychological tests are designed specifically for detecting impairment in patient 
populations and often require trained administrators and qualified personnel for their 
interpretation. They are more likely to be paper-and-pencil measures and require 1-to-
1 administration. As they are not usually designed for frequent repeated testing, they 
have limited or no parallel forms so may suffer from learning effects. That said, 
because they are designed for clinic use, the measures are usually sensitive and 
specific for detecting clinically-relevant impairments and in some cases, validated to 
contribute to the disease diagnosis. 
1.2.2.2 Cognitive tests 
Cognitive tests are designed to measure specific aspects of cognitive function, and as a 
result tend to be more sensitive to subtle changes. Computerised cognitive testing has 
become a niche market within the drug-development process in the pharmaceutical 
industry. This has fuelled the development of cognitive test batteries that cover a 
range of functions to comprehensively identify impairments and enhancements to 
cognition, designed specifically with repeated testing in mind. Because of the 
environment in which they are employed, cognitive test batteries are well-equipped 
for electronic data capture, automation and standardisation of test administration, and 
can sometimes be administered in groups. Training of participants is usually a 
requirement to reduce practice effects, and multiple parallel forms enable repeated 
testing without learning effects. 
A similar distinction can be made between tests that provide a brief, global assessment 
of cognition to be used as screening measures, and more in-depth batteries designed to 
profile differential aspects of cognitive function. There are advantages and 
disadvantages to all measures of cognitive function as no one measure can be ideal in 
all situations. Therefore at the design stage of any research study the relative merits of 
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the available assessment methods need to be considered. In addition to the 
practicalities, the psychometric properties have to be considered. 
1.2.2.3 Reliability 
The reliability of an assessment tool refers to the level of consistency with which it 
provides the measurements. Test-retest reliability is the most important aspect as it 
gives an indication to what extent the same scores will be produced if the assessment 
is repeated, all other things being equal. Test-retest reliability is assessed using 
correlation methods, ranging from -1 to 1, where a value of 1 represents total 
concordance between two assessments. With psychometric data there are a number of 
extraneous factors beyond control that can add noise to repeated measurements, so 
test-retest values in the range of 0.9 are usually deemed acceptable.  
1.2.2.4 Validity 
The validity of an assessment tool refers to the extent to which it actually measures 
what it purports to measure. There are a number of methods for test validation, 
including comparison to established measures of the same concept, and testing the 
ability of the measure to distinguish between groups known to differ on the concept in 
question. Reliability and validity are related concepts, although it is possible to have a 
reliable measure that is not valid; any valid measure must be reliable if change is to be 
measured.  
1.2.2.5 Utility 
The utility of a measure refers to how practical and appropriate it is for assessing the 
population it is intended for. There are no specific metrics to determine utility as the 
factors that need to be taken into consideration vary according to the research 
intended. These can include method of administration, time taken, training or 
qualification requirements of staff, language availability, data handling and 
processing, ease of interpretation etc. Utility is an important consideration as it can 
impact on the quality of data collected and the amount of missing data in a study. 
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1.3 Cognitive function and ageing 
1.3.1 Changes over time 
It is generally accepted that cognitive function declines with age. This is borne out by 
the normative data from neuropsychological and cognitive tests. For example, data 
from the Cognitive Drug Research (CDR) computerised assessment battery normative 
database (v.3) show on the attention task Choice Reaction Time, the speed of response 
in making a simple decision becomes slower (i.e. higher response times) as age 
increases (Figure 1). Similar trends for decline are seen with published norms for 
neuropsychological tests such as the Trail-Making Test 3. There is some debate as to 
whether a certain amount of decline is an inevitable part of the ageing process as the 
biological systems underpinning cognition accumulate damage and naturally 
degenerate. However, there are a number of conditions where distinct pathological 
processes are known to cause cognitive decline. 
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Figure 1: Normative data from the Cognitive Drug Research (CDR) system 
Normative data in five-year age bands for the Choice Reaction Time task from the 
Cognitive Drug Research (CDR) computerised assessment system. 
 
Data shown are mean and standard error. 
 
 
 
 
 
 
 
 
 
 
Figure 2: Distribution of the dementia subtypes 
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1.3.2 Dementia 
Dementia refers to a group of conditions that gradually destroy brain cells and lead to 
progressive decline in mental function. Dementia affects a range of cognitive 
functions including memory, attention, the ability to learn, reason, make judgements, 
communicate and carry out daily activities. Personality changes are often evident and 
patients can suffer from anxiety, suspiciousness, agitation, delusions and 
hallucinations. There are a number of subtypes of dementia (distribution shown in 
Figure 2), the most common being Alzheimer’s Disease (AD). Vascular Dementia 
(VaD) (including mixed dementia) accounts for approximately 20% of dementia 
cases. The diagnosis requires significant cerebrovascular disease to be present that is 
judged to be causally relevant to the cognitive impairment. As with AD, VaD requires 
histopathological confirmation and is a postmortem diagnosis. There are a number of 
risk factors for VaD that are currently incompletely understood. However, 
hypertension is a major risk factor and can be a targeted for intervention. 
1.4 Blood pressure 
1.4.1 Definition 
The heart acts as a pump to force blood around the body through the circulatory 
system of arteries, veins and capillaries. As a pump, it works by generating pressure, 
and the level of blood pressure (BP) depends on a combination of two factors: how 
forcefully the heart pumps, and how narrowed or relaxed the arteries are. Blood 
pressure can be measured using a range of devices, but the traditional gold standard is 
the mercury sphygmomanometer, from which the unit of measurement, millimetres of 
mercury (mmHg), is derived. BP readings are written as two figures, for example 
120/80 mmHg:  
The first figure is the systolic blood pressure (SBP) - the maximum pressure in the 
arteries when the heart contracts and pushes blood out into the body 
The second figure is the diastolic blood pressure (DBP) - the minimum pressure in the 
arteries between beats when the heart relaxes to fill with blood 
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1.4.2 Changes with age 
Blood pressure (BP) increases with age through much of adult life, in particular SBP 
which continues to rise towards the end of life (whereas DBP may remain the same), 
and is thought to be associated with reduced arterial compliance. The results from the 
7-year follow-up of the Healthy Old People in Edinburgh (HOPE) study showed that 
SBP continued to rise in participants who remained disease-free into their ninth 
decade 4. It used to be thought that rising BP was an inevitable natural consequence of 
ageing and therefore did not require treatment. However, it has now become accepted 
that hypertension is a modifiable risk factor for vascular disease. 
1.4.3 Hypertension 
When resting blood pressure is consistently raised beyond certain limits, the risk of 
cardiovascular events increases. If this occurs in the absence of a known underlying 
cause (secondary hypertension), it is referred to as primary or essential hypertension. 
Essential hypertension accounts for approximately 90% of cases, and although there 
are a number of contributing lifestyle factors (smoking, diet, obesity, lack of exercise 
etc.), the exact etiology is unknown. Unless severe, hypertension itself has few 
symptoms and so can go undetected and therefore untreated for years. However, the 
complications associated by hypertension can be serious and include atherosclerosis, 
stroke, aneurysm, heart failure, myocardial infarction (MI), kidney failure and eye 
damage. The prevalence of hypertension varies depending on the diagnostic criteria 
used, however in developed countries between 35 and 50% of the over-65s are 
thought to be hypertensive 5.  
1.4.3.1 Treatment 
There are a number of antihypertensive medications available, and are categorised 
according to mechanism of action 6: 
ACE inhibitors - stop the production of the hormone angiotensin II that makes the 
blood vessels narrow. As a result, the vessels expand, improving blood flow. Tension 
in the circulation is also lowered by the kidneys filtering more fluid from the blood 
vessels into urine. 
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Angiotensin-II receptor antagonists – block the action of angiotensin II. This allows 
the blood vessels to expand, improving blood flow and reducing BP. 
Beta-blockers - block the effect of adrenaline and the sympathetic nervous system on 
the body. This relaxes the heart so that it beats more slowly, lowering BP. 
Alpha-blockers - cause the blood vessels to relax and widen. Combining them with 
beta-blockers has a greater effect on the resistance in the circulation. 
Calcium-channel blockers - reduce muscle tension in the arteries, expanding them and 
creating more room for the blood flow. In addition, they slightly relax the heart 
muscle so it beats more slowly, reducing BP. 
Diuretics - help the body get rid of excess salt and fluids via the kidneys. In certain 
cases, they relax blood vessels, reducing the strain on the circulation. 
1.4.3.2 BP treatment target guidelines 
The BP criteria for defining hypertension and the associated treatment guidelines have 
changed over time, in line with new evidence of the benefits of treatment in reducing 
the risk of cardiovascular events. At the time of the study inception, the ‘Management 
guidelines in essential hypertension: report of the second working party of the British 
Hypertension Society’ were current 7. Evidence from the Systolic Hypertension in the 
Elderly (SHEP) study 8 and the Medical Research Council (MRC) treatment trial of 
hypertension 9 showed benefits to treatment in the over 60’s at reducing 
cardiovascular events as well as stroke. However, there were insufficient data on the 
benefits of treating patients over 80 years of age. The recommendations were that 
treatment was indicated in the elderly for SBP>160 or DBP>90 mmHg.  
1.5 Hypertension and cognitive function  
1.5.1 Cross-sectional studies 
Detailed characteristics of the cross-sectional studies are presented in Appendix I. 
One of the earliest studies of hypertension and cognitive function compared twenty 
newly diagnosed hypertensive men (DBP > 105 mmHg) with twenty normotensive 
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controls 10. Subjects were untreated, with an average age of 50 years. A 
neuropsychological test battery was used that included subtests of the Wechsler Adult 
Intelligence Scale (WAIS), simple reaction time, memory and visual-spatial ability. 
The results showed that hypertensives had slower reaction times and reduced digit 
spans compared to the normotensives. Although the sample size was small and the 
subjects were middle-aged males only, the study was among the first to recognise that 
the relationship between hypertension and cognition warranted further investigation.  
A study reporting cross-sectional data from the Framingham Heart Study examined 
the relationship between neuropsychological test performance and concurrently 
measured blood pressure 11. The analysis included over 2,000 subjects aged 55-89 
years without history of stroke and controlled for age, sex, education, antihypertensive 
medication, smoking and alcohol consumption. There was no consistent relationship 
between blood pressure and cognitive function even when subjects receiving 
antihypertensive medication were excluded. However, the categorisation of subjects 
into groups on the basis of single BP readings pre- and post-testing has since been 
questioned 12.  
A large community population study involving over 3,500 subjects aged 65 years or 
older, investigated the relationship between BP and cognitive function over the entire 
blood pressure range 13. Cognitive function was assessed using a story retelling task to 
measure immediate and delayed memory, digit span to measure attention, and items 
from the Pfeiffer Mental Status Questionnaire to assess orientation. Despite a small 
but significant association between increased DBP and decreased digit span score, the 
results showed no consistent pattern of association across the tests.  
Similarly, a population sample of over 900 healthy community-dwelling adults from 
the Maastricht Aging Study showed no linear relationship between blood pressure and 
various aspects of cognitive function 14. The study included subjects unselected for 
blood pressure status, stratified for age (24-81 years), sex and occupational level. 
Additional analyses comparing a subgroup of hypertensives and matched 
normotensive controls showed impairment on a letter-copying task, but not on any 
other cognitive tests. 
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Conversely, in a community sample of approximately 600 healthy untreated subjects 
over 70 years of age, Mini Mental State Examination (MMSE) scores correlated 
negatively with systolic blood pressure but not DBP 15. To investigate the possibility 
that the relationship followed a J-shaped curve, subjects were divided into low, 
medium and high BP groups. The effects of age and NART-predicted IQ were 
controlled for in multivariate analyses which found significant associations between 
low MMSE score and both high systolic and high diastolic blood pressure. Compared 
with the medium BP groups, MMSE scores were not significantly lower for the low 
systolic and diastolic groups, suggesting that a threshold may exist at which the risk of 
decline becomes significant. 
Analysis of a population sample of over 1100 subjects aged 65-95 years showed that 
diastolic but not SBP predicted cognitive impairment (MMSE < 24) independently of 
sex, age, education, Geriatric Depression Scale score and antihypertensive medication, 
but only for subjects aged 75 years or over 16. However, the sample was characterised 
by low educational levels (only 17.7% had over 5 years in education) compared to 
other population studies. As MMSE scores are influenced by education level 17, the 
degree of impairment in the study may be overestimated.  
Cross-sectional data from the randomisation period of the European Trial in Elderly 
with Systolic Hypertension (Syst-Eur Vascular Dementia Project) showed that blood 
pressure contributed weakly to MMSE score compared with age and education level 
18. For women systolic blood pressure correlated negatively and independently with 
cognitive function; the lack of a significant correlation for men may be due to the 
lower proportion of males in the study. The analysis included 2225 subjects aged 
between sixty and 100 years old, without evidence of dementia based on DSM-III 
criteria where MMSE score was less than 24. The sample was characterised by a high 
level of cognitive functioning due to the selective recruitment of subjects, which may 
have led to a ceiling effect on the MMSE scores. 
An extensive neuropsychological test battery, sensitive to mild cognitive impairment, 
was used in a small study (n = 44) of well-matched hypertensive and normotensive 
healthy elderly subjects 19. Subjects were over 60 years old, with 3-10 years in 
education and MMSE scores over 23. In the hypertensive group, for those on 
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treatment (7 out of seventeen), antihypertensive medication was substituted for 
placebo for the two weeks prior to testing. The results showed that the hypertensives 
had lower levels of performance on the attention tasks of the battery compared with 
the normotensive group, but were not impaired on the memory or judgement tasks. 
In a larger study of similar design, 90 matched pairs of hypertensives and 
normotensives were recruited from general practitioners’ registers 20. Subjects were 
stratified by 10-year age bands from 40-79 years. Hypertension was defined as DBP ≥ 
100 mmHg or SBP ≥ 180 mmHg, or taking antihypertensive medication at the time of 
assessment; controls were defined as having DBP ≤ 90 mmHg and no record of 
hypertensive BP measurements or antihypertensive treatment in the preceding year. 
The hypertensives showed a consistent trend of impairment on the cognitive function 
tests, with significant differences on the Verbal Learning task (immediate recall, total 
recall after repetition, and change in recall after interference). As 89% of the 
hypertensive group were taking antihypertensive medication, it remains unclear 
whether the observed deficits were due to the effect of hypertension or the 
antihypertensive medication itself. In addition, allocation of subjects to groups was 
based on BP readings from one occasion only. 
1.5.1.1 Summary 
The evidence for a relationship between blood pressure and cognitive function from 
cross-sectional studies is equivocal. Large population and community-based 
epidemiological studies report associations with diastolic blood pressure 13, 16, systolic 
blood pressure 15, 18 or no association at all 11, 14. Smaller studies comparing groups of 
hypertensive and normotensive subjects have generally found hypertensives to be 
impaired, but the nature of the impairment varies according to the measures of 
cognition used 10, 19, 20.  
Interpretation of the results across studies is difficult as there are variations on a 
number of important criteria. Appendix I details the main characteristics of the studies 
described above. Perhaps most importantly, the definition of hypertension itself differs 
between studies. The lower SBP bound ranges from as low as ≥ 140 mmHg in some 
studies 13, 14 to ≥ 180 mmHg in another 20. Definitions based on DBP also vary ranging 
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from ≥ 90 mmHg to ≥ 105 mmHg. Although the BP criteria for a diagnosis of 
hypertension have become lower historically, and the recommended cut-off levels 
increase with age 21, the differences between studies do not appear systematic. The 
implications of differing criteria become most apparent in studies that have defined 
hypertensive and control groups based on a single cut-off point. For example, the 
control group defined as SBP ≤ 165 and DBP ≤ 95 mmHg in the study by Palombo et 
al (1997) would have been classified as hypertensive in analyses performed by Scherr 
et al (1991). 
Studies also differ in the number of BP measurements used to classify subjects. In 
particular the use of measurements from a single occasion has been criticised as BP is 
known to be affected in some individuals by virtue of the fact that it is being measured 
– white coat hypertension 22. However in large community studies, time and resource 
constraints will often determine the number of BP readings that can be taken.  
The inclusion of both treated and untreated hypertensives also makes interpretation 
difficult. From cross-sectional data it is not possible to delineate the effects of 
hypertension per se and the effects of the antihypertensive agents on cognition. 
Although the presence of treatment can be controlled for statistically, the mechanism 
by which the antihypertensive achieves its effect will vary according to the agent, and 
may have differential effects on cognitive function.  
There is also wide variation in the age ranges of subjects across the various studies. 
The absence of a linear relationship between BP and cognition over the full adult age 
range 14 yet some significant differences between hypertensives and normotensives in 
older adults, suggests that the strength or nature of the relationship may change with 
age. However, even in those studies concentrating only on the ‘elderly’ there is 
variation in the age criteria used to define the samples.  
A further complication relates to the tendency for BP to fall preceding the onset of 
dementia 23. In studies that have not excluded subjects with possible dementia there is 
the likelihood that a relationship between raised BP and cognitive impairment will be 
weakened.  
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In addition to the specific problems of interpretation highlighted above, cross-
sectional studies in general suffer from methodological limitations inherent in their 
design. In most cross-sectional studies, the temporal relationship of variables is not 
discernible as the data provide only a ‘snapshot’ of a particular point in time. Whilst 
associations between variables can be identified, it is not possible to determine cause-
effect relationships. However, cross-sectional studies are of value in identifying 
relationships for further investigation and generating hypotheses. To investigate 
temporal relationships between hypertension and cognitive function, longitudinal 
studies are required. 
1.5.2 Longitudinal studies 
Studies investigating the relationship between hypertension and cognitive function 
over time can be divided into two groups according to whether the assessment of 
cognitive function was retrospective or prospective.  
1.5.2.1 Retrospective studies 
The retrospective studies have, in general, capitalised on large samples of subjects 
originally recruited to epidemiological studies of cardiovascular risk factors where 
repeated measures of blood pressure have been taken. Assessment of cognitive 
function has been added to the studies much later in the follow-up period. As a result, 
the retrospective studies provide an opportunity to investigate the relationship 
between blood pressure levels during middle-age and cognitive function in later life 
within the same subjects.  
The previous analysis of cross-sectional data from the Framingham Heart Study failed 
to show a consistent relationship between cognitive function and BP measured 
concurrently 11. Due to concerns over the validity of grouping subjects on the basis of 
BP readings from a single occasion, the authors examined the relationship between the 
cognitive data and blood pressure measurements averaged over the 26 years up to, and 
including, the cognitive testing phase 12. The analyses controlled for demographic 
variables and were stratified by use of antihypertensives in the two years prior to 
testing. The results showed that for subjects taking antihypertensive medication at 
follow-up, there was no association between cognitive function and blood pressure. 
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However, for subjects not on medication at assessment, both chronicity of 
hypertension and average systolic and DBP were inversely related to cognitive 
performance. For subjects that had previously been taking antihypertensive 
medication, there was a relationship between cognitive impairment and the probability 
of not being on medication at the time of testing.  
In order to minimise the confounding effects of antihypertensive therapy, the data 
were re-analysed including only those subjects who were untreated during an 8-year 
BP measurement phase 24. The time window of the BP phase was selected in order to 
maximise the number of untreated subjects and as a result, reduced the follow-up 
period between the end of the BP phase and cognitive testing to 14 years. For analysis, 
the full sample was also divided into two groups: subjects who were untreated during 
the BP measurement phase only; and subjects who remained untreated throughout the 
study. The results showed that average BP levels and chronicity of hypertension were 
inversely related to both a composite score of cognition, and individual tests of 
memory and attention measured 14 years later. This was the case for the full sample, 
for the subsample untreated during the BP phase only, and for the subsample who 
remained untreated throughout. 
The data were re-examined further in two studies to investigate the interaction effects 
of age with BP level and chronicity of hypertension 25, 26. Age, ranging from 55 to 88 
years, was analysed both as a continuous variable and stratified into ten-year age 
bands. Multiple linear regression and binary logistic regression analyses produced 
very similar results: the interaction effects of age with BP were trivial or non-
significant; the independent associations between BP and cognition remained; age was 
inversely associated with performance and increased the odds of performing poorly 
more than the BP variables.  
The relationship between midlife BP and late-life cognitive function was also 
examined in a large population sample of Japanese-American men 27. Participants in 
the Honolulu Heart Program were examined for factors relating to coronary heart 
disease and stroke then followed up as part of the Honolulu-Asia Aging Study over a 
25-year period. Cognitive function was measured at the final follow-up using the 
Cognitive Abilities Screening Instrument (CASI), a composite of the Hasegawa 
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Dementia Scale, Mini-Mental State Examination, and the Modified Mini-Mental State 
Examination. Subjects were categorised into low, normal, borderline and high groups 
according to their systolic and diastolic BP, and into good, intermediate and poor 
according to CASI scores. Approximately 58% of the sample had never been treated 
with antihypertensive medication, and treatment status was not associated with 
impaired cognitive function. After adjustment for age and education, the results 
showed that the risk for intermediate and poor cognitive performance increased with 
the level of midlife systolic blood pressure category. Every 10 mmHg increase in 
systolic BP was associated with 7% increased risk of intermediate and 9% increased 
risk of poor cognitive function. When prevalent cerebrovascular accident, coronary 
heart disease and subclinical atherosclerosis were taken into consideration, the 
increased risk of poor cognition was 5%. There was no association with midlife 
diastolic BP.  
Conversely, high midlife diastolic blood pressure but not SBP predicted impaired 
cognitive function 20 years later in the Uppsala community study of Swedish men 28. 
Cognitive function was analysed as a continuous variable and dichotomised at the 
lowest quintile, using a composite score derived from transformed MMSE scores and 
the Trail-Making Test forms A & B. The multivariate model adjusted for age, 
education, previous occupation, stroke diagnosis and medications affecting blood 
pressure. Subjects were split into five categories according to baseline diastolic BP, 
measured to the nearest 5 mmHg. A statistically significant trend indicated that 
cognitive performance at follow-up was highest for those with the lowest DBP at 
baseline; those with high DBP had the poorest performance. In addition, cross-
sectional data at follow-up showed that high systolic and DBP levels from 24-hour 
ambulatory blood pressure monitoring (ABPM), non-dipping, insulin resistance and 
diabetes were associated with low cognitive function.  
Individual changes in systolic blood pressure over time were studied in healthy males 
from the Western Collaborative Group Study 29. Based on numerous BP readings over 
a 25-30 year follow-up period, subjects were classified by SBP as: trackers – high in 
midlife and at follow-up; normals – consistently low/ medium, or increasing over the 
follow-up period; decreasers – high/ medium in midlife decreasing to medium/ low at 
follow-up. Cognitive function was assessed at follow-up using a number of 
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neuropsychological tests, reduced to the three factors of verbal memory, psychomotor 
speed and verbal fluency that emerged from a principal components analysis. After 
adjustment for age, education, depression, stroke and antihypertensive medication, the 
results showed that high SBP trackers performed worse than normals on the verbal 
memory factor, decreasers performed worse than normals on psychomotor speed, but 
there were no differences between the groups on verbal fluency. 
A much shorter follow-up period was employed in an analysis of data from the 
Healthy Old People in Edinburgh (HOPE) study 30. Subjects were aged between 70 
and 88 years at baseline, with no reported health problems or prescription medication. 
Raven’s Progressive Matrices (RPM) and subtests of the Wechsler Memory Scale 
were administered four years later to assess fluid intelligence and memory 
respectively. The results showed that for subjects who remained healthy throughout 
the follow-up period, demographic variables, pre-morbid IQ and BP accounted for 
39% of the variance in RPM scores but only 12% of the memory variance. Subjects 
with high baseline diastolic BP performed worse on the RPM than those with medium 
or low DBP. In addition, subjects diagnosed as hypertensive by their family doctor 
during the follow-up period had significantly lower RPM scores than healthy subjects 
with medium or low DBP; healthy subjects with high DBP  scored between the two 
groups. Whether or not the poor performance of the diagnosed hypertensives is due to 
sustained hypertension is difficult to ascertain, as although they are likely to have a 
greater duration of hypertension, they are also more likely to be treated with 
antihypertensive medication. 
Cognitive decline was the focus of study in a subgroup of males from the National 
Heart, Lung, and Blood Institute (NHBLI) Twin Study 31. Subjects were categorised as 
low, normal, high or mixed according to SBP measurements taken on three occasions 
over a 15-year period. Cognitive function was assessed on two occasions in the 
following 10-year period using the MMSE, digit-symbol substitution (DSS) subtest of 
the WAIS, Benton Visual Retention Test (BVRT) and verbal fluency. For all midlife 
SBP groups, there was significant decline on the DSS with the high SBP group 
declining most and the low SBP group declining least. The low SBP group showed no 
significant decline in MMSE scores; all other groups declined, with the mixed group 
showing the greatest change. There was a tendency for verbal fluency to increase over 
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time, but no differences between the groups. Similarly, there were no differences on 
the BVRT.   
1.5.2.2 Summary 
The retrospective studies often involve large numbers of subjects as, in many cases, 
the samples have been taken from epidemiological studies. The main characteristics of 
the studies described above are presented in Appendix II. Overall, they suggest an 
association between blood pressure levels in middle-age and cognitive function in 
later life. The variables used as measures of blood pressure, such as SBP, DBP, 
average BP readings over follow-up period, and chronicity of hypertension vary 
between studies, as do the measures of cognitive function. However, the general 
nature of the relationship appears consistent: higher blood pressure levels in midlife 
are associated with poorer cognitive function in later life.  
Despite the large numbers of subjects involved, there are some issues regarding the 
generalisability of the findings. In particular, only two of the six reported studies 
(excluding reanalyses) included female subjects 12, 30, representing 17.1% of the total 
number of subjects studied. This is due to the original epidemiological studies of 
cardiovascular risk factors concentrating on males. Although the two studies that did 
include female subjects found no sex differences, it nevertheless warrants caution 
when applying the overall conclusions to the population as a whole.  
In general, the design of longitudinal studies provides an opportunity to examine the 
temporal relationship between variables. However, the retrospective longitudinal 
studies do not necessarily allow conclusions to be drawn regarding cause and effect. 
As the measurements of blood pressure are taken many years before the measures of 
cognition, there is a tendency to infer that raised blood pressure in midlife causes poor 
cognitive function in later life. However, as cognitive function was not measured in 
midlife, the possibility that poor cognition already existed in subjects with raised BP 
cannot be ruled out. To address this issue, prospective longitudinal studies are 
required. 
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1.5.2.3 Prospective studies 
In contrast to measurements from a single timepoint used in the majority of 
retrospective studies, prospective studies involve the assessment of cognitive function 
on successive occasions. This enables investigation of the relationship between 
hypertension and cognitive function over time. As subjects act as their own controls, 
the study design allows the effects of blood pressure on changes in cognitive function 
within the individual to be assessed.  
In a population sample of dementia-free subjects over 75 years of age from the 
Kingsholmen Project in Sweden, overall decline in MMSE scores over the mean 
follow-up period of 3.4 years was minor (0.4 MMSE points per annum) 32. 
Approximately a quarter of the sample declined more than 10%, with the greatest 
declines exhibited by subjects over 85 years of age or with stroke. Analyses showed 
that age, lower education and stroke predicted decline for women; lower education 
and stroke, but not age predicted decline for men. The sex differences may be due to 
lower numbers of males in the study. Although baseline BP did not predict decline, in 
women there was a significant correlation between reduction in systolic blood 
pressure and decline, independent of cardiovascular disease and antihypertensive 
medication use. As the sample included subjects unselected for BP status, it is unclear 
whether the results identify low blood pressure as a risk factor for decline, or whether 
the blood pressure reduction is itself a result of the early dementing process.  
Blood pressure variables also failed to predict decline on the Paired Associate 
Learning Test (PALT) in the Medical Research Council (MRC) Elderly Hypertension 
Trial 33. Hypertensive subjects, untreated and free from serious cardiovascular and 
cerebrovascular disease at baseline were followed up for 4.5 years. Decline was 
calculated for each subject as the slope of the regression line of PALT scores on time. 
Decline was associated with age, male gender, rural residence, depression and low 
intelligence. There were no associations for the cardiovascular variables including 
baseline systolic and diastolic blood pressure, mean SBP over the follow-up period, or 
trial therapy. There were also no associations within the placebo group between 
untreated BP levels and later decline. 
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A further follow-up of a subsample of subjects from the MRC trial was performed 
nine to 12 years after baseline 34. The MMSE was used as the outcome measure after 
log-transformation, and all analyses accounted for baseline cognitive function using a 
factor derived from a principal components analysis of the baseline PALT, Trail-
Making Test (TMT) and Raven’s Progressive Matrices (RPM) scores. Analyses also 
adjusted for apolipoprotein-E allelic status, alcohol, education, diet, lifetime smoking, 
social class and ‘history of dementia’ loading. The results showed that poor cognition 
at follow-up was associated with greater history of dementia loading, older age, 
abstinence from alcohol before the age of 60, and less decline in systolic BP over the 
trial period. However, the effect of SBP decline became non-significant when 41 cases 
of dementia were excluded from the analysis.  
Decline on the MMSE was also used as the outcome measure in the Epidemiology of 
Vascular Ageing (EVA) population study 35. The analyses adjusted for age, gender, 
education, income, alcohol consumption, depressive symptomology, APOE and 
baseline cognitive function, after excluding subjects with stroke during the four year 
follow-up period. Hypertension was defined as SBP ≥ 160 mmHg and/or DBP ≥ 95 
mmHg or taking antihypertensive medication. The results showed that the risk of 
decline of 4 or more MMSE points was 2.8 times greater for the hypertensive group 
compared to the normotensives. The association remained even when the threshold for 
hypertension was reduced to SBP ≥ 140 mmHg or DBP ≥ 90 mmHg. In addition, 
compared to subjects who remained normotensive at baseline and 2 years, subjects 
with chronic high blood pressure were at greater risk of decline. In relation to the use 
of antihypertensive medication, there was no overall association between treatment at 
baseline and decline at 4 years. However, when compared to subjects receiving 
treatment at either baseline or 2 years, those hypertensives that remained untreated 
were more likely to show decline at 4 years. 
Decline on the MMSE over a four year period was also examined in the Healthy Old 
People in Edinburgh (HOPE) study 36, in addition to the retrospective study of fluid 
intelligence and memory reported previously 30. As before, all subjects were aged 
between 70 and 88 years, with no reported health problems or prescription medication 
at baseline. The analysis accounted for baseline MMSE performance, and detected 
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both ceiling effects and regression to the mean effects on MMSE scores. The 
magnitude of decline was relatively small with a mean drop of 0.44 MMSE points 
over four years. The main multiple regression model indicated that older people 
declined faster, higher NART-IQ scores conferred protection against decline, and high 
systolic blood pressure increased risk of decline. There were no significant differences 
in the models predicting decline between subjects who had started medication and 
those who remained untreated, although for those who remained both disease and 
medication-free, systolic BP became marginally non-significant as a predictor.  
The relationship between blood pressure and both cognitive performance and 
cognitive decline was investigated in a large sample of non-institutionalised elderly 
subjects from the Hypertension Detection and Follow-up Program (HDFP) in Boston 
37. The Pfeiffer Mental Status Questionnaire and the East Boston Memory Test were 
used to measure cognitive function at baseline, three and six years. Blood pressure 
was measured at baseline and, for the majority of subjects, BP readings were also 
available from nine years previous. After controlling for age, gender, education and 
time of evaluation, the analyses showed that overall there was no strong linear 
association between BP and cognition. For the analysis of change over time, there was 
little evidence of an effect of BP on either test. However, in terms of the level of 
cognition, subjects with high systolic or diastolic blood pressure either at baseline or 9 
years prior, made significantly more errors on the Mental Status Questionnaire than 
subjects in the medium BP group. There was a suggestion of a U-shaped relationship 
as subjects in the low systolic and diastolic BP groups also had higher error scores 
than those with medium BP. The use of antihypertensive medication did not appear to 
alter the relationship between BP and cognition. 
The possibility of a U-shaped relationship was also examined in the Atherosclerosis 
Risk in Communities (ARIC) study, a very large multiethnic, multi-centre 
investigation of cardiovascular risk factors 38. Although primarily a study of middle-
aged subjects, over 4,800 subjects were aged between 64 and 76 years at the 6-year 
follow-up stage, representing approximately half of the study sample. For the analyses 
hypertension was defined as SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg or taking 
antihypertensive medication at baseline. Decline was measured as change in scores on 
the delayed word recall test, digit-symbol substitution (DSS) subtest of the WAIS-R, 
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and word fluency. After controlling for demographic variables and medication, the 
presence of diabetes at baseline was associated with decline on the DSS test and word 
fluency, and hypertension was associated with greater decline on the DSS test. There 
was no evidence of a U-shaped relationship using the same cut-off points as the HDFP 
study 37, as the low BP group showed the least cognitive decline on the digit-symbol 
substitution and word fluency tests.  
1.5.2.4 Summary 
The prospective studies permit the investigation of the relationship between blood 
pressure and cognitive decline over time. The measurement of cognitive function at 
multiple time points enables subjects to act as their own controls. As such, the natural 
variation that exists in cognitive function test scores within the study population is 
controlled for. The results of the prospective studies however are somewhat mixed, 
with three studies finding no association between blood pressure variables and decline 
32-34, three studies indicating a relationship does exist 35, 36, 38, and one study finding a 
relationship between blood pressure and cognitive performance, but not decline 37. 
The main characteristics of the studies are presented in Appendix III. 
Across the studies the overall level of decline throughout the follow-up period is 
relatively minor. When the studies reporting negative and positive results are 
compared, the studies indicating no relationship tend to have smaller subject numbers. 
It is possible that a combination of fewer subjects and small effect sizes have led the 
negative studies to be under-powered to detect a relationship. However, there are two 
notable exceptions: the MRC trial involved over 2,500 subjects and found no 
relationship between blood pressure variables and decline 33, whereas the HOPE study 
included less than 400 subjects and found raised systolic BP to be a predictor of 
relatively minor levels of decline 36.  
The combination of negative and positive findings does not appear to be related to the 
measures of cognitive function used, as two studies in each category have used the 
same measure: the MMSE. However, the MMSE was originally designed as a 
screening tool and is known to have reduced sensitivity when cognitive impairment is 
mild 39. Therefore, if the negative studies were inadequately powered, it is possible 
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that a relationship would have been detected had a more sensitive measure of 
cognitive function been employed. In addition, the MMSE only provides a global 
measure of functioning. As there is evidence that some aspects of cognitive function 
deteriorate before others 40, it is possible that more comprehensive or more specific 
measures of cognition would have detected a relationship. 
A further complication for interpreting prospective observational studies is the 
previous and concurrent use of antihypertensive medication, as this is not controlled 
by the investigators but tends to rely on standard clinical practice. It cannot be 
assumed that this practice is the same between countries, or indeed sites within a 
country as the extent to which BP treatment guidelines are adhered to is known to 
vary. Given the known cardiovascular benefits of antihypertensive treatment, 
observational studies of untreated hypertensive patients are now regarded as unethical. 
Although the relationship between blood pressure and decline was not found in all 
studies, among the positive studies the relationship is consistent: higher blood 
pressure increases the risk of cognitive decline. The possibility of a U-shaped 
relationship was suggested 37 but refuted 38. Due to the prospective nature of the 
studies where cognition is monitored over time, the relationship between hypertension 
and cognitive decline would appear to be causal. However, as the mechanism by 
which hypertension affects cognitive function is not yet known, it must be borne in 
mind that hypertension and cognition may both be influenced by a third factor.  
Alongside the investigations of blood pressure, evidence from both the negative and 
positive studies associated decline with increasing age, lower educational achievement 
and co-morbidity; higher IQ was found to be protective. Of the risk factors identified, 
blood pressure lends itself more readily to intervention. However, the existence of a 
relationship between blood pressure and cognitive function does not necessarily imply 
that treatment with antihypertensive medication will reverse or halt subsequent 
decline. Therefore the effect of antihypertensive treatment on cognitive function is of 
great interest.  
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1.6 RCTs of antihypertensive treatment and cognitive function  
Randomised controlled trials (RCT) provide the strongest methodology for 
determining the effect of antihypertensive treatment on cognition. Detailed 
characteristics of the RCTs are presented in Appendix IV. 
1.6.1 Systolic Hypertension in the Elderly Program (SHEP) 
The SHEP study provided the earliest data from a large multicentre RCT looking at 
cognitive outcomes 41. Community-screened participants with isolated systolic 
hypertension were randomised to receive a diuretic and/or a beta-blocker versus 
placebo, and assessed annually with a battery of paper-and-pencil neuropsychological 
tests. Despite a large sample size of 4736, the last observation carried forward (LOCF) 
analysis showed no difference between the treatment and placebo groups on cognitive 
outcomes over the average 5 year follow-up period, with cognitive function being 
well-maintained in both groups. However, it has since been suggested that differential 
loss to follow-up could have biased the study towards a null finding of a treatment 
effect 42, and the use of LOCF would contribute to this. 
1.6.2 Medical Research Council (MRC) hypertension treatment trial 
The MRC hypertension treatment trial was a single-blind, randomised, placebo-
controlled trial of a diuretic versus the beta-blocker atenolol in approximately 2500 
hypertensives aged 65-74 years 43. BP was reduced in both treatment groups compared 
to placebo at 9 months, but there were no significant differences between groups on a 
range of neuropsychological tests.  
Similar results were found when followed-up over 4.5 years 44. Using a calculation of 
decline based on the regression of the test score on time, there were no significant 
differences between groups on the cognitive outcomes, either for the Intention-to-
Treat (ITT) analysis or per-protocol analysis.  
1.6.3 The Hypertension Old People in Edinburgh (HOPE) study 
The HOPE study was a single-centre, randomised, double-blind trial of captopril 
versus bendrofluazide treatment in community-dwelling hypertensives between 70 
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and 85 years of age and an MMSE of 20-28 at baseline 45. A range of 
neuropsychological tests was used including the Paired Associates Learning Test 
(PALT) and Trail-Making Test used in the MRC study, with testing taking place in 
participants’ homes. There were no differences between treatment groups on cognitive 
tests at any timepoints (0, 4, 12 & 24 weeks) using a repeated measures ANOVA, 
although participants with the greatest DBP reductions showed improvement on the 
PALT compared to those with the smallest DBP changes. There were no effects of 
SBP. The study is notable as participants were selected with MMSE scores in a range 
that was designed to avoid ceiling effects.  
1.6.4 The Systolic Hypertension in Europe (Syst-Eur) trial 
In the international, multicentre Syst-Eur trial, participants over 60 years old were 
randomised to treatment for isolated systolic hypertension with the calcium-channel 
blocker nitrendipine, with the addition of enalapril/hydrochorothiazide (HCTZ) or 
both if required, versus placebo. Cognition was assessed annually using the MMSE, 
and patients with scores of 23 or less were examined for dementia. The median 
follow-up period was 2 years in the double-blind study, as the trial was concluded 
earlier than planned when a pre-specified interim analysis showed that the primary 
outcome had been met. The study reported a 50% reduction in the risk of dementia 
with active treatment and a mean between-group BP difference of 8/4 mmHg 46. 
However, there was little change in the mean MMSE scores in either group. The 
dementia findings were reinforced when follow-up was extended for a further 2 years 
as an open-label study 47.  
However, the robustness of the findings has since been questioned as the actual 
number of dementia endpoints was low (n=32) and the confidence intervals of relative 
risk were wide, ranging from no effect to a 76% reduction 48.  
1.6.5 Early phase studies 
In addition to the large RCTs, a number of smaller studies have been reported but 
suffer from methodological problems such as being open-label 49, small sample size 
(n=13) 50, or inadequate reporting. In sixty-nine participants aged 30 to 73 years with 
mild to moderate hypertension, improvements were seen in MMSE scores in 
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participants randomised to losartan treatment (23±3 to 27±3, p<0.001) compared to 
hydrochlorothiazide (24±3 to 25±2.7, non-significant) from baseline to study close at 
26 months 51. Although the MMSE changes scores appear impressive, the study did 
not adequately report the direct treatment comparisons. From the data presented it 
appears that between-group conclusions were based on differences between the p 
values of the within-group statistics. 
1.6.5.1 Summary 
The evidence from the treatment studies is the strongest to date, but as yet is far from 
convincing. The Syst-Eur study gives the most encouragement that treatment of 
hypertension may be effective for the prevention of dementia, but clearly the finding 
needs to be replicated. The lack of association of treatment with MMSE scores could 
potentially be due to the limitations of the measure itself, and suggests that more 
sensitive methods of assessing cognition need to be incorporated into clinical trials 
where cognitive outcomes are considered. 
1.7 Rationale and hypothesis 
There is a large amount of literature surrounding the relationship of BP, 
antihypertensive treatment and cognition, and despite methodological issues between 
studies, it suggests that hypertension could be a potential target for intervention to 
prevent cognitive decline. Randomised controlled trials are the gold-standard for 
determining treatment efficacy. However, the results are mixed, and the Syst-Eur 
study provides the strongest indication that antihypertensive treatment could be 
effective at reducing the risk of dementia. To date, cognitive decline has been a 
secondary outcome in studies that have used global assessment tools, not designed 
specifically for clinical trial use. Therefore, investigating the effect of antihypertensive 
treatment on cognition with sensitive cognitive assessments was clearly warranted. 
The Study on Cognition and Prognosis in the Elderly (SCOPE) provided an 
opportunity to test the hypothesis that in older adults with mild hypertension, 
compared to placebo, candesartan-based antihypertensive treatment would reduce the 
rate of cognitive decline. 
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CHAPTER 2: METHODS 
2.1 The SCOPE Study 
The Study on Cognition and Prognosis in the Elderly (SCOPE) was an international, 
multicentre, prospective, randomised, double-blind, placebo-controlled trial 
investigating the effects of candesartan cilexetil on major cardiovascular events and 
cognition in the elderly. The SCOPE trial was sponsored by AstraZeneca. 
2.1.1 Rationale 
At the time of study inception, the lower threshold of DBP below which the risk of 
stroke is not continuously reduced, had not been determined. The Hypertension 
Optimal Treatment (HOT) Study showed that the lowest risk of fatal and non-fatal 
stroke was at a DBP < 85 mmHg in patients with a mean age of 62 years and an initial 
mean DBP of 105 mmHg 52. The question remained unanswered as to whether 
antihypertensive therapy provided protection against stroke in elderly individuals with 
DBP in the range 90-99 mmHg.  
With regard to cognitive function, the Syst-Eur Study showed that treatment of 
isolated systolic hypertension with the calcium-channel blocker nitrendipine reduced 
the incidence of dementia and AD by 50% over the two years of follow-up 46. Taken 
alongside the cross-sectional and prospective longitudinal evidence showing an 
association between hypertension and cognitive function, a clinical trial of the effects 
of antihypertensive therapy on cognition in elderly patients with mild hypertension 
was clearly warranted. The SCOPE trial included cognition as a secondary outcome to 
investigate this. 
2.1.2 Candesartan 
Candesartan cilexetil is an angiotensin II type I (AT1) receptor blocker, the newest 
class of antihypertensive drugs available for clinical use. Angiotensin receptor 
blockers have a good tolerability profile, particularly the absence of the dry cough 
associated with ACE-inhibitors. Candesartan cilexetil provides a dose-related 
antihypertensive effect up to 16mg 53 and shows a smooth profile of BP reduction that 
persists over the 24-hour dosing period. The lack of significant orthostatic effects is 
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especially important in elderly patients to avoid injuries from falls 54. There is also 
evidence from animal studies that angiotensin II impairs learning and memory 
performance 55 and that AT1-receptor blockade may improve performance 
56. The 
combination of suitability for the treatment of hypertension in the elderly and the 
plausibility of possible cognitive effects made candesartan an ideal candidate drug 
around which the SCOPE trial was designed. 
2.1.3 Objectives of the main SCOPE study 
The main objective was to assess the effect of candesartan on major cardiovascular 
events (cardiovascular death, non-fatal myocardial infarction and non-fatal stroke) in 
elderly patients with mild hypertension. Secondary objectives were to assess the effect 
of candesartan on: the incidence of dementia according to modified ICD-10 criteria; 
change in cognitive function as measured by the MMSE; significant cognitive decline 
defined as a reduction in MMSE score ≥ 4 points from baseline score on two 
consecutive occasions; total mortality; cardiovascular mortality; fatal and non-fatal 
myocardial infarction; fatal and non-fatal stroke; impaired renal function; 
hospitalisation; quality of life; and health economics. 
2.1.4 Participants 
Individuals were recruited from participating centres in 15 countries in Europe, Israel 
and North America between March 1997 and January 1999. The target population was 
males and females, aged 70-89 years, with an MMSE score ≥ 24 and treated or 
untreated hypertension (defined as a sitting SBP 160-179 mmHg and /or DBP 90-99 
mmHg) on two consecutive visits separated by a minimum of 14 days. The 
requirement to meet criteria on consecutive occasions beyond the screening visit was 
designed to exclude participants with initial high BP readings that subsequently 
returned to lower levels of their own accord i.e. participants with ‘white coat’ 
hypertension. Treated patients were standardised to hydrochlorothiazide 12.5 mg once 
daily before randomisation. Exclusion criteria are shown in Table 1.  
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2.1.5 Study design 
2.1.5.1 Initial screening / enrolment visit 
At this initial visit, eligibility and exclusion criteria were checked. Written, informed 
consent was obtained and blood pressure, heart rate and MMSE assessments were 
performed. Individuals receiving treatment for hypertension were switched to 
treatment with hydrochlorothiazide. 
2.1.5.2 First qualifying visit 
Eligible individuals returned after a period of at least 14 days to receive repeat BP, 
heart rate and MMSE assessments. In cases where the BP and MMSE criteria were 
met, this constituted their first qualifying visit. All individuals, whether fulfilling the 
inclusion criteria or not, were invited to return in a further 14 days, and at 14-day 
intervals thereafter until the BP and MMSE inclusion were met on two consecutive 
visits. 
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Table 1: Exclusion criteria for the SCOPE study 
General exclusion criteria 
  
Stroke or myocardial infarction within 6 months prior to randomisation 
 Decompensated congestive heart failure 
 Other serious concomitant diseases considered by the investigator to affect survival 
during the next 3-4 years 
 Alcoholism, drug abuse or any other problems which may compromise patients’ 
compliance 
 Currently participating in other clinical study  
 Clinically significant impaired renal function (S-creatinine > 180 µmol/l for males 
and > 140 µmol/l  for females) 
 S-ASAT or S-ALAT more than three times the upper normal limit for the 
laboratory. 
Blood pressure-related exclusion criteria 
  
Need of antihypertensive treatment other than hydrochlorothiazide 
 Standing systolic BP <140 mmHg after 2 minutes, or a history of symptomatic 
orthostatic hypotension 
 Sitting SBP > 180 mmHg or DBP > 100 mmHg 
 Secondary hypertension 
 Known hypersensitivity to the study drug 
 Known contraindications to HCTZ 
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Table 1 continued: Exclusion criteria for the SCOPE study 
Cognitive exclusion criteria 
  
Obvious dementia, even if MMSE score remains above 23 
 Current treatment with antidementia drugs 
 Conditions which preclude MMSE e.g. illiteracy, poor vision or hearing, paralysis, 
aphasia or other speech disorder 
 Vitamin B12 deficiency, untreated or treated less than 12 months 
 Hypothyroidism, untreated or treated less than 12 months 
 Neurosyphilis or AIDS 
 Severe brain disorder that may interfere with cognitive function 
 Severe depression within the last 12 months or psychotic disorder 
 Psychopharmacological treatment instituted within the last 6 months 
 
2.1.5.3 Second qualifying visit / randomisation / baseline visit 
If the BP and MMSE inclusion criteria were met at the second consecutive visit, a 
medical history was taken and individuals underwent a physical examination, 12-lead 
ECG, laboratory analysis, and the documentation of any adverse events. Data were 
faxed to the SCOPE Coordinating Centre at Sahlgrenska University Hospital/Östra, 
Göteburg, Sweden. Individuals fulfilling all of the inclusion and none of the exclusion 
criteria were randomised using a version of the Pocock-Simon procedure 57 with the 
prognostic factors shown in Table 2 to guarantee balance between the candesartan and 
placebo groups. Investigators were informed of the treatment allocation using numeric 
patient identifiers by return fax to ensure double-blind status. Participants were 
randomised to receive either 8 mg candesartan cilexetil or placebo once daily. 
2.1.5.4 Treatment schedule 
Figure 3 shows the study design. After randomisation to 8 mg candesartan or placebo 
once daily, participants with SBP > 160 mmHg or a reduction in SBP < 10 mmHg 
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from baseline, or DBP > 85 mmHg, had treatment doubled to two study tablets (16 mg 
candesartan or placebo once daily). If SBP remained ≥ 160 mmHg or DBP ≥ 90 
mmHg, open label HCTZ 12.5 mg once daily was added. To further achieve the target 
BP additional antihypertensive medications, excluding other AT1-receptor blockers or 
ACE-inhibitors, were permitted at the discretion of the investigator. 
 
Table 2: Prognostic factors used in randomisation procedure 
Prognostic factor 
 age 
 gender 
 previous myocardial infarction 
 atrial fibrillation 
 previous stroke 
 treatment with non-steroid anti-inflammatory agents including aspirin 
 MMSE score 
 level of education (number of years in formal education) 
 body mass index 
 treatment with lipid-lowering drugs 
 chronic treatment with psychopharmacological therapy 
 previously treated with antihypertensive drugs 
 smoking 
 language area 
 
2.1.5.5 Study visits 
Participants returned for scheduled study visits at 1 month (± 7 days) from the 
randomisation visit, 3 months (± 7 days), then every 6 months (± 1 month) until study 
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close. Blood pressure and heart rate were recorded at every visit; MMSE was assessed 
every 6 months; physical examination, ECG and laboratory analysis were repeated at 
1, 12 and 24 months. Additional study visits were permitted at the investigators’ 
discretion according to medical need. Participants were free to withdraw from the 
study at any time but were encouraged to attend follow-up visits for observation if 
study medication ceased. 
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Figure 3: Main SCOPE trial study design 
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2.1.5.6 Study closeout visit 
At the end of the follow-up period, all participants, current and withdrawn, were 
invited back for a final study visit to reduce loss to follow-up. Blood pressure, heart 
rate, MMSE, physical examination, ECG, and laboratory analyses were performed. 
Participants taking study medication were instructed to cease at this visit; replacement 
scripts for bendrofluazide were provided for participants taking HCTZ prescribed 
under the study protocol. Blood pressure was monitored on three occasions in the 
following 6 weeks (± 7 days) before responsibility for BP care was handed back to 
participants’ general practitioners. 
2.1.6 Protocol amendments 
Based on data from the Swedish Trial in Old Patients with Hypertension (STOP-
Hypertension) 58 and a predicted event rate of approximately 40 major cardiovascular 
events per 1000 patient years, randomised participants were scheduled to be followed-
up for a minimum of 24 months. As the event rate was lower than expected, follow-up 
was extended to a minimum of 36 months, provision for which was made in the 
original study protocol 59, resulting in a follow-up range of 3-5 years.  
The BP target in the original protocol was <160/90 mmHg based on accepted 
international guidelines current at the time of study design 60. However, new British 
Hypertension Society guidelines were released in September 1999 when the study was 
ongoing that recommended a lower target of <150/90 mmHg and ideally <140/85 
mmHg applicable to patients in the study population. As such it would have been 
unethical to maintain the higher BP target, therefore in Newcastle the BP target of  
<150/90 mmHg was instituted at participants’ next scheduled study visit. 
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2.2 Newcastle Cognitive Substudy 
2.2.1 Introduction 
Newcastle was one of the UK centres participating in the SCOPE trial, and the 
Newcastle Cognitive Substudy ran concurrently with the main trial at this centre.  
2.2.2 Rationale 
One of the secondary objectives of the SCOPE trial was to assess the effect of 
candesartan on cognitive function assessed using the MMSE. The MMSE and other 
similar brief global measures have been widely used in studies of hypertension and 
cognition. Such measures have distinct advantages when used in large multi-centre 
trials: they involve short administration time; little training is needed to administer 
them; they are available in different languages; and they have good inter-site 
reliability. However, the sensitivity of a particular measure affects the power of a 
study to detect relationships between variables. Although the utility of the MMSE as a 
screening tool for dementia is well established, it has been found to be relatively 
insensitive to mild dementia, suffers from well-recognised ceiling and practice effects, 
and provides little information about the profile of cognitive function 39. There is 
evidence that some cognitive domains are more susceptible to and exhibit decline 
earlier than others 40 hence the assessment of a range of domains is necessary to 
investigate the full nature of the relationship between hypertension and cognition. 
The Newcastle Cognitive Substudy was designed to extend the assessment of 
cognitive function beyond the MMSE, using a comprehensive computerised 
assessment battery and traditional neuropsychological tests of executive function, at 
one centre participating in the SCOPE trial. 
2.2.2.1 Hypothesis 
Compared to placebo, candesartan-based antihypertensive treatment will reduce the 
rate of cognitive decline in older adults with mild hypertension. 
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2.2.3 Normotensive comparison group 
The comparison of the candesartan and placebo groups was designed to determine the 
effect of candesartan on cognitive decline in hypertensives. Previous studies have 
generally found hypertensive patients to have mild cognitive deficits compared to their 
normotensive counterparts. In order to place the magnitude of any study effects in the 
context of normal ageing and decline, the Newcastle Cognitive Substudy also included 
a parallel, non-intervention, observational normotensive comparison group. The 
assessment schedule for the normotensive group followed that of the main SCOPE 
trial with the following exceptions: blood pressure was not measured at 1 and 3 
months as these assessments were included in the SCOPE study participants to assess 
acute drug effects; no further physical examinations, ECG or laboratory analyses were 
performed beyond the baseline visit. At the follow-up visits, if BP was raised and 
confirmed by a repeat BP check after a minimum of 14 days, a letter was sent to the 
participant's general practitioner informing them of the readings and suggesting 
monitoring. As the normotensive group was for observation only, no restrictions could 
be placed on the prescription of concomitant medications, including antihypertensive 
therapy.  
2.2.4 Recruitment 
Primary care medical notes were screened by research nurses attending 10 general 
practice surgeries in the Newcastle and North Tyneside area of the UK. Potentially 
eligible individuals were invited to participate by a letter from their general 
practitioner. Appointments for interested individuals were arranged by the research 
team via telephone to attend the research clinic at the Freeman Hospital for an initial 
screening / enrolment visit.  
As the success of the Newcastle Cognitive Substudy depended to a large extent on 
successful recruitment to the main SCOPE trial, efforts concentrated on the 
recruitment of hypertensive participants initially. Individuals identified by case note 
screening who were potentially eligible for the main SCOPE trial were contacted in 
the first instance. Potentially eligible individuals for the normotensive control group 
who were identified through the hypertensive screening process were contacted 
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toward the end of the hypertensive recruitment period. At this time, a second wave of 
case note screening was initiated to screen for further normotensive individuals. This 
led to overlapping recruitment and follow-up periods: hypertensives were recruited 
between March 1997 and January 1999, and followed up until March 2002; 
normotensives were recruited between June 1998 and March 2000, and followed up 
until June 2003 (Figure 4). 
 
Figure 4: Newcastle Cognitive Substudy timelines 
 
 1997 1998 1999 2000 2001 2002 2003 
 
H = Hypertensive group   Recruitment  
N = Normotensive group   Follow-up  
 
 
2.2.5 Participants  
Participants were males and females, aged 70-89 years, with an MMSE score ≥ 24 on 
two consecutive visits separated by a minimum of 14 days. The exclusion criteria 
were the same as those for the main SCOPE trial (see Table 1), and identical for both 
hypertensive and normotensive groups except in regard to blood pressure-related 
criteria. Based on criteria current at the time of recruitment 7 participants were defined 
as:  
Hypertensive: SBP 160-179 mmHg and/or DBP 90-99 mmHg untreated or HCTZ 
treated, as per SCOPE protocol 
Normotensive: BP < 150/90 mmHg untreated 
H 
N 
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In accordance with the main SCOPE study protocol, individuals with possible 
dementia as defined by an MMSE score <24 and/or reported significant decline in 
cognitive function assessed using the Clinical Dementia Rating scale 61 and IQCODE 
informant questionnaire 62 were not eligible, although no potential participants were 
actually excluded by this criteria. Ethical approval was granted by the Newcastle Joint 
Ethics Committee. Hypertensive participants were recruited to the main SCOPE trial 
in the first instance and gave informed, written consent; participation in the Newcastle 
Cognitive Substudy was optional and required participants to sign a substudy consent 
form. Normotensive participants were recruited to the substudy only and gave 
informed, written consent. Participants were not paid for their participation in either 
the main SCOPE study or the Newcastle Cognitive Substudy, although travel 
expenses were reimbursed on request. GP surgeries received a gratuity for each 
participant randomised in the main SCOPE study. 
2.2.6 Blood pressure measurement 
All BP measurements were taken by a doctor or trained research nurse using a manual 
sphygmomanometer with a cuff of appropriate size in relation to the participant’s arm 
circumference. The diastolic pressure was taken as the pressure at which the 
Korotkoff sounds disappeared (phase V) 22. On each occasion, three readings were 
taken in the seated position after five minutes rest, with the mean of the second and 
third readings used.  
2.2.7 Cognitive assessment 
2.2.7.1 Measures 
Cognitive function was assessed using the Cognitive Drug Research computerised 
assessment battery 63 and traditional neuropsychological tests of executive function, 
the Trail-Making Tests A and B 64 and Verbal Fluency for letters F, A, S and category 
of Animals 3. The subtests, in order of presentation, are described in Table 3. The 
battery took approximately 40 minutes to complete. At the baseline visit only, the 
New Adult Reading Test (NART) was administered as an estimate of pre-morbid 
intelligence 65. Participants were also given two self-report questionnaires to be 
completed at home and returned by post: the Cognitive Failures Questionnaire (CFQ) 
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66 to assess cognitive slips and errors; and the Geriatric Depression Scale (GDS) 67 to 
assess depressive symptomatology. 
The CDR battery was chosen as the main assessment for cognitive function as it was 
specifically designed for use in clinical trials and has been used extensively in this 
field 68. The CDR system demonstrates good test-retest reliability and validity 63, and 
has been shown to be sensitive to detecting change over time in elderly populations 69. 
The system also has multiple parallel forms for each subtest meaning to ensure that 
the same stimuli are not presented at more than one test session per participant, and 
the order of stimuli is randomised on the simple attention tasks to prevent learning of 
stimuli sequences. CDR Ltd also provided ongoing technical support for the duration 
of the study. The traditional test of executive function were chosen because they were 
the most commonly-used measures in the public domain, and have been used 
previously to supplement the CDR battery.  
2.2.7.2 Equipment 
The CDR battery was presented on a Viglen Dossier CDP laptop computer with a 
12.1” TFT colour screen, and participants responded with ‘YES’ and ‘NO’ buttons on 
a proprietary two-button response box (Figure 5) using the index finger from each 
hand. The Trail-Making Test and Verbal Fluency tests were administered according to 
the recommended standard task instructions (Appendix V and VI); participants 
completed the Trail-Making Test in ballpoint pen on photocopies of standard A4 test 
sheets with the time taken for completion recorded by the administrator; participants’ 
responses to the Verbal Fluency tests were recorded verbatim by the administrator on 
standard A4 forms.  
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Figure 5: Equipment used for computerised cognitive testing 
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Table 3: Description of the subtests from the cognitive battery 
 CDR subtest Description 
immediate word recall number of stimuli recalled orally from 12 visually-presented words 
immediate word  
recognition 
speed and accuracy of discrimination of 12 novel and 12 
previously presented words 
simple reaction time speed of detection of a simple repeated stimulus (the word ‘YES’)  
number vigilance speed and accuracy of response to a single target digit in a rapidly 
presented series of digits  
choice reaction time speed and accuracy of discrimination between the words ‘YES’ 
and ‘NO’ 
spatial memory storage and retrieval of visuospatial information in working 
memory using a house with dark and lit windows as the stimulus 
numeric working  
memory  
discrimination of three target digits from a digit sequence using the 
articulatory loop of working memory 
delayed word recall number of stimuli recalled orally from 12 previously presented 
words after a delay 
delayed word 
 recognition 
speed and accuracy of discrimination of 12 previously presented 
words from 12 further novel words 
picture recognition speed and accuracy of discrimination of 14 previously presented 
pictures from 14 novel pictures after a delay 
Traditional neuropsychological tests  
Trail-Making Test  
form A 
timed task in which participant joins with a ballpoint pen, in 
numeric order, the encircled numbers 1 to 25 randomly arranged 
on a page 
Trail-Making Test  
form B 
contains encircled numbers and letters to be joined in alternating 
order 
Verbal Fluency for  
letters  (F, A, S) 
participant produces orally in 60 seconds as many words beginning 
with a given letter, avoiding proper nouns, variations and 
repetitions 
Verbal Fluency for  
category (animals) 
as above, with words belonging to the category of animals and 
beginning with no specific letter 
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2.2.7.3 Testing environment 
Cognitive assessments were performed at the Freeman Hospital, in any one of three 
similar examination rooms located in the Melville Day Hospital, depending on 
availability. Participants were seated at a desk with an adjustable chair to allow for a 
comfortable writing position. The CDR laptop was placed so that the button box was 
within easy reach with relaxed arms, with forearms resting on the desk, and a viewing 
distance to the screen of approximately 50 centimetres. Background noise was kept to 
a minimum. Room temperature and lighting were adjusted as necessary to maintain 
normal office conditions. To reduce missing data, home visits were permitted to 
assess cognitive function where it was not possible for participants to attend the 
hospital clinics. Efforts were made to keep the testing environment as close to the 
clinic conditions as possible. 
2.2.7.4 Procedure 
Standardised task instructions were given verbally by the administrator, present 
throughout each testing session (see Appendix VII). Where it was obvious the 
participant had not understood the task correctly, the instructions were repeated and/or 
reworded. All tests could be restarted or repeated if it was clear from the participant or 
their performance that they had misunderstood the task. Tests were not restarted or 
repeated however if the participant had understood the instructions but performance 
was poor. If a participant was agitated in any way by the testing i.e. by being unable to 
understand the task despite repeated explanations or distressed by their performance, 
the task could be omitted or aborted at the discretion of the administrator. However, 
participants were encouraged to complete as much of each testing session as possible 
and reassured of the confidentiality of the testing. A written log was kept for each 
session documenting the suitability of the data on each subtest, and the reason for any 
missing data. 
2.2.7.5 Assessment schedule  
A training session on the CDR battery was performed at the first qualifying visit to 
familiarise participants with the computerised tests. If an individual met all of the 
inclusion criteria and none of the exclusion criteria at the second qualifying visit, full 
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cognitive assessment was performed constituting the baseline assessment. Further 
assessments were made annually to coincide with, and performed after, the scheduled 
blood pressure visits until study close. An additional CDR assessment was performed 
at 1 month to assess acute effects. Parallel forms of the CDR battery were used at each 
visit to reduce learning effects. The traditional neuropsychological tests were not 
performed at the first qualifying visit or 1 month visits as equivalent forms of the test 
are not available, and short-term repeated testing with the same stimuli would produce 
a sizeable learning effect.  
2.2.8 Study organisation 
2.2.8.1 Personnel 
The Newcastle Cognitive Substudy was undertaken by a multi-disciplinary team, 
supervised by Professor Gary A. Ford, consisting of the following: a Clinical Research 
Associate responsible for physical examinations, medical history taking, ECG 
interpretation and clinical decision-making; research nurses responsible for screening 
primary care medical notes, undertaking BP, heart rate and ECG measurements, 
adverse event monitoring and study drug administration; an assistant psychologist / 
Junior Research Associate responsible for performing cognitive assessments and 
database management; and an administrative assistant for data entry and general study 
administration. A representative from AstraZeneca attended regularly to monitor the 
Case Report Forms (CRF) of participants to fulfil the regulatory requirements of the 
main SCOPE trial.  
2.2.8.2 Role of candidate in the study 
The candidate joined the Newcastle Cognitive Substudy as an assistant psychologist/ 
Junior Research Associate in July 1998 after recruitment of the hypertensive cohort 
had already begun, and performed the majority of the cognitive assessments after this 
date, with the exception of a small number of post-closeout assessments in the 
hypertensive cohort (Table 30) and closeout visits in the normotensive group (Table 
50). The candidate had significant input into the design of the normotensive arm of the 
study, the assessment schedule after the study extension, and the protocol for study 
closeout. The candidate created the relational database and was responsible for the 
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management of all data from the Newcastle Cognitive Substudy and other related 
substudies at the Newcastle site. The candidate performed and interpreted the factor 
analyses. In consultation with Prof. Gary Ford and Prof. John Matthews, the plan for 
statistical analysis was devised and all analyses carried out and reported by the 
candidate. The candidate disseminated the study findings at regional, national and 
international meetings. The candidate led the development of first-authored 
manuscripts for submission to peer-reviewed journals, including analysis and 
interpretation. Where co-author, the candidate provided datasets from the relational 
database for analysis, and contributed significantly to the interpretation and 
intellectual content of the manuscripts.  
2.2.8.3 Data management 
All data from the Newcastle Cognitive Substudy were entered into an in-house 
relational database created using Microsoft Access v.2.0, subsequently updated to 
Access 2000. Data from the CRFs of the main SCOPE trial relevant to the substudy 
(e.g. BP measurements) were entered independently by members of the substudy 
research team after the CRFs had been monitored by AstraZeneca.  
Two methods were used to verify the integrity of the data and reduce transcription 
errors: exploratory data analysis and double data entry 70. Range checks were 
performed on the data fields of physiological variables to ensure that all values were 
clinically plausible. All outliers were verified/corrected by referring to the CRF and 
handwritten clinic source notes. Two-person double data entry was performed by 
creating a dummy database into which all data for a 10% random sample were 
entered. Numeric data fields were compared between the master and dummy 
databases using an automated procedure to highlight discrepancies. Text fields were 
compared manually as judgement was needed to determine whether discrepancies 
were meaningful (e.g. mistyping hypertensive instead of hypotensive) or ignorable 
(i.e. differences in punctuation, use of abbreviations). Subsequent 10% samples were 
entered until a ‘clean’ iteration was achieved where no transcription errors were 
detected in any fields involved in the statistical analyses. This was achieved at the 
second iteration.  
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2.2.8.4 Randomisation code break 
All data relating to the hypertensive groups were entered and checked, and the 
database locked before the randomisation codes were received from the AstraZeneca 
Coordinating Centre. Due to the overlapping follow-up period, data collection was 
ongoing for the normotensive group at the time of the code break. The normotensive 
database was locked before the statistical analyses involving the data were performed. 
2.3 Variable reduction 
2.3.1 Rationale 
The battery of tests used to assess cognitive function in the substudy was designed to 
be as comprehensive as possible. However, as the majority of subtests produced both 
an accuracy and a speed score, this resulted in 22 variables as possible outcome 
measures. Analysis of a large number of outcome variables with repeated statistical 
testing presented the problem of an increased risk of making Type I errors – accepting 
statistically significant differences that have occurred by chance which do not actually 
exist in the population. A number of methods were considered to avoid such errors. 
One option was to select a small number of subtests for analysis based on a priori 
hypotheses. However, the substudy was designed to be as comprehensive as possible 
in the range of cognitive function assessed. In particular the profile of cognitive 
function was of interest, as some areas of cognition are known to be more susceptible 
and show decline earlier than others, allowing differential effects of treatment on 
cognition to be examined. The wide variation in measures used in previous studies 
made it difficult to determine which subtests were more likely to show an effect. Even 
if this were possible, the selection of only those subtests most likely to show 
significant effects would not have been desirable as the areas of cognition not affected 
by treatment were also of interest. Also, as subtests from the CDR battery are timed, 
the analysis of reaction times and accuracy scores from the same test would enable 
speed/accuracy trade-offs to be ruled out as the cause of any effect. 
A second option was to use the Bonferroni adjustment to the statistical tests which 
applies more stringent criteria for statistical significance than p<0.05 based on the 
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number of statistical anlyses performed. Although this would decrease the risk of 
Type I errors, such a procedure has a corollary of the inevitable increase in the risk of 
a Type II error, accepting the null hypothesis when differences do actually exist. The 
consequences of both types of error need to be considered. There is also some debate 
as to the applicability of Bonferroni adjustments to research data with the suggestion 
that it is most appropriate for repeated analyses on the same data 71, as opposed to 
repeated analyses using the same statistical test on different data 72.  The question as 
to what extent the family-wide adjustment should be made has also been raised, with 
the recommendation that statistical significant alone not be relied upon, but that the 
magnitude of effects and quality of the research also be taken into consideration 73. 
The use of factor analytic techniques has been proposed as a means to produce a 
smaller number of cognitive domains for analyses of data with respect to cognitive 
functioning and hypertension 74. Previous studies have demonstrated the utility of the 
approach with neuropsychological measures alone 29, and in combination with 
information-processing paradigms 75, 76. Using data from the Framingham Heart 
Study, Elias and colleagues explored the factor structure of the Kaplan-Albert Battery 
supporting the reduction of variables into two factors 26. The factor structure of the 
CDR system has previously been demonstrated in a large sample of healthy middle-
aged volunteers 77. Thus factor analysis provided a method for reducing the number of 
outcome variables in a meaningful way to reduce the risk of Type I error. 
2.3.2 Factor analysis  
2.3.2.1 Theoretical basis 
Factor analysis refers to a number of statistical techniques that provide a method of 
simplifying complex datasets. By examining the correlation coefficients between the 
variables in a correlation matrix, the interrelationships are condensed into a simplified 
and more understandable form. Factor analysis is particularly useful where there is a 
good a priori reason to believe that variables will be correlated. With the cognitive 
data in the Newcastle Cognitive Substudy, such correlations were likely. Although 
speed of response on a memory task may be independent of speed on an attention task 
to some extent, a certain amount of common variance would be expected i.e. due to 
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the shared physiological processes involved in responding quickly. The 22 variables 
produced from the cognitive tests resulted in a matrix of 242 unique correlations 
which would be impossible to interpret fully without some form of simplification. 
Factor analysis often reveals that a large number of correlations can be accounted for 
by a smaller number of factors. Each factor is a construct which represents the 
relationships between a set of variables. The meaning of the factor must then be 
interpreted or deduced from the factor loadings – the correlations of the variables with 
the factors – in essence, the factor is defined by the variables that make up that factor.  
2.3.2.2 Principal components analysis (PCA) 
Principal components analysis is a specific method of factor analysis that maximises 
the amount of variance accounted for by the factors. No other method of extracting 
factors yields a solution that explains more variance; it is possible with PCA to 
continue extracting components until all of the variance in the matrix is accounted for. 
However, as the purpose of the analysis is variable reduction, it is common to extract 
the fewest factors that explain the majority of the variance. The PCA method extracts 
factors in order of the variance explained which means the last few components are 
small and contribute very little. Deciding on the number of factors to accept in the 
solution is somewhat subjective, although it is common to use the Kaiser technique. 
This involves examining the eigenvalues, as these indicate the proportion of the 
variance explained by each component, and excluding components with eigenvalues 
less than one. The scree plot, a line plot of eigenvalues versus components, is also 
used as a visual guide to select the number of components up to the point that the 
slope begins to flatten (example scree plot Figure 6). Both methods are used as a guide 
but the most important criteria is that the factor solution makes sense in terms of the 
factors that emerge. It is common to examine solutions with more or less factors to 
find the one with the ‘best fit’ to the data in question after factor rotation. 
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Figure 6:  Example scree plot 
Dashed line indicates cut-off guideline of an eigenvalue of 1 
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2.3.2.3 Factor rotation 
It is an artefact of the algebra of PCA that the first factor to emerge is a general factor 
followed by a series of bipolar factors. The first factor will have many large loadings 
that will be difficult to interpret and merely reflect the mathematics by which they 
were computed. Before the factors can be interpreted, the factor solution must be 
rotated.  
The relationship of variables to factors can be represented geometrically in Euclidean 
space. Figure 7 represents the factor loadings of two variables on two factors. Variable 
A loads 0.5 on Factor 1 and 0.5 on Factor 2; variable B loads 0.6 on Factor 1 and 0.6 
on Factor 2. By rotating the axes through 30°, as shown in Figure 8, variable A now 
loads 0.68 on the new Factor 1 and 0.19 on new Factor 2, and variable B loads 0.81 
and 0.23 on the same factors.  
The proportion of variance explained by a factor for a particular variable can be 
calculated by the sum of the squared factor loadings for that variable. Table 4 shows 
the loadings and variance explained by the unrotated and rotated factors for variables 
A and B (the values in the table are approximate as they are taken manually from the 
figures and subject to rounding errors). Both solutions account for the same amount of 
variance but the rotated solution is simpler and easier to interpret.  
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Figure 7: Diagrammatic representation of factor loadings  
Figure shows two variables (A and B) on two factors in Euclidean space 
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Figure 8: Diagrammatic representation of factor rotation 
Figure shows loadings of two variables (A and B) on two factors, with axes rotated 
through 30° 
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Table 4: Factor loadings and variance explained by unrotated and rotated factors 
Variable Factor 1 Factor 2 Variance  
(Σ of squared loadings) 
% Variance 
explained 
      
A unrotated 0.5 0.5 0.25 + 0.25 50 
 rotated 0.68 0.19 0.45 + 0.04 49 
      
B unrotated 0.6 0.6 0.36 + 0.36 72 
 rotated 0.81 0.23 0.66 + 0.05 71 
 
There are two distinct methods of factor rotation with different theoretical 
underpinnings: orthogonal and oblique. With orthogonal rotation, the factors are 
rotated at right angles maintaining the axes at 90° to each other, meaning the factors 
remain uncorrelated. With oblique rotation, the factor axes can be placed in any 
position in factor space, the angle between the axes indicating the correlation between 
them. Oblique rotation has been used in psychology in the search for the underlying 
determinants of personality where it has been argued that factors are likely to be 
correlated due to shared genetic and environmental factors 78. However, as the purpose 
of the factor analysis in this study was simplification and variable reduction, 
orthogonal rotation was chosen such that within a factor the variables (cognitive 
subtests) would be as highly correlated as possible, but the factors (cognitive domains) 
themselves would be as uncorrelated as possible. 
2.3.2.4 Simple structure 
There is an almost limitless number of possible rotated solutions as every factor can 
be rotated in relation to each of the others, with each new position giving different 
loadings. The solutions are mathematically equivalent, giving no mathematical reason 
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to choose one over another. As all solutions can be seen as possible explanations for 
the observed correlations, Occam’s razor dictates that the most parsimonious solution 
be accepted. Therefore the objective of factor rotation is to rotate to simple structure. 
The following criteria for simple structure were proposed by Thurstone (1947) 79: 
1. Each row of the loading matrix should contain at least one zero 
2. Each column should contain as least as many zeros as there are factors 
3. For each pair of factors there should be variables with high loadings on one 
and zero loadings on the other 
4. For each pair of factors a large number of loadings should be zero 
5. For each pair of factors few variables should have high loadings on both 
factors 
In practice, the criteria are very strict and hard to obtain, although the aim of achieving 
simple structure remains. The main importance is that each factor has a few high 
loadings with the remaining loadings being as close to zero as possible. The closer to 
simple structure a solution is the better, as this will make it easier to interpret and 
replicable. The lack of reproduceability of solutions is a criticism of factor analysis 
that can be countered when robust simple structure solutions are produced. 
2.3.2.5 Varimax rotation 
Factor rotation can be performed graphically by hand and to do so is useful for 
understanding the data and the process involved. However, it is time-consuming to 
select the simplest solution and quickly becomes complicated when more than two 
factors are involved. Common statistical packages include analytic routines that 
perform the calculations. The Varimax procedure with Kaiser normalization is an 
orthogonal rotation method that aims at achieving simple structure, maintaining the 
uncorrelated status between factors. It is generally recognised as the most efficient 
procedure and is often used in conjunction with PCA.  
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2.3.2.6 Summary 
In order to identify statistically independent domains of cognitive function, PCA with 
Varimax rotation was chosen as the appropriate factor analytic method, with the aim 
of achieving simple structure by examining various factor solutions. The analyses 
were performed using SPSS v.10. 
2.3.3 Factor analysis dataset 
Cognitive data from the baseline assessments of the hypertensive and normotensive 
cohorts were used as the basis for the factor analysis. Speed and accuracy scores from 
the CDR subtests provided a total of 18 variables for analysis, and the 4 traditional 
neuropsychological tests each provided a further variable. The characteristics of the 
cognitive variables are detailed in Appendix VIII. PCA with varimax rotation was 
performed on the 22 variables from 506 participants, giving a participant to variable 
ratio of 23:1. The recommended minimum in the literature is a 5:1 ratio and a sample 
size of at least 100, although it is generally accepted that a ratio of 10:1 and a sample 
of 200 is more satisfactory 80. 
2.3.4 Composite factor scores 
Following the results of the factor analysis (described in chapter 4), the individual 
subtest scores were combined into composite factor scores. The composite scores 
were calculated by summing unweighted subtest scores with primary loadings on each 
factor 81, with two exceptions: picture recognition accuracy was included in the 
Episodic Memory factor; spatial memory accuracy was included in the Working 
Memory factor to maintain a theoretically meaningful basis to the composite scores. 
To enable the addition of timed and numerical data, the subtests contributing to the 
Executive Function factor were first transformed into z scores. As the Speed of 
Cognition factor consisted of reaction times, scores were transformed by multiplying 
by –1 to provide consistency with the other factors based on accuracy scores, such that 
a higher score indicated better performance in all cases.  
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2.4 Measure of cognitive decline 
2.4.1 Rationale 
Cognitive decline represents the change in cognitive function over time and was 
subject to serial assessment. As such, the cognitive data could be thought of as 
representing a growth curve with the rate of decline being the variable of interest. 
Analysis of the data based simply on a pre-post comparison would not utilise the 
wealth of data provided by the serial measurements. Likewise, the common technique 
of analysing sequential measurements at each time point was also inappropriate as it 
would fail to take account of the fact that the measurements at each visit were related 
to the same participant and therefore highly correlated. Thus, the analysis could show 
at one time point the difference between groups as non-significant, but at the next time 
point indicate a significant effect, the distinction being somewhat artificial. These 
problems were overcome by calculating summary measures of decline using the 
method proposed by Matthews and colleagues 82, and employed in the MRC 
Hypertension Trial 44. The slope of the regression line fitted to an individual’s data 
was used to give a suitable estimate of decline over time. The method is particularly 
useful for dealing with missing data points as the slope can be estimated by the data 
points either side, and when the exact timing of assessments is variable, such as the 
variation in follow-up length due to the duration of the recruitment period. An 
example is shown in Figure 9. 
2.4.2 Derivation of summary measures 
The summary measures were calculated as the slope of the regression line derived by 
regressing composite factor scores at each visit on time of assessment (months since 
baseline) for each participant on each of the five cognitive factors. The resultant 
coefficients of decline were used as the main outcome variables of cognitive change. 
Regression values were calculated in all cases where data from 2 or more assessments 
were available a minimum of 12 months apart. As the 1 month and 6-weeks post-
closeout cognitive assessments were performed primarily to assess acute drug effects 
and did not involve the traditional neuropsychological tests, data from these visits 
were not included in the regression calculations. 
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Figure 9: Example regression plot  
Example regression plot of Speed of Cognition regressed against time of assessment (months from baseline). Higher values indicate worse 
performance. 
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2.5 Statistical analyses 
The plan for analysis was developed and finalised before the study randomisation 
code was broken to ensure impartiality. All analyses were performed using SPSS v 
10.0 for Windows. Significance was set at p<0.05. 
2.5.1 Practice effects 
A subset of hypertensive participants performed the CDR battery twice before their 
baseline visit to assess the influence of practice effects on the baseline data. Repeated 
measure general linear models were used to compare performance between 3 
consecutive test sessions to determine the optimum number of training sessions 
required. 
2.5.2 Tests of equivalence 
Independent samples t-tests and chi-squared tests were used for interval and 
categorical data respectively. 
The baseline characteristics of the hypertensive participants in the Newcastle 
Cognitive Substudy were compared to those reported by the main SCOPE trial 83 to 
demonstrate how representative the substudy sample was.  
The candesartan and placebo groups were compared on the following variables at 
baseline to confirm the adequacy of the randomisation procedure: age; gender; NART 
errors (as an estimate of pre-morbid IQ); years in education; MMSE score; systolic 
and diastolic blood pressure; smoking status; and antihypertensive medication status 
(taking HCTZ at baseline or not).  
The hypertensive and normotensive participants in the Newcastle Cognitive Substudy 
were compared to demonstrate how well matched the two groups were on 
characteristics other than BP.  
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2.5.3 Primary analysis 
The primary analysis compared the rate of cognitive decline between the candesartan 
and placebo groups. Analysis was performed on an intent-to-treat basis; all available 
data from all randomised participants were included. The univariate general linear 
model procedure was used to compare decline on each factor between the two groups, 
controlling for age, estimated pre-morbid IQ and baseline cognitive function as 
covariates. In the event that the groups differed as a result of the tests of equivalence, 
the variable in question was entered as a covariate.  
2.5.3.1 Effect sizes 
Effect sizes of the primary analysis of candesartan over placebo were calculated as 
Cohen’s D using the pooled standard deviation according to the formula:  
D = (mean1-mean2)/(pooled SD) 
where the pooled SD = √ ((SD1² + SD2²) / 2) 
Cohen’s D is the standardised difference between groups and can be conceptualised as 
the number of standard deviations separating the two groups when the pooled SD is 
used. For interpretation, the generally-accepted conventions of effect size were used: 
0.2 = small effect; 0.5 = medium effect; 0.8 = large effect. Effect sizes were computed 
so that negative values represented relative decline and positive values represented 
relative improvement. 
2.5.4 Secondary analyses 
2.5.4.1 Efficacy analysis 
An efficacy (on treatment) analysis was performed. Data from participants who 
continued with the study medication until the end of the study constituted the 
evaluable subset. The statistical methods were the same as those for the primary 
analysis.  
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2.5.4.2 Efficacy subset versus the remainder ITT participants 
Unplanned post-hoc analyses were performed to compare the characteristics of the 
efficacy subset with the remainder of the participants with calculable coefficients of 
decline. 
2.5.4.3 Loss to follow-up 
T-tests and chi-squared tests were used to compare the baseline characteristics of 
participants included in the primary analysis and participants lost to follow-up. The 
chi-squared test was used to check for any systematic differences in the distribution of 
loss to follow-up between the candesartan and placebo groups.  
2.5.4.4 Excluding participants suffering stroke 
As stroke is known to adversely affect cognitive function, the primary analysis was 
repeated excluding participants suffering a stroke during the study. Comparison of the 
baseline characteristics of participants suffering stroke versus participants remaining 
stroke-free was made using t-tests and chi-squared tests. 
2.5.4.5 Excluding participants taking beta-blockers 
As there is evidence to suggest that beta-blockers can adversely affect cognitive 
function, the primary analysis was repeated excluding participants taking beta-
blockers at any time after randomisation. Comparison of the baseline characteristics of 
participants receiving beta-blockers versus participants remaining free of beta-
blockers was made using t-tests and chi-squared tests. 
2.5.4.6 Acute drug effects 
Assessment of cognitive function was performed at the 1 month visit using the CDR 
computerised battery; tests of executive function were not administered because of 
anticipated learning effects. Data from this visit were used to examine acute effects of 
the study medication on cognition. Comparison between the candesartan and placebo 
groups on the change from baseline scores was made using independent t-tests. 
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2.5.5 Normotensive comparison 
The primary analysis was repeated with the inclusion of data from the normotensive 
group to place the magnitude of any treatment effects in the context of normal ageing 
and decline. The univariate general linear model procedure was used to compare 
decline on each factor between the three groups, controlling for age, estimated pre-
morbid IQ and baseline cognitive function as covariates. Where the F test was 
significant at the .05 level, pairwise comparisons were made using the Least Squared 
Difference (equivalent to no adjustment for multiple comparisons). 
2.5.5.1 Effect sizes 
Effect sizes for candesartan and placebo in comparison to the normative control group 
were calculated as Glass’s Delta using the standard deviation of the normotensive 
group according to the formula:  
D = (mean1-mean2)/(normotensive group SD) 
Glass’s Delta can be conceptualised as the number of standard deviations separating 
the treatment group from the normative reference group. For interpretation, the 
generally-accepted conventions of effect size were used: 0.2 = small effect; 0.5 = 
medium effect; 0.8 = large effect. Effect sizes were computed so that negative values 
represented relative decline and positive values represented relative improvement. 
2.5.6 Exploratory analyses: blood pressure as a continuous variable 
Due to the lowering of the BP treatment target to <150/90 mmHg according to British 
Hypertension Society guidelines released during the study, the expected SBP gap of 
approximately 10 mmHg between the hypertensive and normotensive groups was no 
longer maintained. Therefore, although there were differences in the group means, 
there was overlap between groups in the distribution of average SBP over the course 
of the study. As such, BP could be considered a continuous variable regardless of the 
original group allocation. The association between average BP over the course of the 
study and rate of cognitive decline was assessed using partial correlations, performed 
on the hypertensive and normotensive data combined, controlling for factors known to 
affect cognitive function (age, estimated pre-morbid IQ and baseline cognitive 
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function). Pearson correlations were used, with two-tailed significance tested at the 
0.05 level. 
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CHAPTER 3: RESULTS – BASELINE DATA 
This chapter presents the baseline data from the Newcastle Cognitive Substudy, for 
the hypertensive group in comparison to the main SCOPE cohort, and in comparison 
to the normotensive controls. The baseline equivalence of the candesartan and placebo 
groups is detailed. The analysis of practice effects is also presented. 
3.1 Recruitment 
A total of 8593 patient records were screened by study research nurses to identify 
potentially eligible individuals for the main SCOPE trial. A further 1143 patient 
records were screened in the second wave of case note screening to identify 
potentially eligible normotensive individuals. The flow of participants through the 
recruitment process is shown in Figure 10. Of the 1256 individuals that attended the 
research clinic for the initial screening visit, 563 did not meet the inclusion criteria. 
Data regarding the characteristics of the ineligible individuals were not available as 
informed consent, and therefore permission to use such data, was only obtained at the 
initial screening visit when the criteria for enrolment were met. Of the 378 enrolled 
hypertensive participants, 121 were withdrawn before randomisation primarily 
because study BP criteria were not met. Other reasons for withdrawal after enrolment 
included concerns about study side-effects, reluctance to change current 
antihypertensive therapy to HCTZ, and the long-term commitment required. As the 
consent form stated that participants were free to withdraw from the study at any time 
without giving an explanation, reasons for withdrawal were not formally recorded.  
The proportion of potentially eligible participants indicating an interest in the study 
and attending the screening clinic was approximately a third for both the hypertensive 
and normotensive groups. As expected, the proportion that failed to meet the inclusion 
criteria at the initial screening visit was greater for the hypertensive group than the 
normotensive group (53% vs. 31%), due to the more restrictive hypertensive BP 
criteria. Similarly, a lower proportion of normotensive individuals withdrew between 
the enrolment and baseline/ randomisation visits. As a reason for withdrawal was not 
required, the cause of differential dropout rates between the groups is not known 
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although the exclusion of hypertensive individuals with white-coat hypertension could 
account for a higher rate in this group. In addition, it is possible that in individuals 
meeting the study criteria, voluntary withdrawal was lower for normotensive 
participants due to the non-intervention nature of the observational control group. 
Of the 257 hypertensives recruited to the main SCOPE study, 4 participants declined 
to enter the Newcastle Cognitive Substudy. Three participants agreed to participate 
but were unable to attend the baseline cognitive assessment portion of the 
randomisation visit due to personal time commitments, and were therefore withdrawn 
from the substudy. As normotensive individuals were recruited to the substudy only, 
all 256 participants were included. 
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Figure 10: Recruitment to the SCOPE trial and Newcastle Cognitive Substudy 
 
3.2 Hypertensive participants 
The baseline characteristics of the hypertensive participants in the Newcastle 
Cognitive Substudy are shown in Table 5. The Newcastle sample represents 29% of 
the 883 participants recruited in the UK, and 5% of all participants in the SCOPE trial. 
All participants were Caucasian. 
3.2.1 Comparison with the SCOPE cohort 
Comparison with the baseline characteristics of the main SCOPE cohort 83 in Table 5 
shows that the Newcastle cohort was similar in terms of mean age, BP levels, MMSE 
score and the prevalence of previous stroke and atrial fibrillation. The mean age of 76 
years reflects the predominance of participants in the younger age group of 70-79 
years, with one in five participants aged 80 or over in both the Newcastle Cognitive 
Substudy (Figure 11) and the main SCOPE cohort (Figure 12). The distributions of 
SBP, DBP and MMSE score at randomisation were also similar (Figures 13-16). 
 
 potentially eligible participants 
did not reply  
replied 'yes' & seen in research clinic  
did not meet inclusion criteria  
enrolled in study  
withdrew during run-in phase  
completed baseline visit (% of potentially eligible) 
969 (41%) 502 (39%) replied 'not interested' 
611 (26%)  317 (25%) 
798 (33%)  458 (36%) 
420 (53%)  143 (31%) 
378 (47%)  315 (69%) 
121 (32%)  59 (19%) 
257 (10.8%)  256 (20.0%) 
2378 1277 
Hypertensives Normotensive
s 
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Table 5: Baseline characteristics of hypertensive participants 
Data shown are means or percentages.  
 Newcastle 
Cognitive Substudy  
hypertensives 
SCOPE trial 
participants  
 n=250 n=4964 
 
Age, years 
 
76 
 
76 
Females 53% 64% 
MMSE score 29 28 
SBP mmHg 165 166 
DBP mmHg 88 90 
Smokers 15% 9% 
Treated at enrolment with: 
 HCTZ 27% 52% 
 NSAIDs / aspirin 32% 22% 
 Psychotropic drugs 14% 8% 
Previous MI 8% 4% 
Previous stroke 4% 4% 
Atrial fibrillation 4% 4% 
 
MMSE = Mini-Mental State Examination; SBP = systolic blood pressure; DBP = 
diastolic blood pressure; HCTZ = hydrochlorothiazide; NSAIDs = non-steroidal anti-
inflammatory drugs; MI = myocardial infarction.  
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Figure 11: Age distribution at baseline: NCS 
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Figure 12: Age distribution at baseline: main SCOPE study  
0
5
10
15
20
25
30
35
40
45
50
70-74 75-79 80-84 85-90
Age (years)
F
re
q
u
e
n
c
y
 %
 
 
 89 
Figure 13: Distribution of SBP at baseline: NCS 
Distribution of baseline systolic blood pressure (SBP) at baseline of participants in the 
Newcastle Cognitive Substudy (n=250) 
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Figure 14: Distribution of SBP at baseline: main SCOPE study 
Distribution of systolic blood pressure (SBP) at baseline of participants in the main 
SCOPE study (n=4964) 
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Figure 15: Distribution of DBP at baseline: NCS  
Distribution of diastolic blood pressure (DBP) at baseline of participants in the 
Newcastle Cognitive Substudy (n=250) 
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Figure 16: Distribution of DBP at baseline: main SCOPE study 
Distribution of diastolic blood pressure (DBP) at baseline of participants in the main 
SCOPE study (n=4964) 
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Figure 17: Distribution of MMSE at baseline: NCS  
Distribution of Mini-Mental State Examination score (MMSE) at baseline of 
participants in the Newcastle Cognitive Substudy (n=250) 
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Figure 18: Distribution of MMSE at baseline: main SCOPE study  
Distribution of Mini-Mental State Examination score (MMSE) at baseline of 
participants in the main SCOPE study (n=4964 
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The 1:1 ratio of males to females in the Newcastle sample was significantly higher 
than the ratio of approximately 1:2 in the main SCOPE cohort (χ2 = 13.33; df =1; 
p<.001). The proportion of smokers (15% vs. 9%; χ2 = 8.80; df =1; p<.01) and 
participants with a history of myocardial infarction (8% vs. 4%; χ2 = 8.04; df =1; 
p<.01) was higher, and the percentage receiving antihypertensive therapy (27% vs. 
52%; χ2 = 72.42; df =1; p<.001) was significantly lower in the Newcastle cohort 
compared to the SCOPE cohort. As the raw data from the main SCOPE trial were 
unavailable, more detailed statistical analysis was not possible. Comparison with the 
rest of the UK sample would have indicated whether the differences were attributable 
to some aspect of recruitment at the Newcastle centre, or whether they reflected the 
characteristics of the UK population as a whole.  
3.3 Normotensive participants 
The baseline characteristics of the normotensive participants in the Newcastle 
Cognitive Substudy are shown in Table 6. All participants were Caucasian. 
3.3.1 Comparison with hypertensive participants 
Comparison of the hypertensive and normotensive cohorts in Table 6 shows that the 
groups were well matched for demographic characteristics known to affect cognitive 
function such as age, years in education and MMSE score. Within groups there was an 
approximate 1:1 ratio of males to females, although comparison between groups 
showed that the proportion of males was slightly higher in the normotensive group. 
The prevalence of previous MI and stroke was higher in the hypertensive group as 
expected, given the established relationship between hypertension and cardiovascular 
disease. The use of NSAIDS/aspirin was also higher; the prescription of aspirin in 
particular may have been associated with participants’ hypertensive status and medical 
history. Psychotropic medication use was also higher in the hypertensive group, 
although the reason for this is not clear. However, the inclusion criteria for both 
groups stated that any pharmacological treatment could not have been initiated within 
the preceding six months to baseline, ensuring that participants were stable on their 
medication before entry into the study. 
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Table 6: Baseline demographic characteristics of the normotensive participants 
Data shown are mean and (SD), or percentages.  
 Hypertensive Normotensive p 
 n=250 n=256  
 
Age, years 
 
76 (4) 
 
76 (5) 
 
.82 
Females 53% 44% .04 
Education, years 10 (2) 10 (2) .73 
MMSE score 29 (1) 29 (1) .59 
SBP mmHg 165 (8) 131 (11) <.001 
DBP mmHg 88 (7) 73 (7) <.001 
Smokers 15% 16% .64 
Treated at enrolment with: 
 HCTZ 27% n/a n/a 
 NSAIDs / aspirin 32% 16% <.001 
 Psychotropic drugs 14% 6% <.01 
Previous MI 8% 4% .05 
Previous stroke 4% 1% .04 
Atrial fibrillation 4% 2% .18 
 
MMSE = Mini-Mental State Examination; SBP = systolic blood pressure; DBP = 
diastolic blood pressure; HCTZ = hydrochlorothiazide; NSAIDs = non-steroidal anti-
inflammatory drugs; MI = myocardial infarction. 
 94 
Cognitive function subtests: hypertensive vs. normotensives 
Comparison of baseline cognitive function between the hypertensive and 
normotensive groups on the subtests of the CDR battery and traditional 
neuropsychological tests of executive function is shown in Table 7. The hypertensive 
participants performed significantly worse than the normotensives on the majority of 
subtests from the cognitive battery, with the exception of immediate word recognition, 
number vigilance reaction time, choice reaction time accuracy and numeric working 
memory accuracy. The differences existed despite the groups being well-matched on 
baseline demographic characteristics. However, the hypertensive group had a higher 
prevalence of previous cardiovascular and cerebrovascular disease, as well as a higher 
rate of psychotropic medication and prior BP-lowering medication use, which may 
have accounted for the differences in cognitive function between the groups.  
3.3.2 Excluding factors that may affect cognition 
Previous work undertaken by Dr. Frances Harrington had already focussed on group 
differences in the baseline data from the Newcastle Cognitive Substudy 84. The 
analysis compared hypertensive and normotensive participants, excluding those with 
clinical evidence or history of cardiovascular/ cerebrovascular disease, or taking BP-
lowering or psychotropic medication, to provide a sample that differed only in relation 
to BP level. A very similar pattern of subtle deficits was found with hypertensives 
performing worse than normotensives on the majority of subtests reported. Thus it 
was possible to exclude the influence of psychotropic medication, BP-lowering 
medication, and medical history variables as the cause of the observed group 
differences at baseline. 
The group differences in cognitive function were expected as previous cross-sectional 
studies of well-matched groups have generally shown hypertensives to exhibit subtle 
deficits on a variety of cognitive measures. As baseline cognition has also been shown 
to be predictive of future performance and subsequent cognitive decline, the presence 
of subtle deficits in the hypertensive group supported the a priori inclusion of baseline 
cognition as a covariate in the general linear model used to analyse the effects of 
treatment (as detailed in section 2.5.2). 
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Table 7: Comparison of baseline performance on the cognitive subtests 
Accuracy (acc) scores shown are %, where a higher score indicates better 
performance; reaction times (RT) shown are milliseconds, where a lower score 
indicates better performance.  
Data shown are mean and (SD) 
Subtest Hypertensive Normotensive t p 
 n=250 n=256   
       
Immediate word recognition acc 88.5 (11.8) 89.1 (9.9) -.56 .57 
Immediate word recognition RT 950 (227) 904 (198) 2.4 .02 
Simple reaction time RT 358 (113) 322 (60) 4.5 <.001 
Number vigilance acc 99.1 (2.7) 99.8 (1.2) -3.8 <.001 
Number vigilance RT 460 (58) 454 (55) 1.2 .25 
Choice reaction time acc  96.2 (3.7) 96.0 (3.8) .59 .55 
Choice reaction time RT 520 (82) 503 (75) 2.3 .02 
Spatial memory acc 63.7 (31.5) 75.6 (23.7) -4.8 <.001 
Spatial memory RT 1434 (487) 1302 (468) 3.1 .002 
Numeric working memory acc 94.3 (11.7) 95.8 (7.7) -1.7 .10 
Numeric working memory RT 875 (319) 812 (192) 2.7 .007 
Delayed word recognition acc 82.6 (16.5) 86.8 (10.6) -3.3 .001 
Delayed word recognition RT 933 (229) 880 (207) 2.7 .007 
Delayed picture recognition acc 86.0 (14.3) 88.8 (10.9) -2.5 .012 
Delayed picture recognition RT 983 (207) 912 (166) 4.3 <.001 
Immediate word recall # 4.8 (1.7) 5.1 (1.7) -2.1 .03 
Delayed word recall # 2.9 (2.2) 3.3 (2.2) -2.0 .03 
Trail-Making Test form A (secs) 53 (22) 47 (18) 3.2 .001 
Trail-Making Test form B (secs) 147 (70) 127 (62) 3.6 .001 
Verbal fluency (animals) # 15 (5) 16 (4) -2.4 .02 
Verbal fluency (FAS) # 35 (12) 40 (13) -4.7 <.001 
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3.4 Tests of equivalence: candesartan group vs placebo group 
3.5.1 Demographics and medical history 
The baseline demographic characteristics of hypertensive participants in the 
Newcastle Cognitive Substudy randomised to the candesartan group and placebo 
group are shown in Table 8. The groups were very closely matched on all variables 
both in terms of means and standard deviations, with no significant differences on any 
variables, confirming the adequacy of the randomisation procedure performed by the 
SCOPE Coordinating Centre as part of the main SCOPE trial.  
3.5.2 Baseline cognitive function – subtests 
The candesartan and placebo groups were also compared on baseline cognitive 
performance on the subtests of the CDR battery and traditional tests of executive 
function, as shown in Table 9. The randomisation procedure (described in section 
2.1.5.3) was determined by the main SCOPE protocol, and as the detailed cognitive 
assessments were only undertaken in the Newcastle Cognitive Substudy, performance 
on the cognitive function subtests was not included as a prognostic factor in the 
randomised procedure. However, there was very little difference in the performance of 
the candesartan and placebo groups, with only the immediate word recall subtest 
reaching the significance level of p<.05. As baseline cognitive performance was 
entered into the general linear model as a covariate, small differences on individual 
subtests at baseline were unlikely to affect the comparison between the groups on 
rates of decline over time.  
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Table 8: Baseline demographics of candesartan versus placebo groups 
Data shown are mean and (SD), or percentages.  
 Candesartan Placebo p 
 n=124 n=126  
 
Age, years 
 
76 (5) 
 
76 (5) 
 
.46 
Females 53% 53% .99 
Education, years 10 (2) 10 (2) .72 
MMSE score 29 (1) 29 (1) .23 
SBP mmHg 165 (8) 165 (9) .92 
DBP mmHg 88 (7) 88 (7) .20 
Smokers 13% 16% .50 
Treated at enrolment with: 
 HCTZ 27% 27% .94 
 NSAIDs / aspirin 31% 33% .75 
 Psychotropic drugs 13% 14% .89 
Previous MI 11% 5% .09 
Previous stroke 5% 2% .30 
Atrial fibrillation 3% 6% .37 
 
MMSE = Mini-Mental State Examination; SBP = systolic blood pressure; DBP = 
diastolic blood pressure; HCTZ = hydrochlorothiazide; NSAIDs = non-steroidal anti-
inflammatory drugs; MI = myocardial infarction.  
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Table 9: Baseline cognitive performance: candesartan vs placebo groups.  
Accuracy (acc) scores shown are %, where a higher score indicates better 
performance; reaction times (RT) shown are milliseconds, where a lower score 
indicates better performance.   
Data shown are mean and (SD) 
Subtest Candesartan Placebo t p 
 n=124 n=126   
       
Immediate word recognition acc 88.6 (10.5) 88.5 (13.0) .09 .93 
Immediate word recognition RT 944 (207) 956 (245) -.44 .66 
Simple reaction time RT 346 (74) 370 (141) -1.7 .10 
Number vigilance acc 99.1 (2.6) 99.2 (2.8) -.20 .84 
Number vigilance RT 460 (61) 459 (56) .25 .80 
Choice reaction time acc  95.8 (3.8) 96.7 (3.6) -2.0 .05 
Choice reaction time RT 512 (68) 527 (94) -1.5 .14 
Spatial memory acc 62.4 (30.2) 65.0 (32.8) -.65 .52 
Spatial memory RT 1443 (524) 1426 (449) .27 .78 
Numeric working memory acc 93.0 (12.6) 95.6 (9.8) -1.9 .06 
Numeric working memory RT 902 (402) 848 (206) 1.3 .18 
Delayed word recognition acc 83.0 (15.5) 82.3 (17.5) .30 .77 
Delayed word recognition RT 926 (192) 941 (260) -.51 .61 
Delayed picture recognition acc 86.1 (14.6) 85.8 (14.0) .17 .86 
Delayed picture recognition RT 982 (212) 983 (202) -.03 .98 
Immediate word recall # 4.5 (1.6) 5.1 (1.8) -2.5 .01 
Delayed word recall # 2.5 (2.2) 3.2 (2.2) -2.0 .05 
Trail-Making Test form A (secs) 53 (20) 52 (23) .10 .92 
Trail-Making Test form B (secs) 152 (74) 143 (66) .94 .35 
Verbal fluency (animals) # 15 (4) 15 (5) -.51 .61 
Verbal fluency (FAS) # 34 (13) 36 (12) -.98 .33 
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3.5.3 Baseline cognitive function – composite factor scores 
The factor analyses (described in chapter 4) were designed to reduce the number of 
possible outcome variables, and the results produced a method of combining the 
cognitive subtest scores into composite factor scores in a meaningful way. As decline 
on the composite factor scores was the primary outcome measure, cognitive 
performance defined by the factor scores was compared between the randomised 
groups to test for equivalence at baseline, as shown in Table 10. As there was very 
little difference between the groups on the individual subtests that contributed to the 
composite factor scores, as expected the results showed no significant differences in 
baseline cognitive function defined by the composite factor scores.  
 
Table 10: Baseline composite cognitive factors: candesartan vs placebo groups  
A higher score indicates better performance except for Speed of Cognition, where a 
lower score indicates better performance.  
Data shown are mean and (SD) 
Factor Candesartan Placebo t p 
 n=124 n=126   
       
Speed of Cognition 6515 (1404) 6510 (1235) .03 .98 
Continuity of Attention 92.0 (2.7) 92.5 (2.9) -1.4 .17 
Episodic Memory 217 (51) 230 (53) -1.7 .09 
Working Memory 1.55 (0.34) 1.61 (0.36) -1.2 .23 
Executive Function  1.06 (2.99) 1.41 (3.28) -.86 .39 
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3.5 Practice effects 
To determine the optimum number of training sessions required to reduce practice 
effects within the study, performance on the CDR composite scores between training 
session 1 and 2, and baseline were compared in a subset (n=49) of hypertensives who 
underwent two training sessions before their baseline assessment (Table 11). The 
results of training were most pronounced for Speed of Cognition (Figure 19), showing 
an improvement in reaction time scores between training session 1 and training 
session 2. Significant improvement did not occur between training session 2 and 
baseline, indicating that one training session was sufficient to reduce the effects of 
training in the study.  
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Table 11: Practice effects between training and baseline 
Difference scores between training session 1, 2 and baseline assessment in 
hypertensive participants who underwent two training sessions (n=49). A higher score 
indicates better performance except for Speed of Cognition, where a lower score 
indicates better performance.  
Data shown are mean difference and standard error 
Factor Difference: 
training 2 minus 
training 1 
p Difference: 
baseline minus 
training 2 
p 
       
Speed of Cognition -547 (112) <.001 -2 (93) .98 
Continuity of Attention 0.55 (0.41) .19 0.39 (0.40) .33 
Episodic Memory 5.5 (3.5) .13 -6.8 (3.5) .06 
Working Memory -0.02 (0.05) .63 0.05 (0.05) .32 
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Figure 19: Effects of practice on Speed of Cognition  
Speed of Cognition scores across 3 consecutive test sessions (representing training 
sessions 1, 2 and baseline assessments) in hypertensive participants who underwent 
two training sessions (n=49). A higher score indicates worse performance; a lower 
score indicates better performance. 
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CHAPTER 4: RESULTS - FACTOR ANALYSIS 
This chapter presents the results of the factor analytical methods used to investigate 
the inter-correlations of the variables from the cognitive test battery used in the 
Newcastle Cognitive Substudy, with the aim of producing a method of combining 
subtest variables into composite scores in a meaningful way.  
4.1 Principal Components Analysis (PCA) 
Baseline cognitive data from the hypertensive and normotensive participants were 
used as the basis for the factor analyses. 
4.1.1 Solution 1: all baseline data 
In the first instance, all cognitive variables (see Appendix VIII) from the hypertensive 
and normotensive groups combined were entered into the analysis. The correlation 
matrix is shown in Table 12. 
4.1.1.1 Statistical output  
The eigenvalues and variance explained by the extracted components after performing 
PCA are shown in Table 13; five components had eigenvalues greater than unity 
explaining approximately 58% of the variance. Examination of the scree plot (Figure 
20) showed that the slope began to flatten at the third component, accounting for 
approximately 47% of the variance. The scree plot and eigenvalues suggested that the 
number of components selected for rotation should be no less than three and no more 
than five, respectively. As the inclusion of components four and five accounted for an 
additional 11% of the variance, five components were selected for rotation to 
maximise the variance explained in the first solution. The unrotated component matrix 
is shown in Table 14. Varimax rotation with Kaiser normalization produced a rotated 
solution that converged after 8 iterations. The rotated five factor solution is shown in 
Table 15; for ease of interpretation, variable names are listed in full. 
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Table 12: Correlation matrix of baseline cognitive data. For variable definitions, see Appendix VIII 
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IRECALL .34 -.28 -.25 .14 -.27 -.16 .11 -.26 .31 -.24 .15 -.25 .37 -.39 .33 -.28 1.00  
DRECALL .40 -.29 -.23 .16 -.25 -.18 .18 -.23 .25 -.22 .14 -.30 .43 -.44 .33 -.31 .64 1.00  
TMTA -.12 .43 .34 -.21 .38 .09 -.13 .44 -.24 .31 -.07 .44 -.15 .38 -.24 .41 -.27 -.29 1.00 
TMTB -.15 .52 .44 -.20 .41 .13 -.12 .54 -.30 .43 -.12 .56 -.17 .48 -.32 .50 -.40 -.40 .66 1.00
VF_Animals .16 -.39 -.38 .18 -.40 -.09 .08 -.42 .22 -.25 .12 -.33 .17 -.36 .20 -.34 .34 .35 -.32 -.39 1.00
VF_FAS .19 -.28 -.29 .12 -.33 -.05 .11 -.30 .18 -.21 .14 -.29 .22 -.30 .27 -.24 .30 .36 -.35 -.36 .43 1.00
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Table 13: Eigenvalue and variance of components: solution 1 
hypertensives and normotensives using all cognitive variables 
 
7.079 32.177 32.177
2.075 9.433 41.610
1.291 5.870 47.481
1.229 5.588 53.069
1.060 4.817 57.886
.988 4.493 62.379
.927 4.214 66.592
.888 4.036 70.629
.776 3.527 74.156
.715 3.250 77.406
.679 3.086 80.492
.644 2.929 83.421
.548 2.489 85.910
.526 2.392 88.302
.471 2.140 90.442
.389 1.769 92.211
.364 1.654 93.865
.330 1.499 95.364
.318 1.445 96.810
.258 1.174 97.984
.239 1.086 99.070
.205 .930 100.000
Component
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
Total
% of
Variance
Cumulative
%
Initial Eigenvalues
Extraction Method: Principal Component Analysis.
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Figure 20: Scree plot from PCA for solution 1 
Hypertensives and normotensives using all cognitive variables 
Component Number
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Table 14: Unrotated component matrix for solution 1. For variable definitions, see 
Appendix VIII 
.78 .34 .02 .01 .06
.78 .28 -.03 .23 .03
.76 .12 -.28 .13 .08
.76 .27 -.17 .14 .07
.71 .23 .19 .19 -.32
.67 -.01 .19 -.29 .24
.67 .25 -.04 -.10 -.04
.63 .25 .20 .19 -.12
.62 .01 .23 -.27 .26
.62 .33 -.19 -.07 -.07
-.58 .06 -.03 .40 .05
-.55 .53 .11 .04 -.02
-.54 .17 .04 .45 .04
-.53 .49 .09 .08 .00
-.41 .37 -.05 .16 -.17
-.39 .23 -.26 .05 .07
-.43 .49 .38 -.32 .04
-.42 .46 .44 -.25 .10
-.11 .46 -.32 -.08 -.20
.18 -.22 .52 .39 .19
-.38 .09 -.34 -.39 .01
-.16 .23 -.25 .15 .82
CRT2
DPICRT
DRE2RT
DRE1RT
MSRT
TMTB
VIGRT
SPMRT
TMTA
SRT
VF_Animals
DRECALL
VF_FAS
IRECALL
DPICSI
SPMSI
DRE2SI
DRE1SI
CRT2ACC
VIGFA
VIGACC
MSSI
1 2 3 4 5
Component
Extraction Method: Principal Component Analysis.
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Table 15: Rotated component matrix for solution 1 
.81 -.14 -.17 -.15 .04
.79 -.29 -.03 -.07 .03
.78 -.18 -.22 -.01 .10
.74 -.10 -.07 -.22 -.35
.70 -.21 -.38 .03 .13
.68 -.20 -.09 .19 -.02
.67 -.11 -.01 -.25 -.16
.64 -.31 -.06 .05 -.06
.42 -.65 -.01 -.16 .08
-.22 .64 .18 -.13 .16
.39 -.62 .03 -.19 .09
-.33 .60 .09 -.08 .16
-.05 .49 .29 .18 -.03
-.14 .34 .13 .29 .21
-.15 .05 .79 .11 .01
-.15 .06 .79 .01 .05
-.11 .45 .58 .17 .08
-.11 .46 .53 .14 .11
.05 -.02 -.02 -.73 .02
-.30 -.01 .12 .55 .10
.21 .25 .16 .49 -.03
.01 .10 .08 .03 .90
Picture recognition RT - DPICRT
Choice reaction time - CRT2
Immediate word recognition RT - DRE1RT
Numeric working memory RT -MSRT
Delayed word recognition RT - DRE2RT
Simple reaction time - SRT
Spatial memory RT - SPMRT
Number vigilance RT - VIGRT
Trail-making test B (time) - TMTB
Verbal fluency for letters - VF_FAS
Trail-making test A (time) TMTA
Verbal fluency for animals - VF_Animals
Delayed picture recognition acc - DPICSI
Spatial memory accuracy - SPMSI
Delayed word recognition acc - DRE2SI
Immediate word recognition acc - DRE1SI
Delayed word recall accuracy - DRECALL
Immediate word recall accuracy -  IRECALL
Number vigilance false alarms - VIGFA
Number vigilance accuracy - VIGACC
Choice reaction time accuracy - CRT2ACC
Numeric working memory accuracy - MSSI
1 2 3 4 5
Component
Extraction Method: Principal Component Analysis.  
Rotation Method: Varimax with Kaiser Normalization.
 
 
 
4.1.1.2 Simple structure 
Examination of the rotated component matrix shows that the factor solution is close to 
achieving simple structure, according to the Thurstone criteria (described in section 
2.3.2.4). Each row of the matrix contains at least one loading close to zero (<.09) 
except for three variables (verbal fluency for letters, spatial memory accuracy, 
immediate word recall accuracy) where the lowest loadings are ≤.13. Each column 
contains at least as many loadings close to zero as there are factors, with the exception 
of Factor 1 that has three loadings less than .09. In general, each factor has a few high 
loadings with the other loadings being low or close to zero, and the majority of 
variables load primarily on one factor with low loadings on other factors.  
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4.1.1.3 Interpretation 
Factors were interpreted by examining the primary loading of each variable. Factor 1 
consisted of the reaction time scores from the subtests of the CDR assessment battery. 
As the subtests are designed to measure the range of cognitive functions of attention, 
episodic memory and working memory, and the reaction time scores from these 
subtests loaded together, Factor 1 appeared to represent the time taken for an 
individual to formulate a response, labelled Speed of Cognition.  
Factor 2 consisted of the four variables from the traditional neuropsychological tests 
of executive function, with a lower loading from the delayed picture recognition 
accuracy. The loading of the traditional neuropsychological tests together suggests 
that the tests measure an aspect of cognition not covered by the CDR battery, and 
provides support for the construct validity of the tests. Therefore Factor 2 was labelled 
Executive Function.  
Factor 3 had primary loadings from the accuracy scores of the CDR subtests. This 
factor, labelled Episodic Memory, appeared to reflect the ability to recognise and 
recall information from memory independent of the time taken to do so. Interestingly, 
the immediate and delayed word recall subtests that contributed to Factor 3 also had 
secondary loadings on Factor 2, in contrast to near-zero loadings from the immediate 
and delayed word recognition tasks. As the direction of the secondary loadings were 
the same as that for the verbal fluency tests on Factor 2, the loadings perhaps represent 
some aspect of the verbalising response common to the subtests.  
Factor 4 consisted of the accuracy variables from the number vigilance and choice 
reaction time tasks that represent the ability to concentrate on the task at hand without 
making errors, thus labelled Continuity of Attention.  
Factor 5 consisted of the numeric working memory accuracy variable alone, with the 
highest loading of the rotated matrix at .90. The only other variables with notable 
loadings on Factor 5 were a secondary loading of -.35 from numeric working memory 
reaction time, showing the dissociation between speed and accuracy, and a loading of 
.21 from spatial memory accuracy. The spatial memory accuracy variable loaded 
weakly across all five factors; given the nature of the task and its demands on working 
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memory, the loading on Factor 5 would be expected to be higher. Despite having only 
one primary loading, the magnitude of the loading from numeric working memory 
accuracy suggested that Factor 5 was a valid factor, and thus labelled Working 
Memory. 
4.1.1.4 Comparison with Wesnes et al.’s (2000) solution 
The factor structure of the CDR system has previously been demonstrated in a sample 
of 272 healthy middle-aged participants 77. PCA with Varimax rotation was performed 
on 17 variables from the CDR assessment battery. The variables entered in the 
Wesnes et al. study differ slightly to those employed here: traditional 
neuropsychological tests of executive function were not administered in the Wesnes et 
al. study and data were therefore not available; data from the immediate word 
recognition subtest were not available as it is not routinely included with the CDR 
battery for middle-aged volunteers; an additional joystick tracking task was included 
in the battery by Wesnes et al. as a further measure of attention (tracking error); the 
number of stimuli was greater for the majority of subtests in the CDR battery for 
middle-aged participants than the battery used in the Newcastle Cognitive Substudy 
designed for elderly participants (e.g. word recognition, 15 vs. 12 words respectively). 
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Table 16: Factor structure from Wesnes et al. (2000) 
.80 -.16 .17 .05 .09
.77 -.30 .02 .09 .14
.74 -.10 .31 -.17 -.13
.67 .10 .16 -.23 -.37
-.12 .84 .01 .11 .11
-.17 .83 .04 -.02 .07
-.13 .69 .13 .03 -.06
.09 .50 -.19 .33 .10
.10 -.30 .81 .10 .20
.39 -.20 .68 -.16 -.11
.31 .15 .65 -.24 -.08
-.08 .04 -.06 .76 .06
.14 .16 .28 .47 .27
.10 .06 -.45 -.53 -.16
.09 .07 .26 -.62 .04
-.14 .06 .08 .15 .77
.08 .24 -.15 -.01 .73
Picture recognition RT - DPICRT
Word recognition RT - DRE2RT
Numeric working memory RT - MSRT
Spatial memory RT - SPMRT
Immediate word recall accuracy - IRECALL
Delayed word recall accuracy - DRECALL
Delayed word recognition acc - DRE2SI
Delayed picture recognition acc - DPICSI
Simple reaction time - SRT
Choice reaction time - CRT2
Number  vigilance detection RT - VIGRT
Number vigilance detection acc - VIGACC
Choice reaction time accuracy - CRT2ACC
Number vigilance false alarms - VIGFA
Tracking error
Numeric working memory acc - MSSI
Spatial memory accuracy - SPMSI
1 2 3 4 5
Component
Extraction Method: Principal Component Analysis.
 
 
Overall, the five factor solution produced here is in general agreement with the 
Wesnes et al. solution (Table 16). Both solutions come close to achieving simple 
structure with the majority of variables having primary loadings on one factor only, 
with minor loadings on other factors. The Executive Function factor that emerged here 
is absent from the Wesnes et al. solution because the tests were not administered. 
With the exception of the accuracy scores from the picture recognition and spatial 
working memory subtests that have smaller but primary loadings on Factor 2, the 
pattern of loadings on the remaining factors matches those of the Quality of Episodic 
Secondary Memory, Continuity of Attention and Quality of Working Memory from 
Wesnes et al.. However, the main difference between the solutions is the combining of 
Speed of Memory Index and Power of Attention from the Wesnes et al. solution into 
the single factor labelled Speed of Cognition here. Examination of the factor loadings 
from Wesnes et al. shows that although the choice reaction time subtest has a 
secondary loading on Speed of Memory Index, the magnitude of the primary loadings 
on Speed of Memory and Power of Attention suggests that the two factors are indeed 
distinct. As factor solutions are inherently changeable depending on the variables 
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entered into the analysis, it was possible that the inclusion of the executive function 
tests had prevented the Speed of Memory and Power of Attention factors emerging as 
separate factors here. To investigate this the factor analysis was repeated. 
4.1.2 Solution 2: excluding tests of executive function 
The PCA with Varimax rotation was repeated using the data from the hypertensive 
and normotensive groups combined, entering all cognitive variables except for the 
traditional neuropsychological tests of executive function. The correlation matrix 
remained the same as shown in Table 12, with the omission of the last four variables 
(TMTA, TMTB, VF_Animals, VF_FAS). 
4.1.2.1 Statistical output 
The eigenvalues and variance explained by the extracted components after performing 
PCA are shown in Table 17; four components had eigenvalues greater than unity 
explaining approximately 57% of the variance. The scree plot (Figure 21) showed that 
the slope began to flatten at the third component, accounting for approximately 51% 
of the variance. In order to compare with solution 1 the criterion of eigenvalues above 
1 was used, resulting in four components selected for rotation. The unrotated 
component matrix is shown in Table 18. Varimax rotation with Kaiser normalization 
produced a rotated solution that converged after 6 iterations. The rotated four factor 
solution is shown in Table 19. 
4.1.2.2 Simple structure 
Similar to solution 1, the rotated component matrix shows that the factor solution is 
close to achieving simple structure with the majority of rows containing at least one 
loading close to zero. Each column contains at least as many loadings close to zero as 
there are factors, again with the exception of Factor 1. The majority of variables load 
primarily on one factor with low loadings on other factors. 
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Table 17: Eigenvalue and variance of components: solution 2 
hypertensives and normotensives, excluding tests of executive function  
 
5.809 32.274 32.274
2.055 11.417 43.692
1.266 7.031 50.723
1.057 5.874 56.597
.964 5.355 61.952
.910 5.057 67.009
.861 4.784 71.793
.824 4.580 76.372
.765 4.251 80.623
.669 3.715 84.339
.550 3.056 87.395
.487 2.703 90.097
.386 2.145 92.242
.355 1.971 94.213
.325 1.806 96.019
.260 1.443 97.462
.247 1.370 98.832
.210 1.168 100.000
Component
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
Total
% of
Variance
Cumulative
%
Initial Eigenvalues
Extraction Method: Principal Component Analysis.
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Figure 21: Scree plot from PCA for solution 2 
Hypertensives and normotensives, excluding tests of executive function 
Component Number
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Table 18: Unrotated component matrix for solution 2. For variable definitions, see 
Appendix VIII 
 
.81 .25 .02 .07
.78 .10 -.26 .06
.78 .32 .04 .07
.78 .25 -.15 .05
.74 .20 .26 -.26
.67 .25 -.02 -.02
.66 .23 .25 -.07
.64 .33 -.15 .00
-.54 .54 .12 .05
-.52 .50 .10 .09
-.39 .37 .00 -.01
-.37 .24 -.25 .06
-.46 .51 .29 -.14
-.45 .48 .37 .01
-.09 .47 -.29 -.15
.19 -.24 .58 .35
-.39 .11 -.44 -.32
-.15 .23 -.29 .83
DPICRT
DRE2RT
CRT2
DRE1RT
MSRT
VIGRT
SPMRT
SRT
DRECALL
IRECALL
DPICSI
SPMSI
DRE2SI
DRE1SI
CRT2ACC
VIGFA
VIGACC
MSSI
1 2 3 4
Component
Extraction Method: Principal Component Analysis.
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Table 19: Rotated component matrix solution 2 
 
.83 -.10 -.13 .02
.82 -.18 -.14 .00
.79 -.24 .01 .06
.73 -.08 -.19 -.39
.72 -.40 .06 .08
.72 -.11 .09 .04
.70 -.13 -.04 -.04
.68 -.03 -.24 -.19
-.13 .74 -.06 -.01
-.13 .74 .08 -.11
-.18 .72 .17 .14
-.18 .67 .15 .18
-.13 .47 .20 .09
.03 -.03 -.74 .02
-.27 .08 .62 -.05
.18 .28 .47 .07
-.19 .25 .33 .23
.00 .11 -.02 .91
Choice reaction time - CRT2
Picture recognition RT - DPICRT
Immediate word recognition RT - DRE1RT
Numeric working memory RT -MSRT
Delayed word recognition RT - DRE2RT
Simple reaction time - SRT
Number vigilance RT - VIGRT
Spatial memory RT - SPMRT
Immediate word recognition acc - DRE1SI
Delayed word recognition acc - DRE2SI
Delayed word recall accuracy - DRECALL
Immediate word recall accuracy -  IRECALL
Delayed picture recognition acc - DPICSI
Number vigilance false alarms - VIGFA
Number vigilance accuracy - VIGACC
Choice reaction time accuracy - CRT2ACC
Spatial memory accuracy - SPMSI
Numeric working memory accuracy - MSSI
1 2 3 4
Component
Extraction Method: Principal Component Analysis.  
Rotation Method: Varimax with Kaiser Normalization.
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4.1.2.3 Interpretation 
The exclusion of the tests of executive function resulted in a four factor solution 
compared to the five factors that emerged from solution 1. The remaining four factors 
match very well the factors from solution 1, the absence of the Executive Function 
factor being the obvious omission. Factor 1 of the repeated solution contains all of the 
variables that comprised the Speed of Cognition factor from solution 1; the exclusion 
of the tests of executive function did not lead to the discrimination of separate factors 
akin to those of Speed of Memory Index and Power of Attention from the Wesnes et 
al. study. As the Wesnes et al. solution produced five factors using almost identical 
variables, yet solution 2 produced only four, it was of interest to investigate how the 
variables would load if forced to fit to a five factor solution. 
4.1.3 Solution 3: forced five factor solution 
The PCA with Varimax rotation from solution 2 was repeated but replacing the 
eigenvalue criterion for component selection with a fixed number, thus forcing a five 
factor rotated solution. 
4.1.3.1 Statistical output 
The eigenvalues and scree plot were the same as those for solution 2. The unrotated 
component matrix is shown in Table 20. Varimax rotation with Kaiser normalization 
produced a rotated solution that converged after 6 iterations. The rotated five factor 
solution is shown in Table 21. 
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Table 20: Unrotated component matrix for forced five factor solution. For variable 
definitions, see Appendix VIII 
.81 .25 .02 .07 .12
.78 .10 -.26 .06 .15
.78 .32 .04 .07 .00
.78 .25 -.15 .05 .20
.74 .20 .26 -.26 .15
.67 .25 -.02 -.02 .00
.66 .23 .25 -.07 -.13
.64 .33 -.15 .00 -.13
-.54 .54 .12 .05 .12
-.52 .50 .10 .09 .25
-.39 .37 .00 -.01 -.13
-.46 .51 .29 -.14 -.05
-.45 .48 .37 .01 -.05
.19 -.24 .58 .35 .14
-.39 .11 -.44 -.32 .20
-.15 .23 -.29 .83 -.16
-.37 .24 -.25 .06 .62
-.09 .47 -.29 -.15 -.52
DPICRT
DRE2RT
CRT2
DRE1RT
MSRT
VIGRT
SPMRT
SRT
DRECALL
IRECALL
DPICSI
DRE2SI
DRE1SI
VIGFA
VIGACC
MSSI
SPMSI
CRT2ACC
1 2 3 4 5
Component
Extraction Method: Principal Component Analysis.
 
 119 
Table 21: Rotated component matrix for forced five factor solution 
.83 -.17 -.13 -.04 .00
.83 -.10 -.06 -.14 .04
.81 -.24 -.02 .10 .04
.75 -.07 -.17 -.11 -.38
.74 -.41 .03 .09 .06
.69 -.10 .18 -.15 .08
.69 -.13 .01 -.10 -.03
.66 -.01 -.11 -.33 -.13
-.14 .74 -.04 -.03 .01
-.14 .74 .10 .01 -.10
-.17 .71 .09 .25 .11
-.16 .66 .01 .36 .12
-.15 .47 .23 .02 .10
.05 -.02 -.73 -.19 .03
.10 .28 .65 -.25 .16
-.25 .07 .46 .46 -.13
-.11 .22 .02 .76 .08
-.02 .10 .01 .05 .93
Picture recognition RT - DPICRT
Choice reaction time - CRT2
Immediate word recognition RT - DRE1RT
Numeric working memory RT -MSRT
Delayed word recognition RT - DRE2RT
Simple reaction time - SRT
Number vigilance RT - VIGRT
Spatial memory RT - SPMRT
Immediate word recognition acc - DRE1SI
Delayed word recognition acc - DRE2SI
Delayed word recall accuracy - DRECALL
Immediate word recall accuracy -  IRECALL
Delayed picture recognition acc - DPICSI
Number vigilance false alarms - VIGFA
Choice reaction time accuracy - CRT2ACC
Number vigilance accuracy - VIGACC
Spatial memory accuracy - SPMSI
Numeric working memory accuracy - MSSI
1 2 3 4 5
Component
Extraction Method: Principal Component Analysis.  
Rotation Method: Varimax with Kaiser Normalization.
 
 
4.1.3.2 Simple structure 
The rotated solution is not as close to achieving simple structure as the previous 
solutions as there is an increase in the magnitude of secondary loadings from a 
number of variables, such as immediate and delayed word recall accuracy. In 
particular, number vigilance accuracy loads equally across Factors 3 and 4 making it 
difficult to associate the variable with a factor. Compared to solutions 1 and 2, the 
factor matrix is more difficult to interpret. 
4.1.3.3 Interpretation 
The selection of five factors for rotation did not cause Factor 1 to diverge into two 
separate factors similar to those of Speed of Memory Index and Power of Attention 
from the Wesnes et al. solution. The additional factor emerged as Factor 4 and 
consisted of spatial memory accuracy with a lower loading of number vigilance 
accuracy, which was no longer as strongly associated with similar measures of 
attention. As the four factors from solution 2 matched very well with the factors from 
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Wesnes et al., albeit with the merging of Speed of Memory Index and Power of 
Attention, the additional factor from the forced five factor solution added very little. 
The loading of variables from the Speed of Memory Index and Power of Attention 
factors on Factor 1 in all three solutions, suggests that this is a robust factor in this 
sample. As the sample is a combination of normotensive and hypertensive individuals, 
the question arises as to whether Speed of Memory and Power of Attention would 
emerge as a single factor in both populations separately. 
4.1.4 Solution 4: hypertensives only 
The analysis of the hypertensive participants separately also presented the opportunity 
to test the robustness of the Executive Function factor within the sample. Therefore all 
cognitive variables were entered in the PCA analysis. The correlation matrix is shown 
in Table 22. 
4.1.4.1 Statistical output 
The eigenvalues and variance explained by the extracted components after performing 
PCA are shown in Table 23; six components had eigenvalues greater than unity 
explaining approximately 64% of the variance. Examination of the scree plot (Figure 
22) showed that the slope began to flatten at the fifth component, accounting for 
approximately 59% of the variance. In order to be comparable to with solution 1, 
components were selected for rotation based on the eigenvalue criterion of greater 
than unity, therefore six components were selected for rotation, shown in Table 24. 
The rotated six factor solution is shown in Table 25. 
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Table 22: Correlation matrix of baseline cognitive data: hypertensives only. For variable definitions, see Appendix VIII 
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DRE1SI 1.00      
DRE1RT -.30 1.00      
SRT -.15 .50 1.00     
VIGACC .14 -.25 -.18 1.00     
VIGRT -.14 .48 .51 -.32 1.00     
VIGFA -.11 .13 .07 -.36 .09 1.00     
CRT2ACC .12 -.05 .11 .20 .00 -.10 1.00    
CRT2 -.26 .54 .64 -.34 .62 .28 .02 1.00    
SPMSI .28 -.11 -.11 .25 -.16 -.15 .00 -.25 1.00    
SPMRT -.15 .39 .26 -.36 .38 .13 -.02 .44 -.28 1.00    
MSSI .08 -.05 -.02 .06 .02 -.11 .11 -.01 .11 -.11 1.00   
MSRT -.18 .50 .34 -.30 .44 .26 -.07 .54 -.19 .62 -.35 1.00   
DRE2SI .61 -.31 -.24 .25 -.19 -.09 .21 -.22 .17 -.15 .08 -.21 1.00   
DRE2RT -.39 .75 .48 -.17 .41 .13 -.04 .56 -.14 .37 -.02 .45 -.40 1.00   
DPICSI .32 -.15 -.10 .09 -.17 -.09 .15 -.28 .21 -.19 .08 -.18 .27 -.24 1.00  
DPICRT -.29 .61 .42 -.31 .44 .25 -.02 .62 -.16 .51 -.02 .65 -.30 .66 -.29 1.00  
IRECALL .36 -.17 -.20 .21 -.21 -.19 .10 -.24 .25 -.13 .17 -.16 .40 -.28 .27 -.20 1.00  
DRECALL .38 -.26 -.20 .22 -.19 -.20 .12 -.27 .25 -.21 .15 -.24 .43 -.33 .34 -.31 .72 1.00  
TMTA -.23 .45 .27 -.20 .39 .09 -.13 .48 -.25 .31 -.07 .38 -.16 .44 -.28 .42 -.24 -.30 1.00 
TMTB -.20 .44 .32 -.18 .35 .15 -.09 .52 -.24 .34 -.10 .35 -.17 .42 -.37 .39 -.31 -.35 .62 1.00
VF_Animals .22 -.36 -.35 .24 -.39 -.04 .02 -.46 .29 -.26 .09 -.30 .20 -.39 .32 -.32 .28 .29 -.36 -.41 1.00
VF_FAS .34 -.33 -.31 .13 -.35 .05 .05 -.37 .31 -.22 .09 -.23 .27 -.40 .29 -.25 .27 .32 -.35 -.35 .49 1.00
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Table 23: Eigenvalue and variance of components for solution 4 
7.046 32.029 32.029
2.073 9.421 41.450
1.529 6.948 48.398
1.288 5.855 54.253
1.119 5.085 59.338
1.058 4.811 64.149
.991 4.503 68.652
.904 4.110 72.762
.759 3.450 76.212
.744 3.380 79.591
.623 2.830 82.421
.532 2.419 84.840
.504 2.293 87.133
.460 2.093 89.225
.435 1.979 91.204
.386 1.753 92.957
.348 1.580 94.538
.307 1.397 95.934
.275 1.252 97.186
.229 1.040 98.226
.213 .968 99.194
.177 .806 100.000
Component
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
Total
% of
Variance
Cumulative
%
Initial Eigenvalues
Extraction Method: Principal Component Analysis.
 
 
 
Figure 22: Scree plot from PCA for solution 4 
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Table 24: Unrotated component matrix for solution 4. For variable definitions, see 
Appendix VIII 
.79 .31 -.02 -.03 -.18 .07
.75 .14 -.19 .32 .15 -.04
.75 .26 .14 .23 .10 -.01
.73 .28 -.09 .29 .17 .00
.67 .27 .39 -.03 .24 -.27
.65 .02 -.11 -.34 .16 .21
.64 .32 -.08 -.04 -.18 .08
.64 .06 -.11 -.28 .24 .26
-.60 .02 .25 .33 .08 -.01
.59 .33 -.23 .15 -.24 -.14
.58 .25 .32 -.12 .08 -.12
-.56 .54 .00 -.02 .15 .12
-.56 .15 .39 .24 -.01 .05
-.50 .48 .06 -.49 -.03 .03
-.49 .49 .14 -.34 -.04 .07
-.44 .35 .12 .22 -.18 -.20
-.49 .57 .01 .01 .25 .16
.28 -.07 .62 .08 -.31 .13
-.44 .03 -.51 -.01 .33 -.28
-.39 .25 -.08 .41 .31 .08
-.16 .21 -.37 .26 -.39 .60
-.12 .34 -.30 -.07 -.45 -.53
CRT2
DRE2RT
DPICRT
DRE1RT
MSRT
TMTB
VIGRT
TMTA
VF_Animals
SRT
SPMRT
DRECALL
VF_FAS
DRE2SI
DRE1SI
DPICSI
IRECALL
VIGFA
VIGACC
SPMSI
MSSI
CRT2ACC
1 2 3 4 5 6
Component
Extraction Method: Principal Component Analysis.
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Table 25: Rotated component matrix for solution 4 
.81 -.13 -.20 -.02 -.02 -.09
.78 -.11 -.17 .20 -.12 -.10
.77 -.16 -.35 -.08 .01 -.07
.71 -.39 -.07 .28 .06 .12
.65 -.18 -.13 .04 .12 .34
.65 -.12 -.01 .25 -.55 -.06
.61 -.34 .00 .20 .11 .15
.52 -.21 .05 .31 -.35 -.02
.38 -.66 -.04 .06 -.07 -.20
-.30 .64 .14 -.03 .01 -.12
-.25 .61 .29 .15 .02 -.10
.42 -.60 -.02 .03 -.04 -.28
-.06 .53 .29 .00 .05 .29
.05 .52 .19 -.35 .15 -.21
-.26 -.02 .79 -.05 -.03 .17
-.21 .11 .74 .02 .01 .12
.01 .33 .68 -.24 .11 -.12
-.08 .34 .67 -.22 .14 -.03
-.23 .11 .10 -.75 -.04 .11
.11 .07 -.11 .74 -.08 -.07
.04 .06 .12 .01 .88 .01
.06 .07 .13 -.16 .01 .81
Immediate word recognition RT - DRE1RT
Picture recognition RT - DPICRT
Delayed word recognition RT - DRE2RT
Choice reaction time - CRT2
Simple reaction time - SRT
Numeric working memory RT -MSRT
Number vigilance RT - VIGRT
Spatial memory RT - SPMRT
Trail-making test B (time) - TMTB
Verbal fluency for animals - VF_Animals
Verbal fluency for letters - VF_FAS
Trail-making test A (time) - TMTA
Delayed picture recognition acc - DPICSI
Spatial memory accuracy - SPMSI
Delayed word recognition acc - DRE2SI
Immediate word recognition acc - DRE1SI
Immediate word recall accuracy -  IRECALL
Delayed word recall accuracy - DRECALL
Number vigilance accuracy - VIGACC
Number vigilance false alarms - VIGFA
Numeric working memory accuracy - MSSI
Choice reaction time accuracy - CRT2ACC
1 2 3 4 5 6
Component
Extraction Method: Principal Component Analysis.  
Rotation Method: Varimax with Kaiser Normalization.
 
 
4.1.4.2 Simple structure 
The criteria of simple structure are not as well met as in solution 1 as more variables 
have higher secondary loadings, making the factors less well-defined. Factor 6 has 
emerged based primarily on the loading from choice reaction time accuracy only, 
indicating that this is a weak factor. 
4.1.4.3 Interpretation 
Factor 1 again consists of the reaction time scores of the subtests from the CDR 
battery with no separation of the Power of Attention of Speed of Memory factors from 
the Wesnes et al. solution. The traditional tests of executive function load together as 
Factor 2, albeit with lower but primary loadings from delayed picture recognition 
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accuracy and spatial memory accuracy. With the exception of delayed picture 
recognition accuracy, Factor 3 consists of the same variables that constitute the 
Episodic Memory factor from solution 1 and that of Wesnes et al.. Factor 5 is defined 
by numeric working memory accuracy alone, as in solution 1. Factor 4 consists of two 
of the three variables that make up the Continuity of Attention factor from solution 1; 
the third variable, choice reaction time accuracy, here loads separately and forms the 
additional sixth factor in this solution. Given that choice reaction time accuracy loads 
with the other variables of Continuity of Attention in solution 1 and Wesnes et al.’s 
solution, and that the solution is less close to simple structure, the sixth factor is not 
very robust. Overall, the factor structure from solution 1 is demonstrated in the sample 
of hypertensives alone. 
4.1.5 Solution 5: normotensives only 
The analysis of the solution 4 was repeated using data from the normotensive 
participants only. The correlation matrix is shown in Table 26. 
4.1.5.1 Statistical output 
The eigenvalues and variance explained by the extracted components after performing 
PCA are shown in Table 27; six components had eigenvalues greater than unity 
explaining approximately 64% of the variance. It was difficult to determine the 
number of factors for rotation from examination of the scree plot (Figure 23) as there 
was little change in the angle of the slope between components 3 and 8. However, for 
comparability with solution 1, six components were selected for rotation (Table 28) 
based on the eigenvalues. The rotated six factor solution is shown in Table 29. 
4.1.5.2 Simple structure 
As in solution 4 using hypertensives only, the criteria of simple structure are not very 
well met as a higher number of variables have relatively large secondary loadings, 
making the factors less well-defined. A sixth factor has emerged again based primarily 
on the loading from a single variable, although different to that from solution 4. 
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4.1.5.3 Interpretation 
As in all previous solutions, Factor 1 shows no separation into the Power of Attention 
of Speed of Memory factors from the Wesnes et al. solution. The second factor to 
emerge is very similar to the Episodic Memory factor rather than Executive Function, 
as in this solution the traditional tests of executive function load somewhat 
disparately; the verbal fluency variables load together, along with numeric working 
memory accuracy as Factor 3, but the Trail-Making Test variables have low loadings. 
Factor 4 has loadings from two of the attention test variables, whereas Factors 5 and 6 
are weak factors defined by the single variables of spatial memory accuracy and 
number vigilance accuracy respectively. The solution is generally quite difficult to 
interpret due to the high number of secondary loadings, although the emergence of the 
reaction time subtests loading together as a single factor is a robust finding. 
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Table 26: Correlation matrix of baseline cognitive data: normotensives. For variable definitions, see Appendix VIII 
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DRE1SI 1.00      
DRE1RT -.22 1.00      
SRT -.10 .50 1.00     
VIGACC .05 -.10 -.14 1.00     
VIGRT -.23 .52 .60 -.10 1.00     
VIGFA .02 -.02 -.15 .06 -.06 1.00     
CRT2ACC .10 .03 .15 -.04 -.04 -.23 1.00    
CRT2 -.12 .66 .70 -.07 .62 -.03 .01 1.00    
SPMSI .07 -.16 -.14 .03 -.12 -.04 .19 -.14 1.00    
SPMRT -.11 .54 .49 -.10 .43 .02 .02 .57 -.28 1.00    
MSSI .15 .04 -.06 -.02 -.17 .07 .09 .00 .03 .05 1.00   
MSRT -.23 .72 .50 -.05 .53 .01 .04 .68 -.19 .60 -.12 1.00   
DRE2SI .41 -.13 -.07 .21 -.13 -.04 .17 -.08 .10 -.08 .03 -.07 1.00   
DRE2RT -.30 .77 .43 -.12 .46 -.05 -.01 .56 -.21 .48 .02 .62 -.22 1.00   
DPICSI .19 -.17 -.11 .11 -.19 -.16 .22 -.13 .09 -.12 .09 -.18 .22 -.20 1.00  
DPICRT -.16 .77 .56 -.04 .53 -.01 .04 .70 -.20 .64 .05 .70 -.06 .69 -.16 1.00  
IRECALL .31 -.35 -.23 .06 -.29 -.13 .13 -.26 .31 -.29 .10 -.33 .30 -.41 .31 -.31 1.00  
DRECALL .40 -.26 -.19 .11 -.28 -.14 .23 -.19 .21 -.22 .11 -.30 .37 -.42 .24 -.26 .59 1.00  
TMTA -.06 .39 .28 -.19 .37 .10 -.13 .39 -.20 .31 -.05 .39 -.09 .35 -.22 .36 -.27 -.26 1.00 
TMTB -.12 .50 .40 -.12 .40 .07 -.13 .47 -.25 .41 -.05 .47 -.14 .44 -.21 .49 -.41 -.37 .63 1.00
VF_Animals .08 -.34 -.37 .04 -.41 -.07 .11 -.38 .13 -.25 .17 -.31 .10 -.31 .13 -.34 .35 .36 -.26 -.32 1.00
VF_FAS .08 -.24 -.28 .07 -.34 -.11 .13 -.27 .05 -.20 .18 -.32 .15 -.24 .27 -.26 .29 .34 -.34 -.31 .42 1.00
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Table 27: Eigenvalue and variance of components for solution 5 
6.944 31.566 31.566
2.272 10.325 41.891
1.411 6.412 48.303
1.310 5.955 54.258
1.138 5.172 59.430
1.019 4.633 64.063
.902 4.099 68.162
.813 3.697 71.859
.773 3.514 75.373
.718 3.263 78.635
.650 2.955 81.590
.598 2.716 84.306
.518 2.355 86.662
.504 2.291 88.952
.457 2.078 91.030
.387 1.759 92.789
.365 1.659 94.448
.321 1.460 95.909
.300 1.362 97.270
.230 1.044 98.314
.208 .944 99.258
.163 .742 100.000
Component
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
Total
% of
Variance
Cumulative
%
Initial Eigenvalues
Extraction Method: Principal Component Analysis.
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Figure 23: Scree plot from PCA for solution 5 
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Table 28: Unrotated component matrix for solution 5. For variable definitions, see 
Appendix VIII 
.81 .24 -.09 .17 .06 .14
.81 .31 .00 .16 .12 .10
.80 .21 -.01 .02 .14 .06
.79 .34 .04 -.04 .02 .07
.77 .07 -.21 .20 .09 .08
.72 .12 -.03 -.30 .02 .02
.69 -.08 .26 .08 -.20 -.16
.68 .25 .03 .22 .04 -.09
.68 .34 -.07 -.23 -.09 -.06
.57 -.10 .35 .02 -.38 -.11
-.57 .46 .06 -.09 -.13 .11
-.53 .14 -.21 .38 -.10 -.01
-.47 .26 -.28 .42 .10 -.21
-.53 .56 .14 -.02 -.10 .00
-.09 .55 -.32 -.13 -.12 .08
-.26 .52 .48 -.10 .18 -.07
-.33 .42 -.07 .01 .17 -.27
-.32 .39 .60 .00 -.22 -.09
.03 -.36 .48 .30 .09 .43
-.10 .24 .02 .67 -.21 .30
-.17 .08 .24 .00 .81 .11
-.31 .19 -.15 -.35 -.12 .70
DRE1RT
DPICRT
MSRT
CRT2
DRE2RT
VIGRT
TMTB
SPMRT
SRT
TMTA
IRECALL
VF_Animals
VF_FAS
DRECALL
CRT2ACC
DRE2SI
DPICSI
DRE1SI
VIGFA
MSSI
VIGACC
SPMSI
1 2 3 4 5 6
Component
Extraction Method: Principal Component Analysis.
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Table 29: Rotated component matrix for solution 5 
.89 -.08 .01 -.06 -.06 .03
.86 -.18 .03 -.06 -.01 -.04
.84 .01 -.15 .00 .01 -.07
.81 -.13 -.14 -.05 -.06 .03
.75 -.36 .04 -.04 -.09 -.03
.73 -.03 .05 -.02 -.23 -.05
.71 .01 -.28 .19 .04 -.18
.65 -.13 -.41 .03 .03 -.11
.54 -.03 -.19 -.26 -.34 -.33
-.14 .79 .07 -.08 -.03 -.11
.00 .73 -.02 .07 .01 .27
-.22 .61 .25 .29 .23 .05
-.30 .50 .20 .25 .35 .02
.12 .13 .75 -.19 .10 -.10
-.26 .07 .57 .38 -.12 .19
-.37 .07 .56 .20 .05 .01
-.04 .02 .12 -.78 .01 .12
.15 .16 .15 .49 .37 -.05
-.11 .31 .15 .45 -.06 .22
-.16 .07 -.01 -.02 .87 .02
-.03 .16 -.06 -.12 -.03 .85
.42 .08 -.21 -.32 -.26 -.47
Picture recognition RT - DPICRT
Immediate word recognition RT - DRE1RT
Choice reaction time - CRT2
Numeric working memory RT -MSRT
Delayed word recognition RT - DRE2RT
Spatial memory RT - SPMRT
Simple reaction time - SRT
Number vigilance RT - VIGRT
Trail-making test B (time) - TMTB
Immediate word recognition acc - DRE1SI
Delayed word recognition acc - DRE2SI
Delayed word recall accuracy - DRECALL
Immediate word recall accuracy -  IRECALL
Numeric working memory accuracy - MSSI
Verbal fluency for letters - VF_FAS
Verbal fluency for animals - VF_Animals
Number vigilance false alarms - VIGFA
Choice reaction time accuracy - CRT2ACC
Delayed picture recognition acc - DPICSI
Spatial memory accuracy - SPMSI
Number vigilance accuracy - VIGACC
Trail-making test A (time) - TMTA
1 2 3 4 5 6
Component
Extraction Method: Principal Component Analysis.  
Rotation Method: Varimax with Kaiser Normalization.
 
 
4.2 Factor analysis summary 
Solution 1 included all cognitive variables in the analysis in order to help understand 
the intercorrelations between the subtests. The five factor solution was in good 
agreement with a previous factor analysis of the CDR battery 77, with two main 
exceptions: the emergence of an Executive Function factor consisting of traditional 
neuropsychological tests of executive function not administered in the Wesnes et al. 
study; and the variables constituting the Speed of Memory and Power of Attention 
factors in the Wesnes et al. solution loading as one factor labelled Speed of Cognition 
here. Further analyses excluding the executive function tests and on the normotensive 
and hypertensive populations separately, failed to cause the Speed of Cognition factor 
to diverge into two factors. Thus it appears that Speed of Cognition is a robust factor. 
 133 
Therefore the five factor solution produced in solution 1 was used as the basis for 
subsequent analyses of the cognitive data. A diagrammatic representation of the 
relationship of subtests to factors is shown in Figure 24. Individual subtest scores 
were combined into composite factor scores for use in the analyses, as described in 
section 2.3.4. 
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Figure 24: The relationship of subtest variables to factors 
Speed of Cognition 
Delayed picture recognition reaction time 
Choice reaction time 
Immediate word recognition reaction time 
Continuity of Attention 
Numeric working memory reaction time 
Trail-making test form B  
Verbal fluency for letters  
Trail-making test form A  
Verbal fluency for category  
Delayed word recognition reaction time 
Simple reaction time 
Executive Function 
Spatial memory reaction time 
Number vigilance accuracy 
Choice reaction time accuracy 
Number vigilance false alarms 
Working Memory 
Spatial memory accuracy 
Numeric working memory accuracy 
Subtests Factors 
Delayed word recognition accuracy 
Immediate word recognition accuracy 
Delayed word recall accuracy 
Immediate word recall accuracy 
Episodic Memory 
Number vigilance reaction time 
Delayed picture recognition accuracy 
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CHAPTER 5: RESULTS – CANDESARTAN AND BP 
This chapter presents the results of the Newcastle Cognitive Substudy in relation to 
the effects on blood pressure, cardiovascular outcomes and cognitive outcomes 
defined in the main SCOPE protocol. Comparison of the NCS results to the main 
SCOPE study is also presented. 
5.1 Newcastle Cognitive Substudy  
5.1.1 Study visit attendance  
The majority of participants completed the cognitive assessment for the Newcastle 
Cognitive Substudy alongside their scheduled SCOPE study visit. However a small 
number of participants were unable or unwilling to perform the cognitive assessment 
on some occasions. In such cases, the follow-up data from the SCOPE study visit were 
still included in the analysis of BP-related and cardiovascular-related outcomes. The 
number of completed SCOPE study visits and cognitive assessments are shown in 
Table 30, as well as the number of cognitive assessments administered by the 
candidate. The majority of the assessments were performed in the research clinic, with 
only 9 visits that took place in the participants’ homes. Because of the rolling 
recruitment period, not all participants were due for scheduled study visits beyond the 
minimum follow-up period of 36 months; the number of completed visits as a 
percentage of those due is shown for comparison. As expected, the percentage who 
attended each visit diminished over time due to the natural attrition associated with 
withdrawal of consent and death. At the closeout visit all participants, current and 
withdrawn, were invited to attend in order to minimise the loss to follow-up which 
accounted for the higher percentage attendance than the preceding three visits. 
Adjusting for the number of deceased participants at the SCOPE study close (n=36), 
the 193 completed closeout visits represented a 90% attendance rate. 
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Table 30: Number of completed SCOPE study visits  
 
Visit SCOPE visits 
attended 
SCOPE visits 
attended/ visits 
due  
Cognitive 
assessments 
attended 
Cognitive 
assessments 
performed by 
candidate 
months n % n n 
 
Baseline 
 
250 
 
100 
 
250 
 
49 
1 240 96 238 58 
3 230 92 - - 
6 226 90 - - 
12 222 89 215 169 
18 208 83 - - 
24 204 82 198 198 
30 198 79 - - 
36 169 77 161 161 
42 125 73 - - 
48 76 74 75 75 
54 11 65 - - 
Closeout 193 77 182 182 
 
5.1.2 Study drugs and antihypertensive medication 
For the 250 participants in the cognitive substudy, the mean length of follow-up was 
43.1 ±13.7 months (range 0-59 months) with no significant difference between the 
candesartan and placebo groups (44±13 vs. 42±14 months, t=1.11, p=.27). In the 
candesartan group, the mean dose of candesartan was 12±4 mg once daily; 76 (61%) 
participants continued treatment until study close; the average proportion of the 
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follow-up period spent on active treatment was 89%. Only 20% of participants in the 
placebo group were taking placebo with no additional BP-lowering therapy at the last 
study visit attended. Antihypertensive medications in the two groups at the study 
closeout visit are shown in Table 31. 
 
Table 31: Antihypertensive therapy at study closeout visit. 
Data shown are number of participants. Some participants were taking more than one 
additional BP-lowering drug. The total for thiazides includes participants receiving 
add-on 12.5 mg hydrochlorothiazide (HCTZ) as per study protocol. Participants 
receiving angiotensin converting enzyme inhibitors and angiotensin II receptor 
antagonists at study close were not taking study medication.  
 Candesartan Placebo 
 n=99 n=94 
  
HCTZ (initiated before randomisation) 
 
23 
 
22 
Thiazides (prescribed since randomisation) 22 40 
Calcium-channel blockers 18 21 
Beta-blockers 12 20 
Angiotensin converting enzyme inhibitors 5 5 
Angiotensin II receptor antagonists 1 2 
Alpha-blockers 1 3 
No additional antihypertensive therapy 39 20 
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5.1.3 Blood pressure 
For those participants attending the closeout visit, BP fell from 165±8/88±7 mmHg at 
baseline to 141±16/74±9 mmHg at study close in the candesartan group (SBP, 
t=14.51, p<.001; DBP, t=13.98, p<.001), and from 166±8/89±7 to 149±20/77±10 
mmHg in the placebo group (SBP, t=8.37, p<.001; DBP, t=11.88, p<.001). At the 
study closeout visit, the difference in BP was 8/3 mmHg lower in the candesartan 
group (SBP, t=3.07, p<.01; DBP, t=1.87, p=.06). The same results were found when 
analysed using the last observation carried forward. 
The average BP across the study, calculated using data from all planned BP 
monitoring visits after baseline, was 146±11/78±6 mmHg in the candesartan group 
versus 153±10/81±7 mmHg in the placebo group (SBP, t=4.77, p<.001; DBP, t=4.16, 
p<.001). Comparison of the mean BP at each scheduled SCOPE study visit between 
the candesartan and placebo groups is shown in Figure 25. The initial reduction in BP 
from baseline to the 1 month and 3 month visits, achieved with the start of study 
treatment, was much greater in the candesartan group as expected. There is a smaller 
but clear reduction in BP in the placebo group which may be attributable to the 
placebo effect, as up until the 3 month visit participants received a maximum of 2 
study tablets with no additional BP-lowering therapy beyond that being taken at 
randomisation. Alternatively, it is possible that non-pharmacological BP reductions 
could have occurred, perhaps due to modification of lifestyle factors prompted by 
participants’ increased focus on BP by being involved in a hypertension trial. The BP 
difference between the groups remained at a similar magnitude until the 24 month 
visit, after which the size of the difference began to diminish due to the introduction 
of the lower BP target of <150/90 mmHg in accordance with BHS guidelines.  
5.1.4 Cardiovascular outcomes 
All reported cardiovascular events were evaluated and classified by an Independent 
Clinical Event Committee from the main SCOPE trial, blind to participants’ study 
group allocation. Within the 250 participants in the Newcastle Cognitive Substudy, 
stroke occurred after randomisation in 15 participants (7 candesartan, 8 placebo) and 
myocardial infarction in 10 (3 candesartan, 7 placebo). Comparison of the clinical 
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event rate between groups was not planned or performed due to the lack of statistical 
power.  
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Figure 25: Blood pressure at each scheduled SCOPE study visit 
Mean systolic (SBP) and diastolic (DBP) blood pressure at each scheduled SCOPE 
study visit: candesartan group versus placebo group in the Newcastle Cognitive 
Substudy 
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5.1.5 MMSE score and significant cognitive decline 
Overall, cognitive function as measured by the MMSE was well maintained in both 
groups with a mean reduction of approximately a third of an MMSE point over the 
entire follow-up period. For those participants attending the closeout visit, the mean 
MMSE score fell from 28.7 ±1.3 at baseline to 28.3 ±2.3 at study close in the 
candesartan group (t=1.78, p=.08), and from 28.9 ±1.0 to 28.6 ±1.6 in the placebo 
group (t=2.27, p<.05). Between group comparisons showed no significant difference 
in mean MMSE score at the closeout visit (t=-0.85, p=.28), or in the change in MMSE 
score from baseline to study close between the candesartan and placebo groups (-0.38 
±2.1 vs. -0.33 ±1.4, t=-0.21, p=.26).  
It was possible that an effect of treatment might have been obscured by the selective 
withdrawal of those participants with the greatest cognitive decline. In particular, 
participants diagnosed with dementia during the study were unable to continue with 
the SCOPE trial according to the main protocol, and those with significant cognitive 
decline were unable to provide informed consent for the extension of the follow-up 
period. Therefore the analyses were repeated using the last recorded MMSE score 
after baseline. Although the results showed the change in MMSE score to be slightly 
greater than the analyses based only on those participants attending the closeout visit, 
there were no significant differences between the candesartan and placebo groups in 
change scores (-0.55 ±2.3 vs. -0.49 ±1.9, t=-0.23, p=.82), or last recorded MMSE 
scores (28.2 ±2.3 vs. 28.3 ±2.3, t=0.57, p=.57). 
Significant cognitive decline, defined as a reduction in MMSE score ≥ 4 points from 
baseline score on two consecutive occasions, was reported in 11 participants (7 
candesartan, 4 placebo), three of whom were formally diagnosed as having dementia 
(1 candesartan, 2 placebo). As expected, the number of cases of dementia and 
significant cognitive decline were too low for meaningful statistical analysis. 
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5.2 The main SCOPE study 
5.2.1 Summary results 
The results of the main SCOPE study were reported by the SCOPE Executive 
Committee using an intention to treat analysis following the principles of last 
observation carried forward 85. Including the participants in the Newcastle Cognitive 
Substudy, 4964 participants were randomised, with 4937 included in the analysis 
(2477 candesartan, 2460 placebo). The mean length of follow-up was 44.6 months. 
The mean dose of candesartan was 12 ±4 mg once daily and only 16% of the control 
group participants received placebo alone.  
Mean BP was reduced from 166.0/90.3 mmHg to 145.2/79.9 mmHg in the 
candesartan group and from 166.5/90.4 mmHg to 148.5/81.6 mmHg in the placebo 
group (p<.001 for all). The mean difference in BP reduction of 3.2/1.6 mmHg in 
favour of the candesartan group (p<.001 for both) was considerably smaller than that 
predicted in the planning of the SCOPE study. The BP difference was, however, 
associated with a modest, statistically non-significant reduction in major 
cardiovascular events (risk reduction 10.9%, p=.19) and a marked reduction in non-
fatal stroke (risk reduction 27.8%, p=.04).  
Cognitive function was well maintained in both groups; MMSE score fell from 28.5 to 
28.0 in the candesartan group and from 28.5 to 27.9 in the placebo group. There was 
no significant difference in the change in MMSE score (mean difference 0.15, p=.20), 
or the proportion of patients with significant cognitive decline (13.5 vs. 15.2 events 
per 1000 patient-years, p>.20) or dementia (6.8 vs. 6.3 events per 1000 patient-years, 
p>.20).  
5.2.2 Comparison between NCS and SCOPE 
Because the participants in the Newcastle Cognitive Substudy were randomised and 
treated according to the protocol of the main SCOPE study, the characteristics of the 
intervention such as the mean length of follow-up, mean dose of candesartan and the 
proportion receiving placebo without additional antihypertensive therapy were almost 
identical.  
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However, the difference in BP reduction between the candesartan and placebo groups 
was substantially larger in the Newcastle Cognitive Substudy than in the main SCOPE 
trial (approximately 8/3 vs. 3/2 mmHg). The Newcastle subsample was well-matched 
to the main SCOPE cohort at randomisation with very similar starting BP levels; BP 
reductions of a similar magnitude were observed in the placebo groups of both 
samples; therefore, the greater difference between the treatment groups is accounted 
for by the lower levels of BP achieved in the candesartan group in the Newcastle 
Cognitive Substudy compared to the main SCOPE study (approx. 141/74 vs. 145/80 
mmHg). There was no a priori expectation that this would occur, therefore only post-
hoc explanations can be offered as to why this was the case. One possibility is that the 
lower BP targets, instigated in accordance with British Hypertension Society 
guidelines midway through the study, were more vigorously enforced in the Newcastle 
centre than elsewhere. However, this would not necessarily produce a larger BP gap 
between groups as it would be expected to produce lower BP levels in the placebo 
group than those in the main study. Perhaps the likeliest explanation is better 
compliance with study medication at the Newcastle site, possibly due to having a 
dedicated study team in place. 
In terms of cognition as measured by the MMSE score, the results of the Newcastle 
Cognitive Substudy and the main SCOPE study were very similar. Overall there was 
relatively little change in MMSE score, with a decline of less than 0.13 MMSE points 
per year. Similarly, the incidence of dementia in the SCOPE study of 6.5 cases per 
1000 patient-years was in the lower range of what was expected. It was not surprising, 
therefore, that both sets of analyses found no significant effects of treatment on 
changes in MMSE score. The MMSE has a number of shortcomings as a serial 
measure of cognitive function. In particular, it provides a broad assessment of 
cognitive function initially designed as a screening tool, and not suited to detecting 
subtle cognitive changes over relatively short periods of time. Therefore, it is possible 
that any effects of candesartan on cognition may have been obscured by the lack of 
sensitivity of the measure. The extension of the cognitive assessment in the Newcastle 
Cognitive Substudy was designed to investigate this by using a battery of tests 
sensitive to subtle changes over time. 
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CHAPTER 6: RESULTS – EFFECT OF CANDESARTAN   
This chapter presents the primary analysis of the effects of candesartan on reducing 
cognitive decline. Secondary analyses are presented for the efficacy subset, loss to 
follow-up, excluding participants suffering stroke and excluding participants taking 
beta-blockers. Acute effects are also shown. 
6.1 Participants included in the primary analysis 
As described in the Methods section 2.4.2, to calculate the primary outcome measure 
of the slope of decline for an individual, a minimum of two cognitive assessments 12 
months apart were required. Due to the natural attrition associated with death and 
withdrawal of consent, follow-up cognitive data were unavailable for 22 participants. 
Participant flow is shown in Figure 26 according to the CONSORT guidelines. Of the 
228 with calculable coefficients of decline, 159 (70%) participants completed the 
maximum number of assessments (4, 5 or 6 visits depending on time of recruitment); 
14 (6%) had one missing data point; 23 (10%) had two missing data points; 22 (10%) 
missed three assessments; and 10 (4%) missed four assessments.  
6.1.1 Baseline characteristics 
In the sample of 228 participants with calculable coefficients of decline, there were no 
significant differences between the candesartan and placebo groups on baseline 
demographic characteristics (Table 32) with one exception: there was a 7% higher rate 
of previous MI in the candesartan group. Although it reached statistical significance, 
the difference appears to be a ‘play of chance’ from the whole sample of 250 
randomised participants who had a high prevalence of MI (described in section 3.2.1), 
and was therefore a product of the randomisation procedure rather than a selective loss 
to follow-up of participants with previous MI in the placebo group. As in the whole 
recruited sample, there were no significant differences in baseline composite cognitive 
factor scores (Table 33).   
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Figure 26: CONSORT Flow Diagram 
 257 eligible participants 
128 candesartan arm 129 placebo arm 
R 
3 declined substudy 
1 baseline data missing 
1 declined substudy 
2 baseline data missing 
12 with < 2 annual 
assessments 
10 with < 2 annual 
assessments 
112 available for analysis 116 available for analysis 
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Table 32: Baseline demographics of Newcastle Substudy 
Baseline demographic characteristics of hypertensive participants with calculable 
coefficients of decline in the Newcastle Cognitive Substudy randomised to 
candesartan versus placebo. 
Data shown are mean and (SD), or percentages.  
 Candesartan Placebo t / χ2 p 
 n=112 n=116   
 
Age, years 
 
76 (4) 
 
76 (5) 
 
.32 
 
.75 
Females 54% 53% .00 .99 
Education, years 10 (2) 10 (2) .18 .61 
NART errors 18 (8) 18 (9) .57 .82 
MMSE score 29 (1) 29 (1) .61 .54 
SBP mmHg 165 (8) 166 (8) .56 .43 
DBP mmHg 88 (7) 89 (7) .63 .20 
Smokers 14% 17% .37 .54 
HCTZ at enrolment 28% 28% .00 .99 
Previous MI 10% 3% 5.2 .02 
Previous stroke 5% 3% 1.2 .28 
Atrial fibrillation 3% 5% .94 .33 
 
NART = New Adult Reading Test; MMSE = Mini-Mental State Examination; SBP = 
systolic blood pressure; DBP = diastolic blood pressure; HCTZ = 
hydrochlorothiazide; MI = myocardial infarction.  
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Table 33: Baseline cognitive performance: candesartan vs placebo groups  
Comparison of baseline performance on the composite cognitive factors between the 
candesartan and placebo groups, for hypertensive participants with calculable 
coefficients of decline. A higher score indicates better performance except for Speed 
of Cognition, where a lower score indicates better performance 
Data shown are mean and (SD) 
Factor Candesartan Placebo t p 
 n=112 n=116   
       
Speed of Cognition 6398 (1090) 6570 (1257) -1.1 .27 
Continuity of Attention 92.2 (2.6) 92.5 (3.0) -.83 .41 
Episodic Memory 217 (50) 231 (54) -1.6 .11 
Working Memory 1.57 (0.33) 1.61 (0.35) -.45 .34 
Executive Function  1.18 (3.01) 1.37 (3.33) -.45 .65 
 
6.1.2 Effects on BP and cardiovascular outcomes 
In order to determine whether the effects of candesartan on BP and cardiovascular 
outcomes observed in the whole Newcastle Cognitive Substudy sample (section 5.1.3) 
were similar in the 228 participants with calculable slopes of decline, the analyses 
were repeated using this subsample.  
The mean length of follow-up was 45.8 ±9.3 months (range 14-59 months) with no 
significant difference between the candesartan and placebo groups (46.5±8.9 vs. 
45.1±9.8 months, t=1.19, p=.24). In the candesartan group, the mean dose of 
candesartan was 12±4 mg once daily; 76 participants continued treatment until study 
close representing 68% of the sample; the average proportion of the follow-up period 
spent on active treatment was 88%. Only 19% of participants in the placebo group 
were taking placebo with no additional BP-lowering therapy at the last study visit 
attended.  
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As all of the participants that attended the closeout visit also had calculable 
coefficients of decline, the results of the effects of candesartan on BP and MMSE 
scores at study close were the same as the analyses based on the whole recruited 
sample. The incidence of major cardiovascular events was also similar, with 12 
sustaining stroke (4 candesartan, 8 placebo) and 8 myocardial infarction (3 
candesartan, 5 placebo) within the 228 participants with follow-up cognitive data. 
Thus, at the closeout visit, BP fell from 165±8/88±7 mmHg at baseline to 
141±16/74±9 mmHg at study close in the candesartan group (SBP, t=14.51, p<.001; 
DBP, t=13.98, p<.001), and from 166±8/89±7 to 149±20/77±10 mmHg in the placebo 
group (SBP, t=8.37, p<.001; DBP, t=11.88, p<.001). At the study closeout visit, the 
difference in BP was 8/3 mmHg lower in the candesartan group (SBP, t=3.07, p<.01; 
DBP, t=1.87, p=.06).  
 
6.2 Primary analysis: effect of candesartan on cognitive decline 
The primary analysis compared the rate of cognitive decline between the candesartan 
and placebo groups on an intent-to-treat basis. The univariate general linear model 
procedure was used to compare decline on each cognitive factor between the two 
groups, controlling for age, estimated pre-morbid IQ and baseline cognitive function 
as covariates. As the tests of equivalence of the randomised groups found no baseline 
differences on the pre-specified demographic variables, no additional covariates were 
added to the model.  
Table 34 shows the results of the general linear model assessing the effect of treatment 
on the rate of cognitive decline for each composite factor. The candesartan group 
showed significantly less decline in Attention and Episodic Memory than the placebo 
group, with a similar trend for Speed of Cognition. Cohen’s D effect sizes were in the 
small to medium range using the generally-accepted conventions (0.2 = small effect; 
0.5 = medium effect; 0.8 = large effect). There were no differences in the rate of 
decline in Working Memory or Executive Function. The average annual rates of 
decline expressed as a percentage of baseline composite score are also shown in the 
table, and illustrate more clearly the magnitude and direction of the differences.  
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Figures 27-31 display graphically the average annual percentage change, extrapolated 
for the mean length of follow-up. The gradient of the lines in relation to each other 
shows the different trajectories of cognitive function between the groups. For the 
Speed of Cognition factor (Figure 27), the result does not reach statistical significance 
due to the larger variance in the placebo group, although a trend in favour of the 
candesartan group is visible. For Attention (Figure 28) there is a small but clear 
divergence of the two groups, representing an annual decline of 0.5% in the placebo 
group compared to almost no change in the candesartan group. For Episodic Memory 
(Figure 29), the trajectories are clearly different with the placebo group declining and 
the candesartan group showing improvements of a similar magnitude, although the 
graph itself appears somewhat distorted because of the different, but non-significant 
starting points. On the Working Memory factor (Figure 30), the candesartan and 
placebo groups are almost identical, with both groups improving slightly over time, 
perhaps reflecting a practice effect on the tasks involved. The Executive Function 
factor (Figure 31) shows the greatest annual percentage decline of the five factors, 
with both groups having similar trajectories, suggesting no effect of treatment but that 
this factor is the most susceptible to the effects of age.  
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Table 34: Primary analysis of change in cognition: candesartan vs placebo groups 
Primary analysis: comparison of change in cognition between the candesartan and placebo groups, as measured by coefficients of decline on five 
composite factor scores, in all participants with calculable coefficients. Adjusted for age, New Adult Reading Test errors and baseline 
performance. Negative values indicate decline in performance over time. 
Data shown are mean and (SD). 
 Coefficients of Decline   Effect Size   Annual Percentage Change 
from Baseline 
 Candesartan Placebo     Candesartan Placebo 
Cognitive 
factor 
n=112 n=116 F p Cohen's D  % % 
         
Speed of 
Cognition 
-2.3 (25.2) -17.4 (89.2) 2.1 .15 .26  -0.4 -3.2 
Attention 
 
0.004 (0.088) -0.036 (0.184) 4.2 .04 .28  0.1 -0.5 
Episodic 
Memory 
0.14 (1.38) -0.22 (1.21) 4.3 .04 .28  0.8 -1.1 
Working 
Memory 
0.0014 (0.0119) 0.0010 (0.0118) 0.02 .90 .03  1.1 0.7 
Executive 
Function 
-0.0031 (0.0616) -0.0023 (0.0739) 0.004 .95 -.01  -3.2 -2.0 
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Figure 27: Trajectories of the coefficients of decline: Speed of Cognition 
Diagrammatic comparison of the trajectories of the coefficients of decline, for the 
candesartan and placebo groups, on the Speed of Cognition factor. As a higher score 
indicates poorer performance on this factor, the scale has been reversed. 
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Figure 28: Trajectories of the coefficients of decline: Attention 
Diagrammatic comparison of the trajectories of the coefficients of decline, for the 
candesartan and placebo groups, on the Attention factor. 
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Figure 29: Trajectories of the coefficients of decline: Episodic Memory 
Diagrammatic comparison of the trajectories of the coefficients of decline, for the 
candesartan and placebo groups, on the Episodic Memory factor 
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Figure 30: Trajectories of the coefficients of decline: Working Memory 
Diagrammatic comparison of the trajectories of the coefficients of decline, for the 
candesartan and placebo groups, on the Working Memory factor. 
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Figure 31: Trajectories of the coefficients of decline: Executive Function 
Diagrammatic comparison of the trajectories of the coefficients of decline, for the 
candesartan and placebo groups, on the Executive Function factor. 
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6.3 Secondary analyses: efficacy analysis 
6.3.1 Baseline characteristics 
In contrast to the intent-to-treat analysis where data from all participants were entered 
into the analysis regardless of compliance, in the efficacy analysis only those 
participants who remained on allocated treatment throughout the study formed the 
evaluable subset. The baseline demographic characteristics of the candesartan and 
placebo groups in the efficacy analysis are shown in Table 35. There were no 
significant differences between the groups, and as a subset, they closely matched the 
whole group of participants with calculable coefficients of decline from which they 
were selected. Similarly, there were no differences between the groups on baseline 
composite cognitive factor scores (Table 36).  
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6.3.2 Effects on BP and cardiovascular outcomes 
The mean length of follow-up was 48.7 ±6.1 months (range 37-59 months) with no 
significant difference between the candesartan and placebo groups (49±6 vs. 49±6 
months, t=.09, p=.93). In the candesartan group, the mean dose of candesartan was 
14±3 mg once daily. Only 17% of participants in the placebo group were taking 
placebo with no additional BP-lowering therapy throughout the study..  
At the closeout visit, BP fell from 165±8/88±6 mmHg at baseline to 140±15/73±9 
mmHg at study close in the candesartan group (SBP, t=14.61, p<.001; DBP, t=13.84, 
p<.001), and from 165±8/89±7 to 146±15/75±8 mmHg in the placebo group (SBP, 
t=10.90, p<.001; DBP, t=12.39, p<.001). At the study closeout visit, the difference in 
BP was 6/2 mmHg in favour of the candesartan group (SBP, t=2.42, p=.02; DBP, 
t=1.33, p=.19).  
At study close there were no significant differences in MMSE scores between the 
candesartan and placebo groups (28.5±2.1 vs. 28.6±1.5, t=.32, p=.75) with only minor 
changes from the baseline scores (28.7±1.2 vs. 28.8±1.1).  
The incidence of stroke was in proportion to the whole group analysis, with 9 
participants sustaining stroke (2 candesartan, 7 placebo). However, none of the 
participants in the efficacy subset sustained myocardial infarction. This most probably 
reflected the medical decisions made after the clinical event had occurred, with 
medical practitioners recommending the withdrawal of study medication in the 
treatment of myocardial infarction, making those participants ineligible for the 
efficacy analysis.  
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Table 35: Baseline demographics: efficacy analysis 
Baseline demographic characteristics of candesartan versus placebo participants in the 
efficacy analysis of the Newcastle Cognitive Substudy. 
Data shown are mean and (SD), or percentages.  
 Candesartan Placebo t / χ2 p 
 n=77 n=75   
 
Age, years 
 
75 (4) 
 
76 (4) 
 
-1.2 
 
.22 
Females 57% 53% .22 .64 
Education, years 10 (2) 10 (2) -.05 .96 
NART errors 19 (9) 18 (9) .70 .49 
MMSE score 29 (1) 29 (1) -.89 .38 
SBP mmHg 165 (8) 165 (8) -.18 .86 
DBP mmHg 88 (6) 89 (7) -.68 .50 
Smokers 14% 14% .02 .89 
HCTZ at enrolment 21% 20% .00 .93 
Previous MI 8% 1% 3.6 .06 
Previous stroke 6% 1% 2.7 .10 
Atrial fibrillation 0% 3% 2.1 .15 
 
NART = New Adult Reading Test; MMSE = Mini-Mental State Examination; SBP = 
systolic blood pressure; DBP = diastolic blood pressure; HCTZ = 
hydrochlorothiazide; MI = myocardial infarction.  
 156 
Table 36: Baseline cognitive performance: efficacy analysis 
Comparison of baseline performance on the composite cognitive factors between the 
candesartan and placebo groups, for participants in the efficacy analysis of the 
Newcastle Cognitive Substudy. A higher score indicates better performance except for 
Speed of Cognition, where a lower score indicates better performance 
Data shown are mean and (SD) 
Factor Candesartan Placebo t p 
 n=77 n=75   
       
Speed of Cognition 6226 (1046) 6423 (1161) -1.1 .27 
Continuity of Attention 92.2 (2.6) 92.8 (2.5) -.1.5 .15 
Episodic Memory 222 (52) 237 (55) -1.5 .14 
Working Memory 1.59 (0.33) 1.61 (0.38) -.32 .75 
Executive Function  1.33 (2.87) 1.73 (3.16) -.81 .42 
 
6.3.3 Effect on cognitive decline 
The univariate general linear model procedure was used to compare decline on each 
cognitive factor between the two groups, controlling for age, estimated pre-morbid IQ 
and baseline cognitive function as covariates. As there were no baseline differences on 
the demographic variables, no additional covariates were added to the model.  
Table 37 shows the results of the general linear model assessing the effect of treatment 
on the rate of cognitive decline for each composite factor. In contrast to the primary 
analysis, the efficacy analysis found no significant differences between the groups on 
any of the cognitive factors. However, for the Attention and Episodic Memory factors, 
the candesartan group showed small improvements over time compared to small 
declines in the placebo group, similar in magnitude to those observed in the primary 
analysis but failing to reach statistical significance. There was no trend observed on 
the Speed of Cognition factor due to the placebo group not showing the decline on this 
factor that was evident in the primary analysis, and with a much lower standard 
deviation. In general, the annual percentage change from baseline was smaller than 
observed in the primary analysis, due in some part to differences in the baseline scores 
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between the datasets; participants included in the efficacy analysis performed better at 
baseline on the cognitive factors than the whole group from which they were selected.  
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Table 37: Efficacy analysis on change in cognition: candesartan vs placebo groups 
Efficacy analysis: comparison of change in cognition between the candesartan and placebo groups, as measured by coefficients of decline on five 
composite factor scores, in participants who remained on treatment throughout the study. Adjusted for age, New Adult Reading Test errors and 
baseline performance. Negative values indicate decline in performance over time. 
Data shown are mean and (SD). 
 Coefficients of Decline     Annual Percentage Change 
from Baseline 
 Candesartan Placebo    Candesartan Placebo 
Cognitive 
factor 
n=77 n=75 F P  % % 
        
Speed of 
Cognition 
-0.03 (18.8) 0.18 (15.0) 0.0 .93  -0.01 0.03 
Attention 
 
0.012 (0.058) -0.033 (0.051) 1.0 0.30  0.2 -0.4 
Episodic 
Memory 
0.12 (0.93) -0.09 (0.92) 1.7 0.19  0.6 -0.5 
Working 
Memory 
0.0010 (0.0068) 0.0015 (0.0070) 0.6 0.43  0.8 1.1 
Executive 
Function 
0.0091 (0.0372) -0.0003 (0.0475) 1.3 0.26  8.2 -0.2 
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6.3.4 Efficacy analysis versus intent-to-treat 
An efficacy analysis is often performed to demonstrate the pharmacological efficacy 
of a compound, and as it includes only those participants who are compliant 
throughout, the observed effect is usually greater than that of an intent-to-treat 
analysis. Here though, the effect of candesartan on cognitive decline appears to be 
weaker as the differences between the groups are smaller and statistically non-
significant. However, the main characteristic that distinguishes the efficacy analysis, 
and the reason that intent-to-treat analyses are often preferred, is that the evaluable 
subset is selected post-hoc based on observations after baseline. Therefore the 
properties of randomisation do not apply and the possibility of systematic bias cannot 
be ruled out. 
By virtue of the fact they were selected by their compliance, participants included in 
the efficacy analysis had a higher average dose of candesartan and greater average 
length of follow-up. The reduction in BP from baseline was greater than that observed 
in the intent-to-treat analysis, particularly in the placebo group, which resulted in a 
smaller BP difference between the candesartan and placebo groups at study close (6/2 
mmHg, efficacy analysis vs. 8/3 mmHg, intent-to-treat). The smaller BP difference, 
combined with fewer participants in each group available for analysis, may account 
for the absence of significant differences due to a lack of statistical power.  
However, the efficacy subset does also appear to be qualitatively different from the 
intent-to-treat sample as a whole. In particular, none of the participants who 
experienced myocardial infarction during the trial were included in the efficacy subset. 
Also, comparison of Table 33 and Table 39 suggests that participants in the efficacy 
subset had better cognitive performance at baseline. With the reduced variance on all 
factors indicated by the smaller standard deviations, this suggests that the efficacy 
subset consisted of the healthier and more cognitively able participants who were less 
likely to exhibit cognitive decline.  
6.3.5 Efficacy subset versus the remainder of participants 
This was borne out by an unplanned post-hoc comparison between the participants 
included in the efficacy analysis and the remaining participants with calculable 
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coefficients of decline from the Newcastle Cognitive Substudy (i.e. participants 
included in the intent-to-treat analysis but not eligible for the efficacy analysis). The 
baseline demographic characteristics of the two groups (Table 38) show that the 
efficacy subset were younger and less likely to have a history of atrial fibrillation. In 
terms of baseline cognitive performance, participants included in the efficacy subset 
performed significantly better on the Speed of Cognition factor and Episodic Memory, 
with a trend towards better performance in Executive Function (Table 39).  
By definition, the participants that were not included in the efficacy subset were less 
compliant and therefore had a lower mean dose of candesartan compared to the 
efficacy subset (12±4 vs. 14±3 mg once daily, t=2.4, p=.02). Similarly, for those 
participants attending the closeout visit (n=37), BP at study close was significantly 
higher than that of the efficacy subset (SBP 155±25 vs. 143±15 mmHg, t=-3.9, p<.01; 
DBP 79±12 vs. 74±9 mmHg, t=-3.0, p<.01). 
Table 40 shows the results of the univariate general linear model comparing the 
average slopes of decline for the two groups on each factor, controlling for age, 
estimated pre-morbid IQ and baseline cognitive function as covariates. Participants in 
the efficacy subset exhibited significantly less decline in Attention and Speed of 
Cognition, with almost no annual percentage change from baseline, and a notable 
learning effect in Executive Function. Perhaps more interestingly, the standard 
deviations of the decline coefficients on all factors were much smaller in the efficacy 
subset, suggesting that this subset was more homogenous as a group in terms of 
cognitive function, as well individually more stable over time. Again, it must be noted 
though that the selection of the efficacy subset was not at random and the analyses 
were post-hoc. It is therefore not possible to determine cause and effect: whether 
compliance throughout the study led to less decline in cognitive function, or whether 
those participants who exhibited less decline in cognitive function were more likely to 
be compliant and thus be selected for the efficacy analysis.  
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Table 38: Baseline demographics: ‘Efficacy’ vs ‘Remainder’ 
Baseline demographic characteristics of participants included in the efficacy analysis 
(Efficacy) versus participants included in the intent-to-treat analysis but not eligible 
for the efficacy analysis (Remainder). 
Data shown are mean and (SD), or percentages.  
 Efficacy  Remainder t / χ2 p 
 n=152 n=76   
 
Age, years 
 
75 (4) 
 
77 (5) 
 
-2.2 
 
.03 
Females 55% 50% .56 .45 
Education, years 10 (2) 10 (2) .14 .89 
NART errors 18 (9) 18 (8) .44 .66 
MMSE score 29 (1) 29 (1) .35 .73 
SBP mmHg 165 (8) 165 (9) -.11 .91 
DBP mmHg 88 (6) 88 (8) -.07 .94 
Smokers 14% 20% 1.4 .24 
HCTZ at enrolment 27% 29% .10 .75 
Previous MI 5% 9% 1.9 .17 
Previous stroke 4% 4% 0.0 1.0 
Atrial fibrillation 1% 9% 8.3 .004 
 
NART = New Adult Reading Test; MMSE = Mini-Mental State Examination; SBP = 
systolic blood pressure; DBP = diastolic blood pressure; HCTZ = 
hydrochlorothiazide; NSAIDs = non-steroidal anti-inflammatory drugs; MI = 
myocardial infarction. 
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Table 39: Baseline cognitive performance: ‘Efficacy’ vs ‘Remainder’ 
Comparison of baseline performance on the composite cognitive factors between 
participants included in the efficacy analysis (Efficacy) versus participants included in 
the intent-to-treat analysis but not eligible for the efficacy analysis (Remainder). A 
higher score indicates better performance except for Speed of Cognition, where a 
lower score indicates better performance. 
Data shown are mean and (SD) 
Factor Efficacy  Remainder t p 
 n=152 n=76   
       
Speed of Cognition 6323 (1105) 6809 (1259) -3.0 .003 
Continuity of Attention 92.5 (2.5) 92.1 (3.2) .88 .38 
Episodic Memory 229 (54) 213 (48) 1.9 .05 
Working Memory 1.60 (0.35) 1.57 (0.32) .60 .55 
Executive Function  1.53 (3.01) 0.76 (3.45) 1.7 .09 
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Table 40: Change in cognition: ‘Efficacy’ vs ‘Remainder’ 
Comparison of change in cognition between participants included in the efficacy analysis (Efficacy) versus participants included in the intent-to-
treat analysis but not eligible for the efficacy analysis (Remainder), as measured by coefficients of decline on five composite factor scores. 
Adjusted for age, New Adult Reading Test errors and baseline performance. Negative values indicate decline in performance over time. 
Data shown are mean and (SD). 
 Coefficients of Decline     Annual Percentage Change 
from Baseline 
 Efficacy  Remainder    Efficacy  Remainder 
Cognitive 
factor 
n=152 n=76 F P  % % 
        
Speed of 
Cognition 
0.1 (17.0) -30.1 (110.1) 3.3 0.001  0.0 -5.3 
Attention 
 
0.004 (0.05) -0.057 (0.24) 3.1 0.003  0.1 -0.7 
Episodic 
Memory 
0.02 (0.93) -0.17 (1.90) 1.0 0.34  0.1 -1.0 
Working 
Memory 
0.0013 (0.0069) 0.0011 (0.0181) 0.1 0.91  1.0 0.8 
Executive 
Function 
0.0045 (0.0427) -0.0039 (0.1048) 0.8 0.40  3.5 -6.2 
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6.3.6 Efficacy analysis: summary 
The efficacy analysis did not reproduce the significant effects of candesartan on 
cognitive decline that were observed in the primary analysis. This was perhaps due to 
the lower number of cases, and the smaller BP difference between the candesartan and 
placebo groups at study close, reducing the statistical power of the analysis. However, 
as a selective subset of the participants in the intent-to-treat analysis, the efficacy 
analysis participants were not representative as they appeared more cognitively able at 
baseline and remained healthier during the study than the group as a whole. Direct 
statistical comparison of the participants included in the efficacy analysis versus the 
remainder of participants from the intent-to-treat analysis, showed that the efficacy 
group were younger and performed significantly better at baseline on two of the 
cognitive factors. The efficacy subset showed significantly less decline in Attention 
and Speed of Cognition, and as a group showed less variation in the coefficients of 
decline than those participants not included in the efficacy subset. Although the results 
did not show a more pronounced effect of candesartan as may have been expected, 
they demonstrate the value of the intent-to-treat method as the primary analysis. The 
collection and inclusion of all follow-up data from as many randomised participants as 
possible in the primary analysis provided a different picture to that of the efficacy 
analysis; one that would have been distorted by the selective characteristics of the 
sample if the efficacy analysis was solely relied upon.  
6.4 Secondary analyses: loss to follow-up 
Attrition within any study is inevitable but an important factor as it can affect the 
generalisability of the results and the statistical power of the analyses. To maximise 
the number of participants available for the primary analysis, all participants, 
including those withdrawn during the study, were invited to attend the closeout visit. 
Of the 250 participants recruited to the Newcastle Cognitive Substudy, cognitive 
follow-up data were unavailable for 22 cases giving a sample size of 228 for the 
primary analysis: 4 were still participating in the study but died before the first annual 
assessment; 10 withdrew before the first annual assessment and were deceased at 
closeout; 8 withdrew consent and declined the invitation to attend at closeout. 
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Excluding the deceased participants, the withdrawal of consent from only 8 
participants represented a follow-up success rate of 96%. 
The baseline characteristics of participants included in the primary analysis and those 
with less than two cognitive assessments are compared in Table 41. Participants 
without follow-up data were older, more likely to be smokers, and more likely to have 
a history of myocardial infarction; there were no significant differences on other 
baseline demographic variables. Although there were no significant differences on the 
composite cognitive factors at baseline, the withdrawn participants performed slightly 
worse on each of the factors (Table 42), perhaps reflecting their older age and poorer 
health.  
It was particularly important to demonstrate that there were no systematic differences 
between those who completed the study and those who did not. As the cases of loss to 
follow-up were roughly evenly distributed between the randomised groups (12 
candesartan, 10 placebo, χ2 = .24, p=.63), selective attrition due to treatment 
allocation was not evident. Thus, although the participants lost to follow-up were not 
completely representative of those included in the primary analysis, the lack of 
association with treatment allocation indicated that the properties of randomisation 
between the candesartan and placebo groups remained intact. 
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Table 41: Baseline demographics: primary analysis vs ‘lost to follow-up’ 
Data shown are mean and (SD), or percentages.  
 Primary 
analysis 
Loss to 
follow-up 
t / χ2 p 
 n=228 n=22   
 
Age, years 
 
76 (4) 
 
78 (6) 
 
-2.3 
 
.02 
Females 54% 50% .09 .75 
Education, years 10 (2) 9 (1) 1.4 .15 
MMSE score 29 (1) 29 (2) .20 .84 
NART errors 18 (9) 18 (8) .44 .66 
SBP mmHg 165 (8) 165 (11) .02 .98 
DBP mmHg 88 (7) 87 (10) .91 .36 
Smokers 16% 41% 8.4 .004 
HCTZ at enrolment 27% 23% .24 .62 
Previous MI 6% 23% 7.9 .005 
Previous stroke 4% 0% .90 .34 
Atrial fibrillation 4% 9% 1.3 .26 
 
NART = New Adult Reading Test; MMSE = Mini-Mental State Examination; SBP = 
systolic blood pressure; DBP = diastolic blood pressure; HCTZ = 
hydrochlorothiazide; NSAIDs = non-steroidal anti-inflammatory drugs; MI = 
myocardial infarction.  
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Table 42: Baseline cognitive performance: primary analysis vs ‘lost to follow-up’ 
Comparison of baseline performance on the composite cognitive factors between 
participants included in the primary analysis versus participants lost to follow-up. A 
higher score indicates better performance except for Speed of Cognition, where a 
lower score indicates better performance. 
Data shown are mean and (SD) 
Factor Primary analysis Loss to follow-
up 
t p 
 n=228 n=22   
       
Speed of Cognition 6485 (1178) 6790 (2351) -1.0 .30 
Continuity of Attention 92.0 (2.8) 91.6 (2.8) 1.2 .25 
Episodic Memory 224 (53) 219 (50) .35 .72 
Working Memory 1.59 (0.34) 1.49 (0.40) 1.2 .23 
Executive Function  1.27 (3.17) 0.84 (2.69) .60 .55 
 
6.5 Secondary analyses: excluding participants suffering stroke 
It is well known that stroke has a detrimental effect on cognitive function. To 
investigate the possibility that the differences between the candesartan and placebo 
groups observed in the primary analysis were influenced by the incidence of stroke, 
the analyses were repeated excluding participants that suffered fatal/non-fatal stroke 
(4 candesartan, 8 placebo) during the study. The baseline characteristics of the 
participants included in the primary analysis and suffering stroke during the trial 
(Stroke) and participants not suffering from stroke (Non-stroke) are shown in Table 
43. Participants suffering stroke were more likely to be male, older in age, more likely 
to smoke and have a history of myocardial infarction, although as the number of 
participants in the stroke group was low, none of the differences at baseline reached 
statistical significance. The stroke group also had higher baseline BP and poorer 
MMSE scores. The baseline composite factor scores of the participants with and 
without stroke are shown in Table 44. The stroke group had poorer performance on all 
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cognitive factors, with significant differences in Episodic Memory and Executive 
Function.  
The primary analysis was repeated excluding the 12 participants suffering stroke 
during the trial. The results in Table 45 show that the significant effects of candesartan 
on Attention and Episodic Memory persisted when participants with stroke were 
excluded, indicating that the results of the primary analysis were not due to the 
influence of stroke-related cognitive dysfunction during the study. Overall the 
exclusion of participants with stroke made little difference to the average slopes of 
decline or annual percentage change from baseline, with the exception of Executive 
Function.  
In the primary analysis the average annual change in Executive Function from 
baseline was -3.2% and -2.0% for the candesartan and placebo groups respectively. 
Excluding participants with stroke from the analysis indicated a slight annual 
improvement of 0.2% in the candesartan group and a smaller decline of -1.1% in the 
placebo group, though the differences between groups remained non-significant. The 
data showed that participants who went on to suffer stroke during the study had 
performed significantly worse on Executive Function at baseline, and as the 
percentage is calculated as a change from baseline values, the results of the analyses to 
some extent simply reflect this. However, the average slopes of decline also differ 
between the analyses suggesting that there is perhaps an association between stroke 
and Executive Function. The nature of such a relationship is not easily discernible 
from the data. The measurement of Executive Function took place before the stroke 
occurred and therefore may be a risk factor or predictive of future stroke. However, 
poor Executive Function at baseline may reflect subclinical cerebrovascular disease 
such as leukarosis and the presence of white matter changes. Or it is possible that both 
poor Executive Function and future stroke may be under the influence of a third 
factor. 
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Table 43: Baseline demographics: ‘Stroke’ vs ‘Non-stroke’ 
Data shown are mean and (SD), or percentages.  
 Non-stroke Stroke t / χ2 p 
 n=216 n=12   
 
Age, years 
 
76 (4) 
 
77 (5) 
 
.79 
 
.43 
Females 54% 42% .71 .40 
Education, years 10 (2) 10 (2) .58 .56 
NART errors 18 (9) 21 (8) 1.2 .23 
MMSE score 29 (1) 28 (2) -1.7 .09 
SBP mmHg 165 (8) 170 (9) 1.9 .06 
DBP mmHg 88 (7) 92 (6) 1.8 .06 
Smokers 15% 33% 2.9 .09 
HCTZ at enrolment 28% 25% .04 .83 
Previous MI 6% 17% 2.4 .12 
Previous stroke 4% 8% .64 .42 
Atrial fibrillation 4% 0% .52 .47 
 
NART = New Adult Reading Test; MMSE = Mini-Mental State Examination; SBP = 
systolic blood pressure; DBP = diastolic blood pressure; HCTZ = 
hydrochlorothiazide; NSAIDs = non-steroidal anti-inflammatory drugs; MI = 
myocardial infarction.  
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Table 44: Baseline cognitive performance: ‘Stroke’ vs ‘Non-stroke’  
Comparison of baseline performance on the composite cognitive factors between 
participants suffering a fatal or non-fatal stroke during the study (Stroke) versus the 
remaining participants who did not (Non-stroke). A higher score indicates better 
performance except for Speed of Cognition, where a lower score indicates better 
performance. 
Data shown are mean and (SD) 
Factor Non-stroke Stroke t p 
 n=216 n=12   
       
Speed of Cognition 6457 (1161) 7003 (1420) 1.6 .12 
Continuity of Attention 92.4 (2.8) 91.1 (2.6) -1.6 .12 
Episodic Memory 227 (52) 174 (45) -2.8 .005 
Working Memory 1.59 (0.34) 1.56 (0.38) -.34 .73 
Executive Function  1.41 (3.01) -1.15 (4.92) -2.8 .006 
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Table 45: Secondary analysis: change in cognition excluding stroke 
Secondary analysis: comparison of change in cognition between the candesartan and placebo groups, as measured by coefficients of decline on 
five composite factor scores, excluding participants suffering fatal/non-fatal stroke during the study. Adjusted for age, New Adult Reading Test 
errors and baseline performance. Negative values indicate decline in performance over time. 
Data shown are mean and (SD). 
 Coefficients of Decline     Annual Percentage Change 
from Baseline 
 Candesartan Placebo    Candesartan Placebo 
Cognitive 
factor 
n=108 n=108 F P  % % 
        
Speed of 
Cognition 
-1.8 (25.2) -16.5 (92.0) 2.0 0.16  -0.3 -3.0 
Attention 
 
0.005 (0.086) -0.035 (0.189) 3.9 0.05  0.1 -0.5 
Episodic 
Memory 
0.20 (1.32) -0.18 (1.21) 5.5 0.02  0.0 -1.1 
Working 
Memory 
0.0017 (0.0117) 0.0012 (0.0121) .03 0.85  1.3 0.9 
Executive 
Function 
0.0002 (0.0591) -0.0015 (0.0757) .11 0.75  0.2 -1.1 
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6.6 Secondary analyses: excluding participants taking beta-blockers 
There has been concern in the literature that the use of beta-blockers in the treatment 
of hypertension may lead to impairment of cognitive function. At the closeout visit, 
the number of participants in the placebo group taking beta-blockers as additional 
antihypertensive therapy was almost double that of the candesartan group (20 vs. 12) 
(Table 31). In order to investigate whether the results of the primary analysis were 
independent of beta-blocker use, the primary analysis was repeated excluding all 
participants that had taken beta-blockers at any time after randomisation. In line with 
the proportions at closeout, the number taking beta-blockers at any time was higher in 
the placebo group (n=30) than the candesartan group (n=18), giving a sample size of 
180 for the repeated analysis. 
The baseline demographic characteristics of the participants who took beta-blockers 
and those who did not take beta-blockers at any time during the study are compared in 
Table 46. The rate of hydrochlorothiazide use at enrolment was significantly higher in 
participants who went on to be prescribed beta-blockers during the study than those 
who did not. As thiazides are recommended as the first line of antihypertensive 
therapy in UK general practice, the higher rate is not surprising for those participants 
requiring additional medication. Also, as participants receiving antihypertensive 
therapy at study entry were standardised to hydrochlorothiazide, the beta-blocker 
group could include participants receiving hydrochlorothiazide at enrolment but 
subsequently changed to beta-blockers during the study, rather than receiving it as a 
second additional antihypertensive medication. Baseline performance on the 
composite factor scores is compared in Table 47 and shows no significant differences 
between the two groups, although there is a trend towards better performance on 
Speed of Cognition for the beta-blocker group. The exclusion of participants taking 
beta-blockers made no significant difference to the primary analysis (Table 48). 
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Table 46: Baseline demographics: ‘Beta-blockers’ vs ‘Beta-blocker free’ 
Data shown are mean and (SD), or percentages.  
 Beta-blocker 
free 
Beta-blockers t / χ2 p 
 n=180 n=48   
 
Age, years 
 
76 (5) 
 
75 (4) 
 
-.66 
 
.51 
Females 52% 60% 1.2 .28 
Education, years 10 (2) 10 (2) -1.8 .08 
NART errors 18 (9) 17 (9) -.62 .54 
MMSE score 29 (1) 29 (1) 1.3 .19 
SBP mmHg 165 (8) 167 (7) 1.2 .22 
DBP mmHg 88 (7) 88 (7) -.70 .48 
Smokers 17% 13% .51 .48 
HCTZ at enrolment 24% 42% 6.0 .01 
Previous MI 6% 8% .51 .48 
Previous stroke 4% 2% .56 .46 
Atrial fibrillation 4% 4% .01 .93 
 
NART = New Adult Reading Test; MMSE = Mini-Mental State Examination; SBP = 
systolic blood pressure; DBP = diastolic blood pressure; HCTZ = 
hydrochlorothiazide; NSAIDs = non-steroidal anti-inflammatory drugs; MI = 
myocardial infarction.  
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Table 47: Baseline cognitive performance: ‘Beta-blockers’ vs ‘Beta-blocker free’ 
Comparison of baseline performance on the composite cognitive factors between 
participants who took beta-blocker medication at any time during the study (Beta-
blockers) versus the remaining participants who did not (Beta-blocker free). A higher 
score indicates better performance except for Speed of Cognition, where a lower score 
indicates better performance. 
Data shown are mean and (SD) 
Factor Beta-blocker free Beta-blockers t p 
 n=180 n=48   
       
Speed of Cognition 6554 (1215) 6229 (1002) -1.7 .09 
Continuity of Attention 92.2 (2.9) 92.8 (2.3) 1.3 .21 
Episodic Memory 223 (54) 228 (47) .45 .65 
Working Memory 1.58 (0.34) 1.61 (0.35) .41 .68 
Executive Function  1.11 (3.32) 1.87 (2.53) 1.5 .14 
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Table 48: Secondary analysis: change in cognition excluding participants taking beta-blockers 
Secondary analysis: comparison of change in cognition between the candesartan and placebo groups, as measured by coefficients of decline on 
five composite factor scores, excluding participants taking beta-blockers at any time during the study. Adjusted for age, New Adult Reading Test 
errors and baseline performance. Negative values indicate decline in performance over time. 
Data shown are mean and (SD). 
 Coefficients of Decline     Annual Percentage Change 
from Baseline 
 Candesartan Placebo    Candesartan Placebo 
Cognitive 
factor 
n=94 n=86 F P  % % 
        
Speed of 
Cognition 
-0.4 (21.4) -23.1 (102.9) 3.1 0.08  0.0 -4.1 
Attention 
 
0.001 (0.086) -0.045 (0.211) 5.2 0.02  0.0 -0.6 
Episodic 
Memory 
0.27 (1.41) -0.32 (1.30) 8.0 0.005  1.5 -1.7 
Working 
Memory 
0.0016 (0.0122) 0.0012 (0.0132) .07 0.79  1.2 0.9 
Executive 
Function 
-0.0004 (0.0613) -0.0055 (0.0818) .28 0.60  -0.4 -6.3 
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6.7 Acute drug effects 
To compare acute changes between the treatment groups, the difference from baseline 
scores was calculated for each composite from the CDR battery. The traditional tests 
of Executive Function were not administered as 1 month due to concerns over 
learning effects in the measures as parallel forms were not available. The results 
(Table 49) show no significant differences between the groups in change scores 
between baseline and 1 month, indicating no acute effect of candesartan treatment at 
one month.  
 
Table 49: Assessment of acute drug effects 
Comparison of change scores from baseline to 1 month on the composite cognitive 
factors between candesartan and placebo groups. A higher score indicates improved 
performance except for Speed of Cognition, where a lower score indicates improved 
performance. 
Data shown are mean and (SD) 
Factor Candesartan  Placebo t p 
 n=109 n=113   
       
Speed of Cognition -158 (737) -176 (648) 0.19 .85 
Continuity of Attention 0.6 (2.7) 0.3 (2.7) 0.58 .56 
Episodic Memory 1.1 (40) -5.0 (41) 0.94 .35 
Working Memory 0.06 (0.4) 0.07 (0.4) -0.17 .87 
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CHAPTER 7: RESULTS – COMPARISON WITH 
NORMOTENSIVE COHORT  
This chapter presents the data from the normotensive participants to assess their 
suitability as a normative comparison group. The primary analysis of the effect of 
candesartan on cognitive decline is repeated with the normotensive data included to 
put the treatment effects into context. The relationship of BP as a continuous variable 
is then explored. 
7.1 Normotensive control group: follow-up visits 
7.1.1 Study visit attendance  
Unlike the hypertensive participants for whom entry into the Newcastle Cognitive 
Substudy was an optional addition to the main SCOPE study and the cognitive 
assessments were conducted alongside their scheduled study visits, the normotensives 
were recruited solely for entry into the substudy. Therefore at follow-up visits where 
cognition assessments were due (i.e. annual visits after baseline), there were no 
instances where BP-related and cardiovascular-related outcomes were assessed in the 
absence of cognitive data. All of the normotensive assessments were performed in the 
research clinic, versus 9 visits in the hypertensive cohort that took place in the 
participants’ homes. 
The number of completed normotensive study visits are shown in Table 50, including 
the 6-monthly visits where BP, MMSE and concomitant medications only were 
assessed. The number of cognitive assessments administered by the candidate is also 
shown. Because of the rolling recruitment period, not all participants were due for 
scheduled study visits beyond the minimum follow-up period of 36 months. As 
expected, the percentage who attended each visit diminished over time due to the 
natural attrition associated with withdrawal of consent, and death. At the closeout visit 
all participants, current and withdrawn, were invited to attend in order to minimise the 
loss to follow-up.  
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7.1.2 Study visit attendance: comparison with hypertensive cohort  
The proportion of cognitive assessments performed, calculated as a percentage of 
those due, is also shown for the hypertensive cohort in Table 50 (note: the values 
represent cognitive assessments performed, and therefore differ from those in Table 
30, where the data shown are SCOPE study visits attended). Differential attrition rates 
between groups can be a concern, particularly when using a non-randomised control 
group for normative comparison. However, the percentage of cognitive assessments 
successfully conducted was almost identical between the normotensive and 
hypertensive cohorts at each timepoint, supporting the suitability of the normotensives 
as a normative control group in the Newcastle Cognitive Substudy. 
The proportion of completed closeout cognitive assessments as a percentage of the 
sample recruited was similar between the two groups (normotensives 70% vs 
hypertensives 73%) as shown in Table 50. Adjusting for the number of deceased 
participants at the close of the normotensive study (n=13), the 179 closeout 
assessments represents a 74% completion rate of those possible. For approximately 
the same number of assessments conducted, due to the greater number of deaths in the 
hypertensive cohort (n=36), the completion rate as a proportion of visits possible was 
higher in the hypertensive cohort at 85%. Although it was not permitted to elicit 
reasons for attendance/ refusal to attend the closeout visit, it is possible that the 
prospect of receiving a full medical check-up, routine laboratory blood tests and ECG 
within the SCOPE study was perceived as advantageous and made it more likely for 
withdrawn hypertensive participants to consent to return for the closeout visit than the 
normotensives, where such procedures were not performed after baseline.  
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Table 50: Number of completed normotensive cohort study visits  
 
Visit Normotensive 
visits attended 
Cognitive 
assessments 
performed by 
candidate 
Normotensive 
cognitive 
assessments 
performed/ due  
 Hypertensive 
cognitive 
assessments 
performed/ due 
months n n %  % 
 
Baseline 
 
256 
 
256 
 
100 
  
100 
1 248 248 97  95 
6 233 - -  - 
12 223 223 87  86 
18 216 - -  - 
24 203 203 79  79 
30 193 - -  - 
36 175 166 68  64 
42 113 - -  - 
48 35 33 77  74 
54 12 - -  - 
Closeout 179 0 70  73 
  
7.2 Normotensive control group: blood pressure 
7.2.1 Blood pressure measurements 
For the normotensive participants attending the closeout visit, BP changed from 
131±11/73±7 mmHg at baseline to 127±14/72±6 mmHg at study close (SBP, t=3.18, 
p=.002; DBP, t=1.45, p=.148). Similar results were found when analysed using the 
last observation carried forward (129±14/73±7 mmHg). The average BP across the 
study, calculated using data from all planned BP monitoring visits after baseline, was 
131±10/74±6 (SBP, t=-1.14, p=.254; DBP, t=-.98, p=.328). The mean BP levels at 
each scheduled study visit compared to the combined hypertensive group are shown in 
Figure 32; Figure 33 shows the normotensive, candesartan and placebo groups 
separately 
 180 
Figure 32: BP at each scheduled SCOPE study visit: normotensive group 
Mean systolic (SBP) and diastolic (DBP) blood pressure at each scheduled SCOPE 
study visit: normotensive group versus hypertensive group in the Newcastle Cognitive 
Substudy 
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Figure 33: BP at each scheduled visit: three group comparison 
Mean systolic (SBP) and diastolic (DBP) blood pressure at each scheduled SCOPE 
study visit: normotensive group versus candesartan and placebo groups in the 
Newcastle Cognitive Substudy 
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7.2.2 Antihypertensive medication use  
The normotensive participants were free from antihypertensive medication at the time 
of enrolment. However as a non-intervention, observational control group, no 
restrictions could be placed on the prescription of concomitant medications by the 
participants' general practitioners, including antihypertensive therapy during the study. 
Indeed, if BP was raised and confirmed by a repeat BP check after a minimum of 14 
days, a letter was sent to the participant's general practitioner informing them of the 
BP readings and suggesting monitoring in accordance with routine care (described in 
Methods 2.2.3).Twenty-seven participants received one or more antihypertensive 
medications during the follow-up period; the number prescribed each type of 
antihypertensive medication is shown in Table 51. 
 
Table 51: Antihypertensive therapy: normotensive control group  
Data shown are number of participants per medication class. Some participants were 
taking more than one BP-lowering drug. 
 Normotensives 
 n=256 
  
Thiazides 
 
8 
Calcium-channel blockers 7 
Beta-blockers 11 
Angiotensin converting enzyme inhibitors 8 
Angiotensin II receptor antagonists 2 
Alpha-blockers 0 
No antihypertensive therapy 229 
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7.2.3 Treated vs. untreated normotensives 
Comparison of the baseline characteristics of normotensive participants prescribed 
antihypertensive medication versus those that remained untreated during the study 
showed that treated normotensives had higher significantly higher baseline SBP and a 
trend towards higher DBP, as shown in Table 52. 
Table 52: Baseline characteristics of treated vs untreated normotensives 
Data shown are means (SD) or percentages.  
 Treated 
normotensives 
Untreated 
normotensives 
p 
 n=27 n=229  
 
Age, years 
 
76 (4) 
 
76 (4) 
 
.72 
Females 52% 43% .39 
MMSE score 29 (2) 29 (1) .66 
SBP mmHg 134 (9) 130 (11) .03 
DBP mmHg 75 (6) 73 (7) .07 
Smokers 22% 15% .54 
Previous MI 7% 3% .32 
Previous stroke 4% 0% .07 
Atrial fibrillation 4% 2% .49 
 
MMSE = Mini-Mental State Examination; SBP = systolic blood pressure; DBP = 
diastolic blood pressure; MI = myocardial infarction. 
For the normotensive participants attending the closeout visit, in those who remained 
untreated during the study BP fell slightly from 129±11/73±7 mmHg at baseline to 
127±14/73±6 mmHg at the closeout visit (SBP, t=2.62, p=.010; DBP, t=.63, p=.528); 
for the normotensives prescribed antihypertensives, BP was reduced from 134±7/75±7 
to 128±12/71±5 mmHg (SBP, t=2.13, p=.046; DBP, t=2.58, p=.018). The mean of 
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individual changes in BP from baseline to closeout was greater in the treated 
normotensive group compared to untreated normotensives (SBP 6±13 vs 3±14 mmHg, 
t=1.00, p=.317; DBP 4±8 vs 0±8, t=2.18, p=.031) reflecting the action of the 
antihypertensive therapy. 
The average BP across the study, calculated using data from all planned BP-
monitoring visits after baseline, was 131±10/74±6 mmHg in the untreated group 
versus 133±9/73±5 mmHg in the treated group (SBP, t=1.07, p=.286; DBP, t=.74, 
p=.463). Comparison of the mean BP at each scheduled SCOPE study visit between 
the untreated normotensives versus normotensives receiving antihypertensive 
medication during the follow-up period is shown in Figure 34. The figures show that 
mean BP was more variable between visits in the treated group than the untreated 
normotensives, the rises in BP likely precipitating the need for antihypertensive 
medication. Although the figures appear to indicate that BP fell sharply between the 
42 month and 48 month visits, due to the rolling recruitment period the mean BP at 
the 48 month visit was calculated on only 35 participants, and only 7 of those in the 
group receiving antihypertensive medication. Therefore the 48 month BP values could 
reflect a sampling bias more than a true reduction in BP in the groups at this 
timepoint.  
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Figure 34: BP at each scheduled visit: treated vs untreated normotensives 
Mean systolic (SBP) and diastolic (DBP) blood pressure at each scheduled SCOPE 
study visit: normotensive group participants treated with antihypertensive vs untreated 
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7.3 Normotensive control group: length of follow-up 
7.3.1 Length of follow-up 
For the 256 normotensive controls in the cognitive substudy, the mean length of 
follow-up was 38±17 months (range 0-60 months) compared to 43±14 months (range 
0-59 months) for the 250 hypertensive participants (t=3.82, p<.001). For the 
normotensives and hypertensives with calculable slopes of decline, the difference in 
length of follow-up was smaller (43±11, range 12-60 months vs 46±9, range 12-59 
months) but remained statistically significant (t=2.99, p=.003). However, the follow-
up length in the hypertensive group corresponded to the scheduled SCOPE study 
visits, and hypertensive participants were encouraged to attend even after withdrawing 
from the Newcastle Cognitive Substudy to reduce loss to follow-up in the main 
SCOPE study. Of more relevance to the cognitive outcomes is length of follow-up to 
the last cognitive assessment performed, as these data inform the calculation of the 
slopes of decline. Although numerically a slightly longer follow-up period in the 
hypertensive group remained (45±13, range 12-60 months), it was not statistically 
significant (t=1.53, p=.126) and represented a difference of only 47 patient years 
between the normotensives (801 patient years) and the hypertensives (848 patient 
years).  
7.4 Suitability of normotensive control group 
As a non-randomised observational group, the suitability of the normotensive controls 
for use as a normative comparison group was very important. As described in the 
Methods section 2.2.5, the normotensives were recruited to the Newcastle Cognitive 
Substudy using the same inclusion/exclusion criteria applied to the hypertensive 
participants entering the main SCOPE trial, with the single exception of the entry BP 
levels and antihypertensive medication use. As far as possible the same study 
procedures were applied to the normotensives during follow-up, although no 
restrictions could be placed on the use of antihypertensive medications prescribed 
during the study, and there was no requirement or provision for the routine medical 
checks at the closeout visit. In terms of the number of scheduled follow-up visits 
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attended, number of cognitive assessments contributing to the slopes of decline, and 
the length of follow-up, the normotensives were very comparable to the hypertensive 
cohort. Although a small proportion of normotensives required antihypertensive 
medication to control their BP during the study, as the purpose of the control group 
was to provide a naturalistic, observational comparison to put the changes in the 
hypertensive groups into context, the treated normotensives were included in the 
comparison group. This was the a priori intention because it represented the more 
conservative analysis approach, as to exclude them could possibly bias the sample 
towards those participants less likely to show cognitive decline, because of the known 
association between hypertension and poorer cognition.  
7.5 Participants included in the normotensive comparison 
7.5.1 Calculable coefficients of cognitive decline 
As described in the Methods section 2.4.2, to calculate the outcome measure of the 
slope of decline for an individual, a minimum of two cognitive assessments 12 
months apart were required. Due to the natural attrition associated with death and 
withdrawal of consent, follow-up cognitive data were unavailable for 32 normotensive 
participants. Of the 224 with calculable coefficients of decline, 159 (71%) participants 
completed the maximum number of assessments (4, 5 or 6 visits depending on time of 
recruitment); 31 (14%) had one missing data point; 20 (9%) had two missing data 
points; 12 (5%) missed three assessments; and 2 (1%) missed four assessments. The 
number of calculable coefficients of decline was comparable to that of the 
hypertensive group (224 normotensives versus 228 hypertensives) as shown in Figure 
35. The proportion of missing data was almost identical, with the maximum number 
of assessments informing the slopes of decline for approximately 70% of participants 
in both groups (hypertensive cohort described in section 6.1). For the normotensives, a 
smaller proportion of participants had three or four missing assessments. However, 
rather than reflecting better participation for the normotensives per se, this was more 
likely the product of a higher proportion of withdrawn hypertensives returning to 
attend the closeout visit.  
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7.6.2 Baseline characteristics 
Comparison of the normotensive and hypertensive participants with calculable 
coefficients of decline showed that there were no significant differences in baseline 
demographics (), other than those already identified between the overall recruited 
cohorts (detailed in 3.3.1): within groups there was an approximate 1:1 ratio of males 
to females, although comparison between groups showed that the proportion of males 
was slightly higher in the normotensive group; the prevalence of previous stroke was 
higher in the hypertensive group as expected, given the established relationship 
between hypertension and cardiovascular disease; and by definition normotensive 
participants had lower SBP and DBP. 
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Figure 35: Participant flow in the Newcastle Cognitive Substudy  
256 participants 257 eligible participants 
Normotensives 
 
Hypertensives 
 
Not applicable 4 declined substudy 
3 baseline data missing 
32 with < 2 annual assessments 
 
22 with < 2 annual assessments 
 
224 available for analysis 
 
228 available for analysis 
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Table 53: Baseline demographics: normotensive vs hypertensives  
Baseline demographic characteristics of normotensive participants versus hypertensive 
participants with calculable coefficients of decline in the Newcastle Cognitive 
Substudy. 
Data shown are mean and (SD), or percentages.  
 Normotensives Hypertensives t / χ2 p 
 n=224 n=228   
 
Age, years 
 
76 (4) 
 
76 (4) 
 
-.35 
 
.73 
Females 42% 54% 6.04 .01 
Education, years 10 (2) 10 (2) .49 .62 
NART errors 18 (9) 18 (9) .32 .75 
MMSE score 29 (1) 29 (1) -.62 .54 
SBP mmHg 131 (11) 165 (8) 38.43 <.001 
DBP mmHg 74 (7) 88 (7) 22.52 <.001 
Smokers 17% 13% 1.19 .28 
HCTZ at enrolment n/a 28% - - 
Previous MI 4% 6% 1.61 .20 
Previous stroke 1% 4% 4.44 .04 
Atrial fibrillation 2% 4% 1.11 .29 
 
NART = New Adult Reading Test; MMSE = Mini-Mental State Examination; SBP = 
systolic blood pressure; DBP = diastolic blood pressure; HCTZ = 
hydrochlorothiazide; MI = myocardial infarction. 
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7.6.3 Baseline cognitive function 
Comparison of the composite scores at baseline between the normotensive and 
hypertensive participants with calculable slopes of decline is shown in Table 54. 
Similar to the comparison of the overall recruited cohorts on the subtests of the CDR 
battery and tests of executive function detailed in section 3.4, the hypertensive 
participants performed significantly worse than the normotensives on the majority of 
the composite domains, with the exception of Continuity of Attention. Baseline 
differences in cognition were expected, and supported the a priori inclusion of 
baseline performance as a covariate in the general linear models (described in section 
2.5.2). 
 
Table 54: Baseline cognitive performance: normotensives vs hypertensives  
Comparison of baseline performance on the composite cognitive factors between the 
normotensive and hypertensive groups, in participants with calculable coefficients of 
decline. A higher score indicates better performance except for Speed of Cognition, 
where a lower score indicates better performance 
Data shown are mean and (SD) 
Factor Normotensives Hypertensives  t p 
 n=224 n=228   
       
Speed of Cognition 6040 (1140) 6485 (1178) 4.08 <.001 
Continuity of Attention 92.5 (2.2) 92.3 (2.8) -.57 .57 
Episodic Memory 241 (42) 224 (53) -3.49 .001 
Working Memory 1.71 (0.26) 1.59 (0.34) -4.37 <.001 
Executive Function  2.56 (2.83) 1.27 (3.18) -4.50 <.001 
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7.6 Three-group comparison of cognitive decline 
7.6.1 Repeat of primary analysis 
The primary analysis of the Newcastle Cognitive Substudy compared the rate of 
cognitive decline between the hypertensive participants randomised to candesartan or 
placebo on an intent-to-treat basis. To put the rates of decline and magnitude of 
differences between the treatment groups into context, the primary analysis was 
repeated with the inclusion of the follow-up data from the normotensive controls. The 
univariate general linear model procedure was used to compare decline on each 
cognitive factor between the three groups, controlling for age, estimated pre-morbid 
IQ and baseline cognitive function as covariates.  
Table 55 shows the results of the general linear models comparing the candesartan and 
placebo groups to the normotensive controls on the rate of cognitive decline for each 
composite factor. Where the F statistic was significant, post-hoc pairwise comparison 
to the normotensive group using the Least Squared Difference was also examined.  
The placebo group showed significantly greater decline on Attention than the 
normotensive group, with no difference found between the candesartan group and the 
normotensive controls. For the Episodic Memory composite, where significant 
benefits were seen with candesartan compared to placebo in the primary analysis, 
although the overall model did not reach significance, the summary statistics show 
that the placebo group experienced a level of decline approximately twice that of the 
normotensive group, in contrast to a similar magnitude of improvement with 
candesartan compared to normotensive controls. Similarly for the Speed of Cognition 
composite, although not supported statistically, the placebo group showed the greatest 
declines, with the candesartan group exhibiting less decline than the normotensives. 
As in the primary analysis there was relatively little to distinguish between the groups 
on Executive Function, or Working Memory, although the normotensive group 
showed small declines in comparison to improvements of a similar size seen in both 
hypertensive groups.  
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Table 55: Three group comparison: normotensives vs candesartan vs placebo groups 
Three group comparison of cognitive decline: comparison of change in cognition between the normotensive group versus the candesartan and 
placebo groups, as measured by coefficients of decline on five composite factor scores, in all participants with calculable coefficients. Adjusted 
for age, New Adult Reading Test errors and baseline performance. Negative values indicate decline in performance over time. 
Data shown are mean and (SD). 
 Coefficients of Decline    Pairwise Comparisons 
 Normotensives Candesartan Placebo    vs. Candesartan  vs. Placebo 
Cognitive factor n=224 n=112 n=116 F p  p  p 
            
Speed of 
Cognition 
-6.6 (20.4) -2.3 (25.2) -17.4 (89.2) 2.3 .10  .21  .23 
Attention 
 
0.006 (0.096) 0.004 (0.088) -0.036 (0.184) 4.7 .01  .80  .003 
Episodic 
Memory 
-.09 (1.11) 0.14 (1.38) -0.22 (1.21) 2.6 .08  .10  .35 
Working 
Memory 
-0.0010 (0.0117) 0.0014 (0.0119) 0.0010 (0.0118) .05 .96  .77  .97 
Executive 
Function 
-0.0020 (0.0510) -0.0031 (0.0616) -0.0023 (0.0739) .09 .92  .73  .74 
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7.7.2 Effect sizes 
The effect size calculations using Glass’s Delta compared the change over time in the 
candesartan and placebo groups relative to the changes observed in the normotensive 
group. Figure 36 shows the magnitude of effects on each cognitive domain, where the 
zero line indicates the normotensive group for comparison: positive values represent 
better performance over time relative to the normotensives (either larger 
improvements or smaller declines); negative values represent worse performance over 
time relative to the normotensives (either larger declines or smaller improvements). 
Glass’s Delta can be conceptualised as the number of standard deviations separating 
each treatment group from the normative reference group and interpreted using the 
generally-accepted conventions (0.2 = small effect; 0.5 = medium effect; 0.8 = large 
effect). 
The largest differences appeared for Speed of Cognition where the placebo group 
showed a medium-sized decline compared to the change experienced by the 
normotensives, in contrast to less decline than the normotensives shown by the 
candesartan group. Similarly for Episodic Memory, the placebo group showed a 
small-to-medium size decline in comparison to the small decline in the normotensive 
group, whereas the candesartan group showed improvement over time. For Attention, 
the placebo group showed a small-to-medium decline, whereas change over time in 
the candesartan group matched that of the normotensives, showing minor 
improvements in both groups. For Working Memory, both hypertensive groups 
showed small improvements over time contrasted with similar-sized declines in the 
normotensives to produce a small effect size indicating improvement. However, the 
relative improvements could potentially be an artefact of the significantly different 
starting points of the hypertensive groups compared to the normotensives (Table 54), 
as no significant effects were found in the General Linear Models where baseline 
performance was controlled for as a covariate. For Executive Function there was little 
difference between any of the groups with effect sizes close to zero. 
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Figure 36: Effect sizes for candesartan and placebo groups compared to normotensive controls 
Effect sizes for each cognitive domain, calculated using Glass’s Delta for the candesartan and placebo groups in comparison to the normotensive 
control group. For each domain, negative values indicate worse performance over time (larger declines or smaller improvements) in comparison 
to the normotensives; positive values indicate better performance (smaller declines or larger improvements) relative to the normotensives. 
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7.7 Exploratory analyses: blood pressure as a continuous variable 
7.7.1 Rationale 
At the inception of the Newcastle Cognitive Substudy, the BP eligibility criteria 
created a minimum SBP gap of 10 mmHg between the normotensive and hypertensive 
groups at recruitment, expected to be maintained due to the treatment target of 
<160/90 mmHg. Approximately 6 months after the end of the recruitment period in 
the SCOPE study, new British Hypertension Society guidelines recommended a lower 
treatment target BP of <150/90 mmHg applicable to patients in the study population, 
which was implemented at participants’ next scheduled study visit. As this was the 
upper BP bound for the ongoing normotensive recruitment, and the level above which 
recommendations were made to normotensive participants’ general practitioners for 
additional BP-monitoring/treatment during the study, the 10 mmHg SBP gap between 
groups was no longer maintained. Therefore, although there were differences in the 
group means, there was overlap between groups in the distribution of average SBP 
and DBP over the course of the study, as shown in Figure 37. Although participants 
were defined according to BP at the time of recruitment, changes in BP during the 
study resulted in crossover of the boundaries, i.e. some ‘normotensive’ participants 
became hypertensive during the study; likewise some ‘hypertensive’ participants were 
well-controlled on BP-lowering therapy and achieved normotensive BP levels. The 
distribution of SBP and DBP at the closeout visit is shown in Figure 39. Examination 
of the frequency distribution of the average BP over the study follow-up period 
(Figure 38) showed that SBP and DBP were both approximately normally distributed. 
As such, BP in the study could be considered a continuous variable regardless of the 
original group allocation.  
7.7.2 Analysis 
Average BP over the course of the study was chosen as the variable of interest as this 
best reflected the overall ‘burden’ of BP, and coincided with the time period over 
which cognitive decline was measured.  
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The association between average BP over the course of the study and rate of cognitive 
decline was assessed using partial correlations, performed on the combined data from 
hypertensive and normotensive participants with calculable slopes of decline, 
controlling for factors known to affect cognitive function (age, estimated pre-morbid 
IQ and baseline cognitive function). 
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Figure 37: Boxplot SBP and DBP for three groups 
Data shown are minimum, first quartile, median, third quartile, and maximum (excl. outliers, n=7). 
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Figure 38: Histogram of average SBP and DBP  
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Figure 39: Distribution of SBP and DBP at the closeout visit 
Distribution of systolic (SBP) and diastolic blood pressure (DBP) at the closeout visit, 
by group. Reference lines indicate the normotension criteria of 150/90 mmHg. 
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7.7.3 Relationship of average BP and cognitive decline 
The partial correlation coefficients were very low and not statistically significant, 
except for a correlation of -.10 between DBP and Attention, and a trend towards 
significance for the correlation of -.09 between Attention and SBP (Table 56). The 
correlations were negative, indicating an association between higher BP across the 
study and greater decline in Attention (a negative slope indicating impairment). 
However the magnitude of the correlations were small, accounting for approximately 
1% of the variance only.  
The results suggest that BP ‘burden’ as measured by average BP over the study period 
is not a major contributing factor to cognitive decline, over and above the variance 
accounted for by age, IQ and baseline cognition.  
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Table 56: Partial correlations of BP and cognitive decline  
Partial correlation analyses performed on the coefficients of decline for the 
hypertensive and normotensives combined, controlling for age, New Adult Reading 
Test errors and baseline cognitive function. Negative correlations indicate higher BP 
associated with greater cognitive decline/ lower BP associated with lesser cognitive 
decline.  
Values are Pearson correlation coefficients, with two-tailed significance tested at the 
0.05 level. 
Cognitive domain SBP DBP  
 r p r p 
     
Speed of Cognition -.07 .14 -.03 .60 
Attention -.09 .07 -.10 .03 
Episodic Memory -.07 .20 -.03 .58 
Working Memory .03 .59 .03 .56 
Executive Function  -.03 .52 -.07 .18 
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CHAPTER 8: DISCUSSION  
8.1 Executive summary 
The primary analysis from the Newcastle Cognitive Substudy of the SCOPE trial 
suggests that there is potential for angiotensin-receptor-blocker (ARB)-based 
antihypertensive treatment to reduce the cognitive decline associated with 
hypertension in older adults. With an average systolic BP difference of 8 mmHg 
between the candesartan-treated and placebo-treated groups, significant reductions 
were found in the rate of decline over 3-5 years for the cognitive domains of Attention 
and Episodic Memory. There was also a trend for benefit to Speed of Cognition, 
although the result failed to reach statistical significance because of the large standard 
deviation in the placebo group. There were no differences in the rates of change 
between groups on Working Memory or Executive Function. Although differences 
were seen on the Attention composite, and aspects of attention are necessarily 
involved to some extent in performing working memory and executive function tasks, 
the emergence of Attention from the principal components analysis as a distinct factor 
supports the notion that the scores were free to vary independently. Comparison with 
normative data from the well-matched normotensive control group showed the decline 
on Speed of Cognition to be similar for the candesartan group, who showed 
improvements in Attention and Episodic Memory relative to the normotensives. Based 
on the accepted interpretation of effect sizes, the magnitude of effects were in the 
small-to-medium range. However, as hypertension is a chronic condition, with 
prolonged treatment even small effects could be clinically important. The results 
provide support for further studies with larger numbers of participants and longer 
duration to determine the efficacy of ARBs or other BP-lowering treatments in 
preventing the cognitive sequelae of hypertension.  
The Newcastle Cognitive Substudy also demonstrated differential effects on the 
various domains of cognitive function that were not detected in the main SCOPE trial 
using a brief global measure (MMSE), supporting the comprehensive measurement of 
cognition in future trials. In particular, the use of computerised testing methods 
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showed that such assessment is feasible with older adults, bringing the benefits of 
standardisation of test stimuli, reduction of administrator bias, millisecond precision 
timing, and electronic data capture. Using factor analysis, the number of outcome 
variables was reduced in a meaningful way to maintain statistical power. The 
calculation of coefficients of decline using individual regression plots maximised the 
quality of the data by taking into account the repeated nature of assessments, and was 
able to handle missing datapoints and the variable length of follow-up. This approach 
provides a sensitive methodology for detecting cognitive change over time.  
 
8.2 Main findings 
8.2.1 Baseline results 
Previous studies have generally shown hypertension to be associated with adverse 
effects on cognition, and analysis of the baseline data from the Newcastle Cognitive 
Substudy (NCS) comparing the normotensive and hypertensive cohorts confirmed 
this. Although very well-matched on baseline demographic characteristics, as 
expected the hypertensive group had a higher prevalence of previous cardiovascular 
and cerebrovascular disease, prior BP-lowering medication use, as well as a higher 
rate of psychotropic medication, which could possibly have accounted for the 
differences in cognitive function. The previously-published work of Dr Frances 
Harrington 84 excluded participants with these factors to compare the hypertensive and 
normotensive participants from the NCS that differed only in BP levels. A very 
similar pattern of subtle deficits was found with hypertensives performing less well 
than normotensives on the majority of subtests reported. Although psychotropic 
medications such as benzodiazepines are known to impair cognition, 
psychopharmacological therapy use was not controlled for in the primary analysis 
because patients were stable on the medications at study entry (the eligibility criteria 
excluded patients with treatment instigated within 6 months of enrolment), and 
psychotropic therapy was included in the randomisation stratification. The 
identification of impairments associated with hypertension was important as it 
supported the notion that hypertensives carry a deficit that can be targeted for reversal 
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or prevention with treatment. More importantly, as the NCS participants were 
community-dwelling individuals recruited from GP surgeries, it provided support that 
the NCS sample was representative of normotensives and hypertensives in the general 
population in this regard. 
Similarly, the NCS hypertensives were well-matched to the participants in the main 
SCOPE trial with regard to the means and distributions of factors known to affect 
cognitive function such as age, SBP, DBP, and baseline MMSE scores. There were 
minor differences in the ratio of males to females, proportion of smokers, history of 
MI and percentage receiving antihypertensive therapy. As a single centre in an 
international multicentre trial, any site- or country-specific effects would ideally be 
tested, but as the raw data from the main SCOPE trial were not available, more 
detailed analyses were not possible. Albeit with this caveat, it was reassuring that the 
NCS sample was generally representative of the main SCOPE cohort and that the 
results could be extrapolated with some confidence.  
8.2.2 Comparison to the main SCOPE trial 
The intention-to-treat LOCF analysis of the 4964 patients in the main SCOPE study 
reported a modest, statistically non-significant reduction in major cardiovascular 
events with candesartan-based treatment (risk reduction 11%, p=.19), and a reduction 
in the secondary outcomes of non-fatal stroke (risk reduction 28%, p=.04) and all 
stroke (risk reduction 24%, p=.056) 85. The mean difference in BP reduction was 
approximately 3/2 mmHg in favour of the candesartan group, considerably smaller 
than predicted in the planning of the trial. The results were somewhat disappointing in 
relation to the effects of cognitive decline and prevention of dementia, with mean 
MMSE scores falling approximately 0.5 of a point in both groups and the proportion 
of patients with significant cognitive decline or developing dementia being no 
different. In the NCS, the BP difference at the closeout visit was larger than that of the 
main SCOPE study at 8/3 mmHg. However, similar to the main trial, the change in 
MMSE scores from baseline was small at approximately a third of an MMSE point, 
and was no different between the treatment groups (incidence of dementia was too 
low to be meaningfully analysed). In contrast, using the Cognitive Drug Research 
(CDR) computerised assessment system and traditional measures of executive 
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function, significant beneficial effects of candesartan-based treatment were found in 
reducing decline on a number of cognitive domains, even with a much smaller sample 
size than the main SCOPE trial. Specifically, benefits to Attention and Episodic 
Memory were seen with candesartan-based treatment compared to placebo, and a 
reduction in decline on Speed of Cognition, although this failed to reach statistical 
significance. Effect sizes were in the small-to-moderate range.  
Although compared to the main SCOPE study the NCS achieved a larger BP 
difference between treatment groups, which may have contributed to the effects seen 
with candesartan, the comparable results between the studies on the MMSE suggest 
that BP difference per se is not sufficient to account for the group differences. Rather, 
the sensitivity of the assessment methods used for detecting change is more likely. 
The MMSE was originally developed as a screening measure and is widely used for 
this purpose worldwide by physicians and in clinical trials. However, it has a number 
of shortcomings as a serial measure of cognitive function. In particular, it has no 
recognised parallel forms, meaning that repeated testing over relatively short periods 
of time can result in learning effects of the test stimuli, thus obscuring any real 
declines. The baseline characteristics of the SCOPE study 83 showed that the 
participants were well-functioning at study entry, with a mean MMSE score of 28.5, 
and approximately a third scoring the maximum of 30, making ceiling effects a real 
possibility. Indeed, subsequent unplanned post-hoc analyses were performed and the 
authors concluded that both learning and ceiling effects did occur in the main SCOPE 
trial 86. Another drawback of the MMSE is that it is a global assessment of cognitive 
function, providing a brief snapshot based on a summed score only. Although within 
the MMSE there are individual items regarding different functions, it does not allow 
for detecting change in specific aspects of cognition, and as a paper-and-pencil 
measure it does not adequately tap into relevant domains such as attention. Therefore, 
even when overall change is detected, it is not always clear which specific areas of 
cognition are affected.  
These measurement issues were identified and addressed, and formed the rationale 
behind the NCS. The use of computerised testing provided a sensitive assessment of a 
range of cognitive functions with a validated tool, as the CDR system has been used in 
a large number of clinical trials across all phases of the drug development process 68. 
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Importantly, parallel forms were used to prevent learning of task stimuli across visits 
and a training assessment was performed prior to the baseline assessment to 
familiarise participants with the use of the system and reduce procedural learning 
effects. For the assessment of executive function however, traditional paper-and-
pencil measures were employed as the CDR system does not have any tasks that cover 
this domain, and as with the MMSE, these traditional tests also suffer from a lack of 
parallel forms.  
The factor analyses employed in the NCS provided a method for reducing the number 
of potential analysis variables, by combining the individual subtests into meaningful 
composite scores based on empirical data. Factor analyses have been performed 
previously with data from the CDR system in healthy middle-aged volunteers 77 and 
patients with Dementia with Lewy Bodies 69 producing very similar factors, and the 
approach has been recommended 74 and used in studies of hypertension and cognition 
26. By using PCA with varimax rotation, the fewest factors explaining the maximum 
amount of variance were extracted. The factor solution chosen produced five factors 
labelled: Speed of Cognition, Attention, Episodic Memory, Working Memory and 
Executive Function. By definition, within each factor the subtest variables were highly 
correlated; between factors the variables were as uncorrelated as possible. Based on 
the factor solution, the individual subtest variables were combined into composite 
scores representing these five relatively independent domains of cognition. By 
combining the variables in this way, the risk of Type I error was reduced and changes 
in cognition were more easily characterised. Compared to the MMSE, the test battery 
in the NCS provided a comprehensive and sensitive assessment of cognitive function 
that was able to detect changes in specific domains of cognition, whilst maintaining 
statistical power. 
A further issue that may have contributed to the lack of effects seen on the cognitive 
outcomes in the main SCOPE trial was the use of statistical analyses that failed to 
fully take account of the repeated measures design of the study. The analysis of 
change in MMSE scores was based on the intention-to-treat LOCF principle, 
comparing the baseline and last observation scores between the treatment groups. For 
the assessment of significant cognitive decline, a reduction in MMSE score of 4 points 
or more at two consecutive visits had to occur. Because of the rolling recruitment 
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period, the length of follow-up for an individual could vary between 36 and 60 
months. On the assumption that a longer follow-up period gives more opportunity for 
decline to occur, it is possible that effects in the patients with longer follow-up could 
have been obscured by a lack of change in patients with shorter follow-up. In addition, 
the data from the repeated MMSE assessments were only used to inform the 
‘significant cognitive decline’ criterion, and not used in the analysis of MMSE scores 
overall, meaning that the full quality of the data collected was not utilised. In contrast, 
the NCS used data from all annual visits to calculate individual slopes of decline on 
the five composite scores for each participant, taking account of the high inter-visit 
correlations seen with repeated cognitive assessments of the same individual. By using 
the number of months from baseline in the regressions, variations in the timing of the 
assessments, missed assessments, and differential length of follow-up between 
participants were easily dealt with in the analysis. Therefore, the combination of the 
measure used and the statistical approach may both have contributed to the lack of 
effects seen in the main SCOPE trial. It is a matter for speculation whether the use of 
more sensitive cognitive measures, or a greater difference in BP between the treatment 
groups, as observed in the NCS, would have produced differences in cognitive decline 
in the main SCOPE study. 
8.3 Results in context 
The results from the NCS add to the equivocal evidence from previous randomised, 
controlled trials of antihypertensive medication that have cognitive or dementia-
related endpoints. In the SHEP study no differences were found over a five year 
follow-up period between a diuretic and/or  beta-blocker treatment group and placebo 
on a range of cognitive tests 41, although it has been suggested the loss to follow-up of 
cognitively-impaired participants may have obscured the true effect of treatment 42. 
Similarly, no differences in cognition were found between older adults randomised to 
a diuretic, beta-blocker or placebo treatment over 54 months in the MRC treatment 
trial of hypertension 44. This finding is particularly interesting as the study used the 
same statistical methodology for analysing the repeated assessment data, albeit using a 
different battery of cognitive tests. However, the MRC study and the NCS studies are 
not directly comparable because of major differences in the design and treatment 
regimes.  
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The main evidence in support of the benefits of antihypertensive treatment on 
cognitive outcomes comes from the Syst-Eur trial. Participants randomised to active 
treatment with the calcium-channel blocker nitrendipine for isolated systolic 
hypertension showed a 50% reduction in the incidence of dementia over the two-year 
follow-up period compared to placebo, although on average there was little change in 
MMSE scores between the groups 46. The dementia findings were reinforced when 
follow-up was extended for a further 2 years as an open-label study 47. However, the 
robustness of the findings has since been questioned as the actual number of dementia 
endpoints was low (n=32) and the confidence intervals of relative risk were wide, 
ranging from no effect to a 76% reduction 48.  
Comparability between studies is a major problem highlighted in a recent Cochrane 
review of BP-lowering for the prevention of cognitive impairment and dementia in 
patients with hypertension but no history of cerebrovascular disease 87. The systematic 
review only selected double-blind randomised controlled trials, and as the MRC 
treatment study was single-blind it was not included. Comparing the SHEP, Syst-Eur 
and SCOPE studies was reported as problematic as large numbers of patients left the 
double-blind treatment, particularly in SCOPE where the changes in BP treatment 
target guidelines resulted in a high proportion of participants receiving additional 
open-label antihypertensive therapy. The meta-analysis performed on the incidence of 
dementia data from the 3 studies found no significant difference between treatment 
and placebo, and although there was an 11% relative risk reduction of dementia with 
BP-lowering, the effect was not significant. Change in MMSE was not reported in the 
SHEP study, and the combined results from Syst-Eur and SCOPE did not indicate a 
significant benefit of treatment. The authors concluded that there was no convincing 
evidence that BP-lowering prevents cognitive decline or dementia.  
Post-hoc analyses of the SCOPE trial data have further investigated the effects on 
dementia and cognitive decline. To permit direct comparison with the SHEP and 
Syst-Eur studies, a pre-defined subgroup analysis of patients with isolated systolic 
hypertension (ISH) was performed 88. From the 4964 patients randomised, 1518 met 
the criteria for ISH (SBP>160 mmHg and DBP<90 mmHg); 754 randomised to 
candesartan and 764 to the placebo group. BP was significantly reduced in both 
groups with a between-group difference of 2/1 mmHg. The relative risk of all stroke 
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(fatal and non-fatal) was reduced by 42% with candesartan-based treatment. As in the 
total SCOPE cohort, baseline MMSE was high at 28.6 in both groups and reduced by 
approximately 0.5 of a point, with no significant difference in change scores between 
the groups. There was no significant difference in the incidence of dementia (the 
incidence of significant cognitive decline was not reported).  
Post-hoc analysis of SCOPE patients not receiving additional antihypertensive therapy 
after randomisation (n=2098) was also performed 89, more closely reflecting the 
original design of the study as a placebo-controlled trial (although 12.5mg HCTZ was 
permitted as per protocol) 59. Blood pressure fell by 21.8/11.0 mmHg in the 
candesartan group (n=1253) and by 17.2/8.4 mmHg in the placebo group (n=845), and 
benefits were seen with candesartan in the relative risk of major cardiovascular events, 
cardiovascular mortality and total mortality. Despite a greater BP difference of 4.7/2.6 
mmHg than in the total SCOPE cohort, there were no differences between the 
candesartan and placebo groups on change in MMSE scores, as both groups fell 
approximately .5 of a point from the baseline of 28.5. Similarly, no differences were 
observed between groups in the proportion of patients with significant cognitive 
decline or developing dementia.  
A further post-hoc analysis looked at the influence of baseline cognitive function on 
the SCOPE outcomes, and compared the effects of candesartan in patients with lower 
cognitive function (LCF defined as MMSE 24 to 28; n=2070) and higher cognitive 
function (HCF defined as MMSE 29 to 30; n=2867) separately 86. In the LCF group, 
change in MMSE score was significant smaller with candesartan-based treatment (-
0.04) compared to placebo (-0.53), but there was no difference between treatments in 
the HCF group (-0.80 vs. -0.73). The proportion of patients with significant cognitive 
decline did not differ between the candesartan or placebo groups in either the LCF or 
HCF analyses. However, the incidence was higher in LCF than in HCF participants 
(6.6% vs. 3.6%, p<.001), as was the incidence of dementia (4.4% vs. 1.0%, p<.001). 
The additional post-hoc analyses were performed as the authors accepted that the 
MMSE had limitations and suffered from practice and ceiling effects in the SCOPE 
trial. This supports the call for the use of more sensitive cognitive tests, such as those 
used in the NCS, to be included in trials where cognitive outcomes are of interest.  
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Against the backdrop of previous intervention studies with cognitive outcomes, the 
NCS adds to the evidence base showing beneficial effects of antihypertensive 
treatment. At the very least the evidence overall demonstrates that antihypertensive 
therapy is not detrimental to cognition. However, none of the studies to date have been 
designed with the prevention of cognitive decline as the primary outcome. Although 
the NCS was a substudy of the main SCOPE trial, it demonstrates that comprehensive 
cognitive testing can be employed in such trials with the correct analysis approach and 
methodology. Placebo controlled trials are no longer justified on ethical grounds 
because of the known benefits of antihypertensive treatment on reducing 
cardiovascular events, therefore any future trial with cognition as a primary outcome 
would be a head-to-head comparison. Due to the high proportion of participants 
receiving additional therapy, the NCS was to a large extent a comparison of two 
antihypertensive regimens rather than a true placebo-controlled trial, yet because of 
the methodology employed was still able to detect differences between them.  
8.4 Possible mechanisms of action 
8.4.1 Blood pressure reduction  
The effects of the candesartan-based treatment in the NCS were observed with an 
average BP difference of 8/3 mmHg between the groups across the study, which was 
greater than that observed in the main SCOPE trial. There are a number of potential 
mechanisms by which BP could influence cognitive decline, including the rate of 
cerebral atrophy, white matter lesion progression, or the occurrence of silent brain 
infarction. In a subset of the NCS participants, serial MRI scans were performed two 
years apart and volumetric changes in white matter hyperintensities and atrophy were 
measured. Hypertension was associated with increased rates of whole brain atrophy 
and white matter changes, and there was a trend for candesartan treatment to reduce 
the risk 90.   
The analysis of BP as a continuous variable did not find BP ‘burden’, as measured by 
the average BP over the study period, to be a major contributing factor to cognitive 
decline over and above the variance accounted for by age, IQ and baseline cognition. 
The correlation analyses could reflect a true absence of an association over the full 
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range of BP, or perhaps suggest a threshold effect. The implication would be that there 
is a cut-off beyond which further BP-lowering confers no additional benefit to 
cognition. A prospective study of intensive BP-lowering regimens would be required 
to fully test this hypothesis.  
8.4.2 Drug class effect 
Although there was a difference in BP maintained between the treatment groups, BP 
in the placebo group was significantly reduced in the study due to the unavoidably 
high use of additional therapy to meet the treatment target guidelines. As the effect 
size analysis showed that placebo participants experienced cognitive decline despite 
the significant reduction in BP, this suggests beneficial effects in the candesartan 
group could be due to non BP-related pharmacological properties of AT1 receptor 
antagonism. Diminished regional cerebral blood flow responses during some memory 
tasks have been found in hypertensives using positron emission tomography 91. As a 
vasodilator capable of crossing the blood-brain barrier, it is possible that candesartan 
could affect cognition via improved cerebral perfusion. Pre-treatment with 
candesartan was found to be protective against ischemia by normalising the cerebral 
blood flow response in spontaneously hypertensive rats 92.  
Similarly, there is evidence from behavioural and neurochemical studies that 
angiotensin II can induce inhibition of cholinergic-mediated brain function 93; the 
action of candesartan would be expected to reduce this inhibition and therefore 
improve aspects of cognition such as attention. Two previous studies have also found 
the suggestion of beneficial effects of similar ARBs to candesartan. Hypertensive 
patients aged 75-89 years were randomised to losartan or atenolol, and despite 
equivalent reductions in BP, improvements were seen on an episodic memory task in 
the losartan group compared to no change with atenolol over 6 months 94. Similar 
benefits specific to episodic memory were seen in an open-label study of valsartan or 
enalapril over 16 weeks by the same group 95.  
Whether the effects seen in the NCS result from the BP differences between the 
treatment groups or reflect a drug class effect is a matter for speculation as the study 
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was not designed to test these hypotheses. To do so would require a head-to-head 
comparison of different classes of compounds, with well controlled BP targets. 
8.5 Strengths of study 
The NCS was a randomised controlled trial based on the main SCOPE study, and as a 
result benefited from the study infrastructure in terms of administration, study drug 
blinding and data monitoring. The well-designed substudy was supported by a 
dedicated multi-disciplinary team to aid the smooth running of the study and ensure 
the quality of the data. The substudy was particularly strong for having an additional 
normotensive group for normative comparison to put the magnitude of cognitive 
changes into context.  
Attrition and loss to follow-up are major concerns in longitudinal studies as they can 
introduce bias if there are systematic differences between treatment groups. Efforts 
were made on a practical level to maintain participation including the provision of 
dedicated parking spaces for study visits, reimbursement of travel expenses or pre-
booked taxis, a dedicated direct dial telephone line to study staff, regular newsletters 
and an annual social/educational event for participants. This helped reduce attrition, 
and the high proportion of participants attending the closeout visit provided valuable 
long-term data that may otherwise have been lost to follow-up. 
The use of computerised testing was found to be a highly effective approach in the 
NCS. In addition to being the most appropriate method of assessing attention because 
of the sensitive timing mechanism, computerised testing standardised the presentation 
of test stimuli to reduce administrator bias. The availability of validated parallel forms 
enabled repeated testing without learning effects, and permitted training sessions to be 
performed to familiarise participants with study procedures and reduce practice 
effects. The test battery used covered a range of cognitive functions enabling the 
differential effects on cognition to be investigated. The factor analytic methods 
reduced the number of outcome variables in a meaningful way to maintain statistical 
power, and the calculation of slopes of decline using individual regression plots 
adequately dealt with missing data and variations in length of follow-up.  
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8.6 Limitations 
The main limitation of the NCS is that it was a single-centre study and without access 
to the main trial database it is difficult to fully assess how generalisable the findings 
are to the full study population. However, with the exception of the greater BP 
difference between groups at the end of trial which was most likely due to better 
compliance at the Newcastle centre, all of the comparison statistics conducted suggest 
the NCS cohort was representative of the main trial.  
As it was a substudy, the NCS was not powered to the same extent as the main trial, 
and was not designed to determine efficacy of candesartan as a treatment to prevent 
cognitive decline. Despite this, significant benefits were seen using the comprehensive 
test battery in much smaller sample size compared to the MMSE in the main SCOPE 
trial. The sensitivity of the computerised battery was primarily responsible for this. 
Regarding the assessment of executive function, as the CDR system does not measure 
this specifically, traditional neuropsychological tests were used. These pencil-and-
paper tests have inherent limitations, most notably the lack of parallel forms, and in 
future studies alternative tests with better psychometric properties might usefully be 
considered (e.g. the Color Trails Test is analogous to the standard Trail-Making Test 
but has validated parallel forms). 
8.7 Future work 
The NCS provides a sound methodology for the design of the cognitive aspects of 
future studies. Indeed, an international, multicenter, cognitive substudy of the 
PRoFESS study (Prevention Regimen For Effectively avoiding Second Strokes) has 
recently been completed using the same measures and statistical approach for 
determining cognitive decline. With 565 participants, the study provides a sizeable 
sample for repeating the factor analyses on the same measures. This would serve as a 
useful validation of the cognitive domains and the use of the composite scores as 
analysis outcomes.  
To determine the efficacy of antihypertensive treatments for the primary prevention of 
cognitive decline and dementia, larger clinical trials of adequate duration using 
sensitive measures need to be designed around cognitive endpoints. However, long-
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term placebo-controlled studies in hypertension are now deemed unethical because of 
the known cardiovascular benefits of treatment. As the BP treatment guidelines have 
lowered target BP over time, and physicians maintain better BP control in their 
patients, achieving large BP reductions in studies will become more difficult. If a 
threshold effect exists, even intensive BP-lowering may not demonstrate effects on 
cognition. Therefore future studies might usefully target populations that are at higher 
risk for cognitive decline, such as post-stroke patients, or putative prodromal dementia 
states such as Mild Cognitive Impairment or Age-Associated Memory Impairment. 
Thus it remains to be seen whether antihypertensive treatment will become the first 
line of defence in preventing dementia and cognitive decline, but given the known 
cardiovascular benefits of treatment, it continues to be an avenue of investigation 
worth pursuing. 
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Appendix I: Characteristics of cross-sectional studies 
Characteristics of cross-sectional studies investigating the relationship between blood pressure and cognitive function 
Authors Study design/ 
analysis 
N Age 
(years) 
BP criteria 
(mmHg) 
Exclusion 
criteria 
Inclusion 
criteria 
Neuropsychological/ cognitive 
tests 
Conclusions 
10 group comparison 
HT vs. NT 
20:20 mean 
49:51 
HT DBP >105 history of 
neurological 
disorder, 
diabetes or 
alcoholism 
newly 
diagnosed, 
untreated, males 
only 
WAIS (digit span, arithmetic, 
vocabulary, block design, 
object assembly, digit symbol 
substitution), vigilance / SRT, 
Purdue pegboard, WCST, 
WMS (logical memory), Rey-
Osterreith Figure, DeRenzi 
Rods Test, Tonal Memory 
test, Token Test, BDAT 
hypertensives sig. 
slower on SRT, 
reduced digit span  
11 ordinal logistic 
regression 
controlling for 
age, sex, 
education, anti-
hypertensive 
medication, 
alcohol & 
smoking 
2032 55-89 none; 
for analysis 
definite HT SBP 
≥160 and/or 
DBP ≥95 
history of stroke subjects from 
Framingham 
Heart Study 
WAIS (digit span, 
similarities), WMS (logical 
memory immediate and 
delayed, visual reproduction, 
paired-associate learning, 
word fluency) 
No sig. association 
between BP and 
cognition 
13 linear logistic 
regression 
controlling for 
age, sex, 
education, 
medication, 
history of stroke, 
3627 ≥65 none;  
for analysis HT 
SBP ≥140 
and/or DBP ≥90 
none non-
institutionalised 
story retelling test for 
immediate & delayed memory, 
WAIS (digit span), Pfeiffer 
Mental Status Questionnaire 
small but sig. 
association between 
increased DBP and 
lower digit span; no 
consistent pattern 
across tests 
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Authors Study design/ 
analysis 
N Age 
(years) 
BP criteria 
(mmHg) 
Exclusion 
criteria 
Inclusion 
criteria 
Neuropsychological/ cognitive 
tests 
Conclusions 
depression, 
alcohol, smoking, 
self-assessed 
health 
14 hierarchical 
regression 
analysis 
controlling for 
age, sex, 
education; tested 
SBP, DBP, anti-
hypertensive 
medication and 
vascular risk 
factors 
943 stratified 
for age; 
24-81  
none; 
for analysis HT 
SBP ≥140 
and/or DBP ≥90 
overt 
cerebrovascular 
disease (incl. 
stroke), 
Parkinson’s, 
dementia, 
epilepsy, 
psychotropic 
medication 
MMSE ≥24 word learning task, concept 
shifting task, Stroop Colour 
Word Test, letter/ digit 
substitution test, word fluency 
no linear relationship 
between BP and 
cognition; when age, 
sex & education 
adjusted for, HT did 
worse on letter/ digit 
substitution than 
matched controls 
15 correlation; 
multivariate 
analyses 
controlling for age 
& IQ: subjects 
divided into 3 
groups 
598 >70; 
mean 76 
none; 
low ≤135/75 
med 136-181/ 
76-95 
high >181/95 
prescription 
medication, any 
reported health 
problems 
healthy subjects 
from Healthy 
Old People in 
Edinburgh 
(HOPE) study 
MMSE, NART MMSE correlated 
negatively with SBP, 
but not DBP; after 
adjusting for age & 
IQ, sig. association of 
high SBP & high 
DBP with low MMSE 
16 logistic regression 
analysis  
1106 65-95; 
mean 74 
none;  
mean 145/82 
cerebrovascular 
disease, 
psychotropic 
medication 
 MMSE DBP predicted 
impairment (MMSE 
<24) in over 75s, but 
not in 65-74 year olds 
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Authors Study design/ 
analysis 
N Age 
(years) 
BP criteria 
(mmHg) 
Exclusion 
criteria 
Inclusion 
criteria 
Neuropsychological/ cognitive 
tests 
Conclusions 
18 correlation; 
stepwise linear 
regression; 
multiple logistic 
regression 
controlling for 
age, sex & 
education 
2225 60-100; 
mean 70 
isolated systolic 
HT: SBP 160-
219 and DBP 
<95 
dementia  MMSE SBP contributed 
weakly to MMSE 
compared to age & 
education; for women 
SBP correlated 
negatively with 
MMSE 
19 group comparison 
HT vs. NT 
17:27 >60; 
mean 
77:75 
HT SBP >165 
and/or DBP >95 
or taking anti-
hypertensive 
medication  
stroke/ TIA 
Parkinson’s, 
dementia, 
epilepsy, 
psychiatric 
disorders, 
chronic disease, 
alcohol abuse 
anti-
hypertensive 
medication 
replaced with 
placebo 2 weeks 
prior 
WAIS (digit span), word list 
generation, finger tapping, 
SRT, CRT, visual search/ 
cancellation, Buschke-Fuld 
selective verbal reminding, 3 
words – 3 shapes test, Weigl 
sorting test 
HT impaired on 
attention tasks 
(tapping and 
incidental memory) 
but not memory or 
judgement tasks 
20 HT vs. NT 
matched pairs; 
ANOVA tested 
effects of age, 
hypertension and 
medication 
90 
pairs 
40-79 in 
10-year 
bands 
HT SBP ≥180 
or DBP ≥100 or 
taking anti-
hypertensive 
medication; NT 
DBP ≤90 and 
12m of no anti-
hypertensive 
medication or 
raised BP 
history of stroke  letter cancellation, WAIS 
(digit span, digit-symbol 
substitution), Rey Auditory 
Verbal Learning test 
trend for HT to 
perform worse; sig. 
worse on Verbal 
Learning (recall and 
retention) 
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BDAT = Boston Diagnostic Aphasia Test; BMI = Body Mass Index; CRT = Choice Reaction Time; HT = hypertensive; MMSE = Mini-Mental 
State Examination; NT = normotensive; SRT = Simple Reaction Time; TIA = transient ischemic attack; WAIS = Wechsler Adult Intelligence 
Scale; WCST = Wisconsin Card Sort Test; WMS = Wechsler Memory Scale. 
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Appendix II: Characteristics of retrospective longitudinal studies 
Characteristics of retrospective longitudinal studies investigating the relationship between blood pressure and cognitive function 
Authors Study design/ analysis Sample Exclusion criteria Inclusion criteria Neuropsychological
/ cognitive tests 
Conclusions 
12 longitudinal BP readings 
(chronicity and average 
SBP & DBP) and 
cognitive function. 
ordinal logistic 
regression/ linear 
regression stratified by 
anti-hypertensive use in 
last 2 yrs; adjusted for 
age, sex, alcohol, 
education, occupation, 
smoking.  
n = 1993; ♁1175; 
age: 55-89; 
BP criteria: none, 
for analysis HT 
SBP ≥160 and/or 
DBP ≥95; 
follow-up yrs: 26 
previous stroke, 
unknown anti-
hypertensive 
medication status, 
missing 
neuropsychological 
data 
sample from 
Framingham 
Heart Study 11 
education-adjusted 
composite of: 
WAIS (digit span, 
similarities), WMS 
(logical memory 
immediate and 
delayed, visual 
reproduction, 
paired-associate 
learning, word 
fluency) 
no association between 
cognitive performance and BP 
for subjects on anti-
hypertensives. Chronicity and 
average SBP & DBP levels 
were inversely related to 
cognitive performance in 
untreated subjects. For 
previously treated subjects, sig. 
relation between cognitive 
impairment and probability of 
being off medication at testing 
24 compared average BP 
when untreated and 
cognitive test 
performance at follow-
up; multivariate linear 
regression controlling for 
age, education, gender, 
occupation, alcohol, 
smoking.  
n = 1702; 
age: 55-89; 
BP criteria: none; 
follow-up yrs: 
cognitive testing 
12-14 yrs after final 
BP measurements 
previous stroke sample from 
Framingham 
Heart Study 11 
WAIS (digit span, 
similarities), WMS 
(logical memory 
immediate and 
delayed, visual 
reproduction, 
paired-associate 
learning, word 
fluency) 
BP levels and chronicity were 
inversely related to composite 
score and measures of attention 
and memory (logical memory, 
visual reproductions, digit span 
backwards), for full sample, 
subsample untreated at BP 
measurements, and subsample 
untreated throughout study 
96 reanalysed data from 24 
using multiple linear 
n = 1695; excl. 7 subjects with 
unknown anti-
same as 24 same as 24 interaction effects of age × BP 
level and age × chronicity were 
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Authors Study design/ analysis Sample Exclusion criteria Inclusion criteria Neuropsychological
/ cognitive tests 
Conclusions 
regression to assess 
interaction effects of age 
and BP 
age analysed as 
continuous variable 
and groups (55-64; 
65-74; 75-88) 
hypertensive 
medication status 
trivial or non-significant. 
Independent associations 
between BP and cognition 
remained 
25 reanalysed data from 24 
using multiple binary 
logistic regression to 
calculate odds ratios for 
poor cognitive 
performance for 
increases in DBP, SBP 
and age 
n = 1695; 
criteria same as 24 
excl. 7 subjects with 
unknown anti-
hypertensive 
medication status 
same as 24 Performance in the 
lower 50th and 25th 
percentiles on tests 
from  24 
BP and chronicity were 
inversely associated with 
performance on visual and 
verbal memory tests. Age was 
inversely associated with 
performance on all tests. Odds 
for poor performance were 
higher for age than BP variables 
27 multiple logistic 
regression controlling for 
age and education  
n = 3735 males; 
age: mean 78 at 
follow-up; 
BP criteria: none, 
for analysis SBP 
low <110, normal 
110-139, borderline 
140-159, high >160 
follow-up yrs: mean 
25 
none community and 
institutionalised 
subjects from the 
Honolulu Heart 
Program 
CASI scores 
grouped for analysis 
as good 92-100, 
intermediate 82-91, 
poor <82. 
risk for intermediate and poor 
cognitive function increased 
with level of midlife SBP 
category. Every 10 mmHg SBP 
increase was associated with 
increased risk of intermediate 
(7%) and poor (9%) cognitive 
function. Adjustment for CVA, 
CHD and subclinical 
atherosclerosis reduced strength 
of relationship to 5%. No 
association with midlife DBP. 
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Authors Study design/ analysis Sample Exclusion criteria Inclusion criteria Neuropsychological
/ cognitive tests 
Conclusions 
28 multivariate models 
adjusting for age, 
education, occupation, 
stroke diagnosis, 
medications affecting BP 
n = 999 males; 
age: 69-75, mean 
72.4; 
BP criteria: none; 
for analysis: DBP 
<71, 75-80, 85-90, 
95-100, ≥105 
follow-up yrs: 20 
none population-based 
cohort from 
Uppsala, Sweden 
composite score 
derived from 
transformed MMSE 
& Trail-Making 
Test A & B; 
outcome analysed 
as continuous and 
dichotomised at 
lowest quintile 
high baseline DBP (but not 
SBP) predicted impaired 
cognitive function at follow-up, 
even after excluding previous 
stroke. Cross-sectional data at 
70yrs showed high 24h ABPM, 
non-dipping, insulin resistance 
and diabetes associated with low 
cognitive function. Strongest in 
untreated subjects. 
29 Compared trackers (SBP 
high in midlife & follow-
up) with normal 
(consistently low/ 
medium, or increasing 
over follow-up) and 
decreasers (decreasing 
from high/ medium to 
medium/ low) 
GLM adjusting for age, 
education, depression, 
stroke, anti-hypertensive 
medication 
n = 717 males; 
age: mean 75 at 
follow-up; 
BP criteria: none, 
for analysis SBP 
low <120, medium 
120-139, high 
≥140;  
follow-up yrs: 30 
analysis of 
cognitive data 
excluded 7 subjects 
with MMSE <23 
Western 
Collaborative 
Group Study 
subjects: healthy, 
white males, free 
from heart disease 
at baseline 
 
verbal memory, 
psychomotor speed 
and verbal fluency 
factors from PCA 
of measures (Iowa 
screening battery, 
MMSE, DSS, color 
Trail-Making Test, 
Color-Word 
Interference Test, 
CVLT) 
High SBP trackers performed 
worse than normals on verbal 
memory  
SBP decreasers performed 
worse on psychomotor speed 
than normals. No differences in 
verbal fluency. 
 
 
30 multivariate regression 
models using age, 
gender, education, class, 
length of follow-up, 
n = 387; ♁235; 
age: 70-88, mean 
prescription 
medication or any 
reported health 
problems at 
healthy subjects 
from Healthy Old 
People in 
Edinburgh 
NART, fluid 
intelligence (RPM), 
memory score 
(derived from 
demographic variables, pre-
morbid IQ and BP accounted for 
39% of variance in RPM at 
follow-up, but only 12% of 
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Authors Study design/ analysis Sample Exclusion criteria Inclusion criteria Neuropsychological
/ cognitive tests 
Conclusions 
NART, SBP & DBP, for 
subjects who remained 
healthy throughout and 
whole sample 
75 at baseline; 
BP criteria: none; 
for analysis DBP 
low <80; medium 
80-90; high >90 
follow-up yrs: 4 
baseline (HOPE) study 15 immediate and 
delayed logical 
memory subtests of 
WMS-revised) 
memory variance. BP was 
related prospectively to fluid 
intelligence but not memory 
31 BP measurements taken 
at 3 visits over first 15 
yrs; cognitive data 
measured twice in 
following 10 yrs. 
Chi-square test and 
ANOVAS to examine 
association of midlife 
SBP category with 
demographic, avge BP, 
CVD, CHD, PAD, and 
cognitive change 
n = 392 males; 
age: mean 72.5 at 
follow-up; 
BP criteria: none, 
for analysis SBP 
low <120, normal 
120-139, high 
≥140, mixed: no 
pattern across visits; 
follow-up yrs: 25 
none subgroup of 
National Heart, 
Lung, and Blood 
Institute (NHBLI) 
Twin Study 
MMSE, DSS, 
BVRT, verbal 
fluency 
Mean 10-yr decline on DSS 
observed for all midlife SBP 
groups with high SBP group 
declining most, low SBP least. 
Low SBP group showed no 
decline on MMSE; other 3 
groups did, with mixed group 
showing greatest decline. Verbal 
fluency tended to increase over 
time with no differences 
between groups. No differences 
on BVRT. 
ABPM = ambulatory blood pressure monitoring; BVRT = Benton Visual Retention Test; CASI = Cognitive Abilities Screening Instrument 
incorporating Hasegawa Dementia Scale, Mini-Mental State Examination and the Modified Mini-Mental State Examination; CHD = coronary 
heart disease; CVA = cerebrovascular accident; CVD = cerebrovascular disease; CVLT = California Verbal Learning Test; DSS = digit-symbol 
substitution subtest of the Wechsler Adult Intelligence Scale; GLM = general linear model; PAD = peripheral arterial disease; PCA = principal 
components analysis 
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Appendix III: Characteristics of prospective longitudinal studies 
Characteristics of prospective longitudinal studies investigating the relationship between blood pressure and cognitive function 
Authors Study design/ analysis Sample Exclusion criteria Inclusion criteria Neuropsychological
/ cognitive tests 
Conclusions 
32 multiple logistic 
regression controlling for 
age, gender, education, 
anti-hypertensive 
medication, cardiac 
dysrhythmia, heart 
failure, stroke, CHD, BP 
n = 924; 
age: 75+; 
BP criteria: none 
follow-up yrs: mean 
3.4 
dementia/ mild 
cognitive 
impairment 
Kingsholmen 
Project population 
sample 
MMSE minor decline (0.4 points per 
annum). 23.4% declined more 
than 10%. Age, lower education 
and stroke predicted decline for 
women. Education and stroke, 
not age in men. In women, SBP 
reduction correlated with 
decline 
33 multiple regression 
controlling for age, 
gender, area of residence, 
NART & RPM, self-
report depression, 
antidepressant meds, 
SBP, DBP, anti-
hypertensive meds, 
cholesterol, BMI, 
smoking, ischaemia 
n = 2567; 
age: 65-74 
BP criteria: SBP 
160-209 mmHg 
follow-up yrs: 4.5 
serious 
cardiovascular, 
cerebrovascular or 
intercurrent illness; 
anti-hypertensive 
medication at 
baseline. Subjects 
were randomised to 
beta-blocker, 
thiazide diuretic or 
placebo 
subjects enrolled 
in the Medical 
Research Council 
trial of the 
treatment of 
moderate 
hypertension 
PALT co-efficient 
(slope of the 
regression line for 
each subject by 
regressing PALT 
scores on time) 
decline on PALT associated 
with age, male gender, rural 
residence, depression and low 
intelligence (NART & RPM). 
No sig. associations for 
cardiovascular variables (incl. 
SBP or DBP, mean SBP over 
follow-up, trial therapy). No 
association between untreated 
(placebo) group and PALT 
decline 
34 general factorial 
MANOVA, adjusting for 
baseline cognitive 
function, APOE, alcohol, 
education, diet, lifetime 
smoking, social class, 
n = 387; 
mean age: 70.2; 
mean SBP: 184 
as 33 as 33 log transformed 
MMSE controlling 
for baseline 
cognitive function 
(PALT, TMT A & 
poor cognition at Time 2 
associated with greater history 
of dementia, older age, 
abstinence from alcohol before 
60, less decline in SBP over trial 
period. Decline in SBP became 
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Authors Study design/ analysis Sample Exclusion criteria Inclusion criteria Neuropsychological
/ cognitive tests 
Conclusions 
‘history of dementia’ 
loading 
mmHg 
follow-up yrs: mean 
9-12 
RPM) non-significant when 41 
dementia cases excluded 
35 multiple logistic 
regression adjusting for 
age, gender, education, 
income, alcohol, 
depressive symptoms, 
APOE, baseline 
cognitive function 
n = 1373; 
age: 59-71, mean 
65 at baseline; 
BP criteria: none; 
for analysis HT 
SBP≥160 and/or 
DBP≥95 or taking 
anti-hypertensives; 
follow-up yrs: 4 
stroke during 
follow-up 
subjects from the 
Epidemiology of 
Vascular Ageing 
(EVA) study 
decline on MMSE ≥ 
4 
risk of decline over 4 years was 
increased with high BP. 
Chronicity was also associated 
with increased risk of decline. 
Untreated hypertensives at 
greater risk than treated 
hypertensives 
36 stepwise regression 
analysis: age, education, 
social class, health status, 
medication use, SBP, 
DBP, NART-IQ, MMSE 
n = 387; 
age: 70-88, mean 
75 at baseline; 
BP criteria: none; 
follow-up yrs: 4 
as 30 healthy subjects 
from Healthy Old 
People in 
Edinburgh 
(HOPE) study; as 
30 
change in MMSE 
scores 
baseline variables predicted 
approx. a quarter of the variance 
in change scores. Age and high 
SBP increase risk of cognitive 
decline; higher NART-IQ scores 
are protective. Effect of SBP on 
decline was less for subjects 
who remained both disease and 
medication-free 
37 multivariate regression 
models controlling for 
age, gender, education 
n = 2068; 
age: 65-81 at 
institutionalised subjects from the 
Hypertension 
Detection and 
9-item Pfeiffer 
Mental Status 
Questionnaire, 6-
no strong linear association 
between BP and cognition. No 
effect of BP on memory, or 
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Authors Study design/ analysis Sample Exclusion criteria Inclusion criteria Neuropsychological
/ cognitive tests 
Conclusions 
and time of evaluation baseline; 
BP criteria: none; 
for analysis SBP 
low <130, med 130-
139, high ≥160; 
follow-up yrs: 6 
& BP from 9 yrs 
pre-baseline 
Follow-up 
Program (HDFP) 
item East Boston 
Memory Test 
change over time on either test. 
For Mental Status Qu., 
SBP≥160 9yrs prior to baseline 
was associated with increased 
errors at follow-up. U-shaped 
association found between 
baseline SBP & DBP and errors 
with low and high BP groups 
performing worse 
38 multivariate analyses 
controlling for age, 
gender, education, race, 
study site, CNS-relevant 
medication 
n = 10,963; 
age: 47-70 at 
baseline; 
BP criteria: none; 
for analysis HT 
SBP≥140 or 
DBP≥90 or taking 
anti-hypertensives 
at baseline; 
follow-up yrs: 3.6-
8.8, mean 6 
history of stroke or 
transient ischemic 
attack 
population sample 
from the 
Artherosclerosis 
Risk in 
Communities 
(ARIC) study 
Delayed Word 
Recall test, digit-
symbol substitution 
(WAIS-revised), 
Word Fluency (F, A 
& S) 
presence of hypertension at 
baseline was associated with 
greater decline on the digit-
symbol substitution test. 
Presence of diabetes was 
associated with greater decline 
in scores on the digit-symbol 
substitution test and word 
fluency 
APOE = apolipoprotein-E allelic status; BMI = body mass index; BP = blood pressure; CHD = coronary heart disease; DBP = diastolic blood 
pressure; HT = hypertensive; MMSE = Mini-Mental State Examination; NART = New Adult Reading Test; PALT = Paired Associate Learning 
Test; RPM = Raven’s Progressive Matrices; SBP = systolic blood pressure; SD = standard deviation; TMT A = Trail-Making Test form A; 
WAIS = Wechsler Adult Intelligence Scale; WMS = Wechsler Memory Scale.
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Appendix IV: Characteristics of intervention studies 
Characteristics of prospective studies investigating the effect of antihypertensive medication on cognitive function 
Authors Study design / 
antihypertensive 
medication  
Sample / target BP 
levels 
Exclusion 
criteria 
Inclusion criteria Neuropsychological
/ cognitive tests 
Conclusions 
43 single-blind, randomised, 
placebo-controlled 
thiazide diuretic vs. β-
blocking agent 
additional therapy: adalat 
n = 2401; 
age: 65-74, mean 70.3; 
BP criteria: SBP 160-
209 and DBP ≤113 
target: SBP <150 (160-
179 at entry) or SBP 
<160 (180-209 at 
entry); 
follow-up: 1 & 9m 
major physical 
illness 
Medical Research 
Council trial; 
untreated 
hypertensives 
from primary care 
NART, RPM, 
PALT, TMT A, 
self-rating 
depression 
questionnaire 
No significant differences at 1 
or 9 months on any 
neuropsychological tests. BP 
was significantly reduced at 9 
month in treatment groups 
compared to placebo 
44 same as 43 n = 2584; 
entry criteria same as 
43; 
follow-up: 4.5 years 
same as 43 same as 43 PALT, TMT A; 
coefficient of 
change calculated 
as the slope of the 
regression line of 
test score on time 
No significant differences 
between groups on cognitive 
outcomes, for intention-to-treat 
and protocol analysis. Also no 
differences in group remaining 
on allocated medication only 
50 phase I: single-blind, 
randomised, placebo-
controlled HCTZ/ 
triamterene vs. atenolol 
n = 25; 
age: 61-79, mean 70.6; 
neurological/ 
psychiatric 
disorder, 
cardiovascular 
MMSE ≥26 Automated 
Psychomotor Test 
(APT) battery: 
DSS, CAT, CRT, 
Target BP achieved in 18/20 
subjects in treatment group. 
Improvement on DSS, CAT, 
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Authors Study design / 
antihypertensive 
medication  
Sample / target BP 
levels 
Exclusion 
criteria 
Inclusion criteria Neuropsychological
/ cognitive tests 
Conclusions 
vs. nifedipine vs. 
captopril; 
2-week placebo run-in 
BP criteria: placebo 
phase SBP ≥165 and 
DBP 95-125; 
target: SBP <165 and 
DBP <95; 
follow-up: 1 & 4 weeks 
(baseline at end of 
placebo run-in phase) 
disease, 
hypertensive 
end organ 
damage, drugs 
affecting CNS, 
moderate 
alcohol intake 
Critical Flicker 
Fusion Threshold, 
Cognitive 
Flexibility Test, 
PWAT, Inspection 
Time Threshold 
PWAT and Inspection Time 
Threshold at 1 week. Further 
improvement at 4 weeks on 
CAT only. No change in 
placebo group or 2 non-
responders to treatment. Age, 
education, social status or 
handedness not related to 
improvement 
50 phase II: double-blind, 
randomised, cross-over 
study of nifedipine vs. 
captopril; 
2-week placebo run-in, 2 
week treatment, 2 week 
placebo washout, 2 week 
treatment 
n = 13; 
age: mean 67.9; 
BP criteria: as above 
follow-up: 6 weeks 
(baseline at end of 
placebo run-in phase) 
as above as above abbreviated 
Automated 
Psychomotor Test 
(APT) battery: 
DSS, CAT, CRT, 
PWAT 
Target BP achieved with 
nifedipine and captopril. 
Improvement seen on DSS, 
CAT, CRT and PWAT. No 
differences in BP control or 
APT improvement between the 
two antihypertensives. Phase I 
& II suggest improvement due 
to BP control rather than direct 
CNS effect of drugs 
41 phase III: multicentre, 
double-blind, 
randomised, placebo-
controlled, stepped-care 
treatment of thiazide 
and/or atenolol vs 
placebo 
n = 4736; 
age: 60-94, mean 72 
BP criteria SBP 160-
220 & DBP<90  
follow-up: annual for 
not reported Isolated systolic 
hypertension 
DSS, Addition test, 
Finding A’s, Boston 
Naming, Letter sets 
test, delayed 
recognition span 
Little change in cognition in 
either group over 5 years. 
Concluded the absence of 
detrimental effects 
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Authors Study design / 
antihypertensive 
medication  
Sample / target BP 
levels 
Exclusion 
criteria 
Inclusion criteria Neuropsychological
/ cognitive tests 
Conclusions 
mean 5 years 
45 double-blind, randomised 
trial of captopril vs. 
bendrofluazide; 
2-week placebo run-in 
phase 
n = 81; 
age: 70-85, mean 76.1; 
BP criteria: median 
SBP 160-220 & DBP 
100-120 or SBP 180-
220 & DBP ≥85; 
follow-up: 0, 4, 12 & 
24 weeks 
symptomatic 
hypotension, 
heart failure, MI 
or heart 
condition in last 
6 months, 
diabetes, or 
haematological, 
renal or hepatic 
dysfunction  
newly-diagnosed 
hypertensive, 
community-
residents with 
mild cognitive 
impairment 
(MMSE 20-28) 
NART, Logical 
Memory 
(immediate & 
delayed), PALT, 
RPM, ASRT,  
TMT A 
No differences between 
treatment groups on cognitive 
tests at any time points (repeated 
measures ANOVA). Subjects 
with greatest DBP reduction at 
24 weeks had improved ASRT 
& PALT scores compared to 
subjects with lowest DBP drop. 
No effects for SBP 
46 double-blind, RCT of 
nitrendipine plus possible 
enalapril/HCTZ 
n = 2418; 
age: 60+, mean 70 
BP criteria: SBP 160-
219 & DBP <95 
follow-up: 24m 
no dementia Isolated systolic 
hypertension  
MMSE, dementia 
diagnosis 
50% reduction in incidence of 
dementia with active treatment. 
No change in MMSE in either 
group. Open-label follow-up 
supported dementia finding 
51 double-blind, randomised 
trial of losartan vs. 
HCTZ; 
2-week untreated run-in 
phase 
n = 69; 
age: 30-73, divided into 
<60 & ≥60 for analysis; 
BP criteria: DBP 90-
114 in run-in phase; 
recent MI, 
stroke, renal or 
liver failure, 
congestive heart 
failure 
uncomplicated 
essential 
hypertension, 
homogenous for 
BMI, min 5 years 
education 
MMSE, Sandoz 
Clinical Assessment 
Geriatric (SCAG) 
Both treatments significantly 
lowered BP; losartan more 
effective than HCTZ. The 
losartan group showed 
significant improvement in 
MMSE and SCAG scores; 
HCTZ changes were non-
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Authors Study design / 
antihypertensive 
medication  
Sample / target BP 
levels 
Exclusion 
criteria 
Inclusion criteria Neuropsychological
/ cognitive tests 
Conclusions 
follow-up: 26m 
significant 
49 open-label, randomised 
trial of cilazipril vs. 
atenolol in hypertensives 
previously atenolol-
treated. Atenolol 
withdrawn in treatment 
group at week 0; 
treatment started at week 
2 
n = 26; 
age: 65-84, mean 72.3; 
BP criteria: DBP >90 
after atenolol 
withdrawal; 
follow-up: 2, 6, 10 & 
18 weeks 
CVA in last 2 
years, recent 
MI, diabetes, 
drug or alcohol 
abuse history, 
psychotropic 
medication 
atenolol-treated 
for min 1 year 
identified from 
GP records 
CDR battery 
consisting of: SRT, 
digit vigilance, 
CRT, memory 
scanning, delayed 
word recognition, 
picture recognition 
Trend for improvement on all 
subtests at 2 weeks for atenolol 
withdrawal vs. atenolol group; 
significant for CRT. Pattern of 
further improvement at 6, 10 
and 18 weeks. Differences 
between groups due to 
improvement in treatment group 
and decline in atenolol group 
 
ASRT = Anomalous Sentences Repetition Task; BMI = body mass index; CAT = Continuous Attention Test; CDR = Cognitive Drug Research 
computerised assessment battery; CNS = central nervous system; CRT = Choice Reaction Time; CVA = cerebrovascular accident; DBP = 
diastolic blood pressure; DSS = digit-symbol substitution subtest of the Wechsler Adult Intelligence Scale; HCTZ = hydrochlorothiazide; MI = 
myocardial infarction; MMSE = Mini-Mental State Examination; NART = New Adult Reading Test; PALT = Paired Associate Learning Test; 
PWAT = Paired Word Association Test; RPM = Raven’s Progressive Matrices; SBP = systolic blood pressure; SRT = simple reaction time; 
TMT A = Trail-Making Test form A 
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Appendix V: Trail-Making Test administration instructions 
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Appendix VI: Verbal Fluency test administration instructions 
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Appendix VII: CDR task instructions 
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Appendix VIII: Data characteristics of the CDR variables 
* indicates variables entered into the factor analyses. Format denotes the [maximum number of characters].[number of decimal places] 
Task Abbreviation Format Example Unit  Derivation Range 
 Data element       
Practice Choice Reaction Time       
 Practice Choice Reaction Time Accuracy CRT1ACC 6.2 XXX.XX % Percentage of stimuli responded to 
correctly  
0 to 100 
 Practice Choice Reaction Time Mean CRT1 8.2 XXXXX.XX msec Mean speed of individual correct 
responses  
150 to 30000 
Immediate Word Recall       
* Immediate Word Recall Words Correctly 
Recalled 
IRECALL 2.0 XX # Number of words correctly recalled  0 to 12 
Immediate Word Recognition       
 Immediate Word Recognition Original 
Stimuli Accuracy 
DRE1OACC 6.2 XXX.XX % Percentage of original stimuli 
correctly identified 
0 to 100 
 Immediate Word Recognition New Stimuli 
Accuracy 
DRE1NACC 6.2 XXX.XX % Percentage of novel stimuli 
correctly identified 
0 to 100 
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Task Abbreviation Format Example Unit  Derivation Range 
 Data element       
* Immediate Word Recognition Sensitivity 
Index 
DRE1SI 6.3 -X.XXX #  Sensitivity Index -1 to 1 
* Immediate Word Recognition Speed Mean DRE1RT 8.2 XXXXX.XX msec Mean speed of individual correct 
responses to all stimuli 
250 to 30000 
Simple Reaction Time       
* Simple Reaction Time Mean SRT 8.2 XXXXX.XX msec Mean speed of individual correct 
responses  
100 to 30000 
Number Vigilance (now known as Digit Vigilance)     
* Number Vigilance Targets Detected VIGACC 6.2 XXX.XX % Percentage of targets responded to 
within time window  
0 to 100 
* Number Vigilance Speed VIGRT 7.2 XXXX.XX msec Mean speed of individual responses 
to targets within time window  
100 to 1500 
* Number Vigilance False Alarms VIGFA 3.0 XXX # Number of responses falling 
outside of specified time window  
0 to 999 
Choice Reaction Time       
* Choice Reaction Time Accuracy CRT2ACC 6.2 XXX.XX % Percentage of stimuli responded to 
correctly  
0 to 100 
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Task Abbreviation Format Example Unit  Derivation Range 
 Data element       
* Choice Reaction Time Mean CRT2 8.2 XXXXX.XX msec Mean speed of individual correct 
responses  
150 to 30000 
Spatial Working Memory       
 Spatial Working Memory Original Stimuli 
Accuracy 
SPMOACC 6.2 XXX.XX % Percentage of original stimuli 
correctly identified  
0 to 100 
 Spatial Working Memory New Stimuli 
Accuracy 
SPMNACC 6.2 XXX.XX % Percentage of novel stimuli 
correctly identified  
0 to 100 
* Spatial Working Memory Sensitivity Index SPMSI 6.3 -X.XXX #  Sensitivity Index -1 to 1 
* Spatial Working Memory Speed Mean SPMRT 8.2 XXXXX.XX msec Mean speed of individual correct 
responses to all stimuli  
 
150 to 30000 
Numeric Working Memory (previously known as Memory Scanning)     
 Numeric Working Memory Original Stimuli 
Accuracy 
MSOACC 6.2 XXX.XX % Percentage of original stimuli 
correctly identified 
0 to 100 
 Numeric Working Memory New Stimuli 
Accuracy 
MSNACC 6.2 XXX.XX % Percentage of novel stimuli 
correctly identified 
0 to 100 
* Numeric Working Memory Sensitivity Index MSSI 6.3 -X.XXX #  Sensitivity Index -1 to 1 
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Task Abbreviation Format Example Unit  Derivation Range 
 Data element       
* Numeric Working Memory Speed Mean MSRT 8.2 XXXXX.XX msec Mean speed of individual correct 
responses to all stimuli 
150 to 30000 
Delayed Word Recall       
* Delayed Word Recall Words Correctly 
Recalled 
DRECALL 2.0 XX # Number of words correctly recalled  0 to 12 
Delayed Word Recognition       
 Delayed Word Recognition Original Stimuli 
Accuracy 
DRE2OACC 6.2 XXX.XX % Percentage of original stimuli 
correctly identified 
0 to 100 
 Delayed Word Recognition New Stimuli 
Accuracy 
DRE2NACC 6.2 XXX.XX % Percentage of novel stimuli 
correctly identified 
0 to 100 
* Delayed Word Recognition Sensitivity Index DRE2SI 6.3 -X.XXX #  Sensitivity Index -1 to 1 
* Delayed Word Recognition Speed Mean DRE2RT 8.2 XXXXX.XX msec Mean speed of individual correct 
responses to all stimuli. 
250 to 30000 
Picture Recognition       
 Picture Recognition Original Stimuli 
Accuracy 
DPICOACC 6.2 XXX.XX % Percentage of original stimuli 
correctly identified  
0 to 100 
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Task Abbreviation Format Example Unit  Derivation Range 
 Data element       
 Picture Recognition New Stimuli Accuracy DPICNACC 6.2 XXX.XX % Percentage of novel stimuli 
correctly identified  
0 to 100 
* Picture Recognition Sensitivity Index DPICSI 6.3 -X.XXX #  Sensitivity Index -1 to 1 
* Picture Recognition Speed Mean DPICRT 8.2 XXXXX.XX msec Mean speed of individual correct 
responses to all stimuli  
250 to 30000 
Trail-Making Test       
* Trail-Making Test Form A TMTA 3.0 XXX secs Time taken to complete  0 to 300 
* Trail-Making Test Form B TMTB 3.0 XXX secs Time taken to complete  0 to 300 
Verbal Fluency       
* Letters F, A and S VF_FAS 3.0 XXX # Number of correct words  0 to 200 
* Animals VF_Animals 3.0 XXX # Number of correct words  0 to 200 
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